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Many parasites have evolved to release products that inhibit host defence 
mechanisms such as enzymes in the mammalian host, in order to promote and sustain 
their survival within the host. The human filarial nematode Brugia malayi produces 
larval microfilariae, which circulate in the blood stream. Their most abundant 
secreted product is a serine protease inhibitor Bm-SPN-2. Serine protease inhibitors 
(Serpins) are reported to be involved in how the nematodes avoid host immune 
defences, and in the case of Bm-SPN-2, the protein was found to specifically inhibit 
the enzymatic activity of human neutrophil elastase and cathepsin G in a dose-
dependent manner. More recently, these two enzymes have been linked to the 
activation of a major innate cytokine IL-33, which is stored as a full-length 270-aa 
protein in the cell nucleus, and released as an active C-terminal domain upon 
stimulation.  
As full-length (FL) human and murine IL-33 are not commercially available, 
soluble murine and human FL-IL-33 were produced in transfected HEK 293T cells, 
following mutation of the nuclear binding motif. In this form, IL-33 is no longer 
retained in the nucleus and can be purified as a soluble protein. It was confirmed that 
once cleaved, recombinant human IL-33 was able to induce significant IL-6 secretion 
by mast cells. Bm-SPN-2 was then shown to block human full-length IL-33 cleavage 
by inhibiting human neutrophil cathepsin G in a dose dependent manner, supporting 
the hypothesis that Bm-SPN-2 may act in vivo to prevent IL-33 activation and the 
promotion of the TH2 immune response. However, in the in vivo setting, it was 
unexpectedly found that IL-33R (ST2) gene deficiency did not enhance the survival 
of B. pahangi microfilariae. Furthermore, in the absence of IL-33R, murine immune 
responses to microfilariae were not significantly altered compared to wild-type 
BALB/c mice, other than in a significant increase in IL-33 expression. Hence while 
Bm-SPN-2 can act in vitro to forestall one of the key events in TH2 induction, this 
has not yet been shown to be crucial to the immune response to the parasite in vivo.   
	  
	  



















































Many parasites have evolved to release products that inhibit host defence 
mechanisms in order to promote and sustain their survival within the host. The 
human filarial nematode Brugia malayi produces larval microfilariae, which circulate 
in the blood stream. Their most abundant secreted product is a serine protease 
inhibitor Bm-SPN-2. Bm-SPN-2 was found to inhibit two host enzymes which have 
recently been linked to the activation of a key host defence system (IL-33) to 
eliminate the parasite. To study this system, I first produced the individual parasite 
and host proteins Bm-SPN-2 and IL-33. I then verified that recombinant Bm-SPN-2 
inhibited these two host enzymes. Finally, I investigated whether this inhibitory 
function is crucial to parasites avoiding host defences by conducting experimental 
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1.1  Human  helminths  and  filariasis  
1.1.1  Helminths  and  burden  of  helminthiases 
Helminths are invertebrate worms that are divided into the two major phyla 
Platyhelminthes (flatworms) and Nematoda (nematodes), both of which include 
many important parasites of humans and animals. The Platyhelminthes comprise the 
Trematodes (also known as flukes) and the Cestodes (tapeworms) (Figure 1.1).  
1.1.1.1  Trematodes  
Trematodes, which have small flat leaf-like bodies, include parasites such as 
Schistosoma haematobium, S. mansoni and S. japonicum (blood flukes), Clonorchis 
sinensis, Fasciola hepatica, F. gigantica and Opisthorchis viverinni (liver flukes), 
Paragonimus spp. (lung flukes) and Fasciolopsis buski (intestinal flukes). Although 
most of these are restricted to tropical environments, fascioliasis is a worldwide 
problem particularly in livestock. 
Blood fluke larvae develop into adult schistosomes and form separate sexes, 
but live conjoined in blood vessels where the female lays eggs in mammals. Eggs 
from faeces hatch in water and liberate larvae (miracidia) that penetrate the 
freshwater snail intermediate host. Transmission occurs by cercariae which emerge 
from snails, penetrating human skin during contact with contaminated water. The 
above Schistosoma spp. cause schistosomiasis in humans, which currently afflicts 
approximately 207 million humans globally (Hotez et al. 2008). 
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Figure 1.1 Simplified classification of major helminth parasites by means of 
transmission. Top line: taxonomic grouping; second line: route of infection; bottom line: 
parasite species, parasites causing human disease are in RED and mouse model parasites in 
BLACK. Adapted from Hewitson and Maizels, 2014. 
 
The life cycle of fascioliasis is complex, involving a final host (particularly 
livestock) where adult worms live, an intermediate host (water snail) where the 
larvae develop and a carrier such as water or aquatic plants (Malone 1986). Adult 
liver flukes live in hepatic bile ducts where they cause hepatic disease in domestic 
ruminants and humans. Eggs are evacuated into faeces and hatch into larvae that 
move into the snail. More larvae from the snail are released into the water and swim 
to attach to the leaves or stems of aquatic plants where metacercariae are formed. 
Infection occurs when water containing metacercariae is drunk or when uncooked 
cyst-contaminated aquatic vegetation is eaten. More than 40 million people from 
more than 75 countries have been reported to have Fascioliasis (Hotez et al. 2008). 
The World Health Organization (WHO) notably mentioned that no countries can be 
considered free from the risk of fascioliasis.  
1.1.1.2  Cestodes  
Cestode life-cycles involve predator-prey transmission between two terrestrial hosts, 
in which larval metacestodes form cysts in the tissues of herbivores, and 
subsequently grow into adult tapeworms in the small intestine in carnivores. The 
larvae of Taenia spp. cause cysticercosis in pigs, cattle and humans (0.4 million 
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cases in Latin America), while those of Echinococcus cause hydatid disease in 
domestic and wild animals, and even humans and lead economic losses in livestock. 
The definitive carnivore hosts of Echinococcus are canids, particularly dogs and 
foxes. 
1.1.1.3  Nematodes  
The nematodes (also known as roundworms) include the major intestinal worms 
(soil-transmitted helminths) and the filarial worms that cause lymphatic filariasis (LF) 
and onchocerciasis (Figure 1.1). Worldwide, more than 2 billion people are infected 
with soil-transmitted helminths (STH) (Bethony et al. 2006). The main species of 
STH that infect people are the roundworm (Ascaris lumbricoides), the whipworm 
(Trichuris trichiura) and hookworms (Necator americanus and Ancylostoma 
duodenale). They are transmitted through soil contaminated with faeces in areas 
lacking adequate sanitation or hygiene. 
Ascaris infections involves fecal-oral transmission of infective eggs. Adult 
ascarids live in the small intestine and feed on intestinal contents, they steal nutrition 
from the host. A female produces a huge number of eggs (~200,000 eggs per day), 
excreted with the feces. Freshly-excreted eggs are fertilized for embryonation and 
become infective in 9-40 days. The eggs’ high resistance to external environmental 
conditions enable them to remain viable in soil for several years. Infections are 
transmitted by ingestion of infective eggs containing L3 larvae, which hatch in the 
intestinal tract, and penetrate the mucosal barrier and then systemic circulation to the 
lung. About 10-14 days after infection, the larvae penetrate the alveolar wall, move 
up to trachea, ascend the bronchial tree to the throat, and are swallowed down to 
oesophagus to return to the intestinal tract where they mature as adults, which 
continues the life cycle. Adult worms can live 1 to 2 years. Ascaris infections in 
humans (1.221 billon in developing regions of Asia, Africa, and Latin America) 
cause gastroenteritis, protein depletion and malnutrition, poor growth and 
development in small children. Heavy infections can cause life-threatening gut 
obstruction that may affect working capacities, and impair physical growth. 
Whipworm infection is directly transmitted by oral ingestion of infective eggs. 
The adult worms (~4cm in length) live in the cecum using their anterior portion to 
embed into the mucosa epithelium, whereas broader posterior helps female worms 
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oviposit numerous eggs (3,000 to 20,000 eggs per day). The unembryonated eggs are 
passed out with the feces become infective in 15 to 30 days. After ingestion of the 
infective eggs, eggs hatch in the small intestine and mature as adults in the colon, 
which complete the life cycle. Adult worms can live about 1 year. Trichuris 
infections in humans (795 million cases in developing regions of Asia, Africa and 
Latin America) cause intestinal manifestations: diarrhoea, abdominal pain, straining, 
colitis and rectal prolapse (Bethony et al. 2006). Trichuris infections have also been 
reported to compromise cognitive function in children (Nokes et al. 1992).    
Hookworm infection is mostly acquired by walking barefoot on contaminated 
soil via transdermal transmission. The eggs, passed in the stool, hatch in the 
environment and develop into infective stage L3. These infective larvae migrate to 
tips of vegetation or soil enabling them to infect passing barefoot mammals by 
penetrating the skin. Then they migrate through the blood vessel to the heart then to 
the lungs. Finally, they reach the small intestine and mature into adults after 
penetrating into the pulmonary alveoli, ascending the bronchial tree to the pharynx 
and are swallowed. Adult worms can live 1 to 2 years or even longer. Heavy 
infections by Ancylostoma and Necator lead chronic intestinal blood loss that results 
in anaemia in humans, especially children lacking footwear. There are estimated to 
be 740 million cases in developing regions of Asia, Africa, and Latin America 
(especially in areas of rural poverty). 
The filarial nematode infections are transmitted by arthropod vectors. 
Onchocerca infection is spread by blood-feeding black flies, while lymphatic 
filariasis by mosquitoes. In addition, Wuchereria (the causative agent of lymphatic 
filariasis) is transmitted by a number of mosquito species mostly from the genera 
Mansonia, Culex, Aedes (which also transmit Dengue/Yellow/Zika Fever)(Miller 
and Mitchell 1991), and Anopheles (which also spread human Plasmodium causing 
malaria) (Manguin et al. 2010). Adult filarial worms reside in lymphatic or 
connective subcutaneous tissues of their hosts. Onchocerca infections lead to 
nodules, skin lesions and river blindness in humans (37 million cases in Sub-Saharan 
Africa), while those of Wuchereria and Brugia cause elephantiasis (120 million cases 
in developing regions of India, southeast Asia, and sub-Saharan Africa).  
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As this is the filarial parasite studied here, it will be described in more detail 
in the next section.  
1.1.2  Lymphatic  filariasis   
Lymphatic filariasis (LF), a neglected tropical disease, is caused by the nematodes 
Wuchereria bancrofti (which is responsible for 90% of the cases), Brugia malayi and 
Brugia timori. Brugia pahangi is a closely related filarial nematode that is naturally 
found in cats, and may also cause clinical infection of humans manifesting as 
lymphatic filariasis (Tan et al. 2011). The genome of B. pahangi was found to have a 
high similarity to B. malayi, with extensive synteny and few genes specific only for 
one species (Lau et al. 2015).  
Lymphatic filariasis can cause a wide variety of clinical symptoms: 1) Some 
patients show no apparent clinical symptoms; 2) For those who have clinical 
symptom, acute adenolymphangitis (ADL) is often the first manifestation. It involves 
high fever, painful, lymph node and lymphatic inflammation (lymphangitis and 
lymphadenitis), and transient local edema (Nutman and Kazura 2011). 3) Swelling of 
the upper or lower extremities is the most common chronic manifestation, which 
causes lymphedema of the arms, legs and even breasts. 4) In many endemic areas, 
disease of the male genitalia is far more common than that of lymphedema, which 
cause hydroceles and severe disfigurement of genitalia; 5) Impairment of the renal 
lymphatics causes a rare but serious manifestation chyluria; 6) A distinct syndrome 
called tropical pulmonary eosinophilia (TPE) appears in some patients (Nutman and 
Kazura 2011). It includes paroxysmal cough and wheezing, adenopathy, blood 
eosinophilia (>3000 eosinophils/µl) and high levels of total serum IgE (10 000-100 
000ng/ml). Lymphatic filariasis is closely related to parasites that cause river 
blindness in humans, and heartworm infections in dogs (Hoerauf et al. 2003, Fu et al. 
2012). Thus, the above severe clinical manifestations make LF as one of the leading 
causes of permanent and long-term disability, reducing worker productivity in many 
tropical countries, causing massive economic losses (Perera et al. 2007, Nutman and 
Kazura 2011). Its life cycle (Figure 1.2) involves mosquitoes and humans and a 
correspondingly complex set of interactions with the human host immune system 
(Maizels et al. 1993, Molehin, Gobert and McManus 2012). 
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Figure 1.2: Life cycle of lymphatic filariasis. During a blood meal on an infected host, a 
female mosquito takes up microfilariae from the bloodstream. Parasites develop from 1st to 
3rd stage larvae (L1-L3) in the thoracic muscles of the mosquito over 10-14 days. During the 
next blood meal, mosquitoes introduce infective L3 onto the skin of the human host. Larvae 
penetrate and migrate to the lymphatics where they develop into adults and mate (releasing 
microfilariae over 5-10 years), causing recurring lymphadenitis, elephantiasis and 
hydrocoele. Bloodstream microfilariae released by female worms can also cause tropical 
pulmonary eosinophilia. From Nutman and Kazura, 2011. 
 
1.1.2.1  Epidemiology  of  lymphatic  filariasis    
At the start of Global Programme to Eliminate Lymphatic Filariasis (GPELF) in 1997, 
there were an estimated 120 million cases of filariasis infection in both rural and urban 
areas in about 81 countries (Figure 1.3). The greatest number of W. bancrofti infections 
are in Southeast Asia, sub-Saharan Africa and the western Pacific. The infection is 
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prevalent in India, Indonesia, Papua New Guinea, the Philippines and several Pacific 
countries such as parts of Fiji and Tahiti. Infection with B. malayi is limited to Asia and 
several Pacific island groups (Figure 1.3). Fewer than 10 to 20 million persons in these 
areas are infected with B. malayi, which may coexist with W. bancrofti (Nutman and 
Kazura 2011). A smaller number in the Lesser Sunda island archipelago, including 
Timor and nearby islands, are infected with B. timori. 
 
Figure 1.3: World map of lymphatic filariasis infection. (Nutman and Kazura 2011). 
 
1.1.2.2  Large-­scale  treatment  and  current  status  
According to GPELF, several control strategies were utilized to interrupt transmission, 
including mass drug administration (MDA) and vector control. The target of MDA is to 
reduce the level of microfilaraemia in infected persons to the level that can no longer 
sustain LF transmission by mosquito to new hosts. The two principal regimens for 
MDA are: 1) the combinations of two filaricidal medicines given once yearly to entire 
at-risk population in endemic areas in the following way: Albendazole (400 mg) 
together with either ivermectin (150–200 mcg/kg) or with diethylcarbamazine citrate 
(DEC) (6 mg/kg) for 4-6 years (Gyapong et al. 2005); or 2) exclusive use of cooking 
salt fortified with DEC for 1-2 years (Lammie et al. 2007). 
However, the major obstacle to implementing MDA programs is that adverse 
drug reactions (ADRs) occur after DEC and ivermectin intake. The drug can produce 
adverse reactions such as arthralgia, drowsiness, epididymitis, fever, headache, 
lymphangitis, lymphadenitis, nausea, orchitis etc. These reactions are related to the 
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dose-related chemical toxicity of the drug or, occasionally, with the death of the parasite 
(Norões et al. 1997), or with the gender of the patients in Brazil (Lima et al. 2012). In 
Indonesia, moderate reactions (fever, headache and body aches) are manifest in 
elephantiasis patients with high densities of circulating microfilariae, starting between 2 
to 24 hours following DEC intake (Haarbrink et al. 1999). In central Africa, in countries 
coendemic with Loa loa, serious adverse events (including encephalopathy and death) 
occurs in people with high levels of Loa microfilariae in the blood, when treated with 
ivermectin (Boussinesq et al. 2003). 
Without a vaccine, vector-mosquito control remains the only accessible 
methodology against lymphatic filariasis (Bockarie et al. 2009). The aim of mosquito 
control is to interrupt the transmission of LF and other mosquito-borne infections. As 
mentioned above, Wuchereria is transmitted by no fewer than 4 disparate mosquito 
genera including Mansonia, Culex, Aedes (Dengue/Yellow/Zika Fever) (Miller and 
Mitchell 1991) and Anopheles (malaria) (Manguin et al. 2010). Thus, it makes vector 
control highly problematic. The mosquito-borne Zika virus outbreak in the Americas in 
2016 proved that mosquito control has not yet has been successful (Yakob and Walker 
2016). 
During the first 10 years of GPELF, the number of people receiving MDA 
treatment, increased from 3 million in 12 countries in 2000, to 500 million in 53 
countries in 2011 (Ichimori et al. 2014). However, after 20 years of MDA and vector 
control, 947 million people in 54 countries worldwide remain threatened by 
lymphatic filariasis (Modi et al. 2017). To date, there is still no licensed vaccine 
available and current vaccine candidates only provide partial protection in animal 
models (Taylor, Hoerauf and Bockarie 2010, Arumugam et al. 2014, Maizels and 
McSorley 2016, Hartmann et al. 2014). Large-scale treatment with massive drug 
programmes annually, and mapping all threatened areas worldwide costs a great deal 
of money and research resources, even though anthelminthic drugs have been 
donated by three different companies (Ichimori et al. 2014). Potential vaccination 
could protect humans and animals once and for all. There is also concern that 
resistance may develop to the limited number of drugs available, and so there is an 
urgent need to discover new targets for vaccine and drug development. Thus, 
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understanding the depth of the relationship between filarial parasite and host makes 
meaningful.  
1.1.2.3  Available  research  models  for  lymphatic  filariasis  
Although 90% of filariasis cases are due to W. bancrofti, this species cannot be 
maintained in the laboratory, as it only infects primate hosts (Palmieri et al. 1983). 
Among several mouse models of filariasis, recent studies have focussed on 
Litomosoides sigmodontis, which permits researchers to investigate both the 
developmental biology and immunology of filarial parasites (Babayan et al. 2010, 
Taylor et al. 2009). However, it has proven possible to study the human parasite B. 
malayi in the laboratory, as this species will infect the rodent Meriones unguiculatus 
(the Mongolian jird, also a permissive host for Brugia pahangi (Ash and Riley 1970a, 
Ash and Riley 1970b). In the mouse, although infective larvae do not survive for more 
than a few days, adult worms or microfilariae may be transferred and live for many 
weeks or months.  The laboratory life cycle of L. sigmodontis, B. malayi and B. pahangi 
are shown in Figure 1.4.  
 
Figure 1.4: The laboratory life cycle of research models of filariasis. Adapted from 
Maizels et al., 2004. 
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B. malayi and W. bancrofti are closely related species, and indeed it is not easy 
to distinguish between clinical diseases caused by these different agents, and they are 
spread by similar mosquito vector species. At the molecular level, the limited studies on 
W. bancrofti indicate that it is very similar to B. malayi (Morgan et al. 1986). 
Interestingly, B. malayi infection is a zoonosis in that there are feline and primate 
reservoirs, corresponding to its ability to infect some rodent species. Thus, research into 
B. malayi is both logistically feasible and relevant to lymphatic filariasis in general.  
1.2  Immune  regulation  by  helminth  parasites    
Parasitic helminths infect more than 2 billion people worldwide, nearly one third of 
the human population, thus can cause marked disability and morbidity. Helminths 
are complex eukaryotic pathogens with large genomes, can live for a considerable 
length of time in the human host (Maizels and Yazdanbakhsh 2003, Muller and 
Wakelin 2002). Both their extremely high prevalence, and their longevity, indicate 
that helminth parasites are able to very effectively dampen or block the immune 
system of their host. 
In many helminth infections, a T helper 2 (TH2) immune response is dominant, 
which is typically marked by the cytokines interleukin-4 (IL-4), IL-5, IL-13, the 
immunoglobulin E (IgE) isotype, and also high levels of tissue and blood eosinophilia, 
as well as mucosal mastocytosis and goblet cell hyperplasia in intestinal infections 
(Maizels and Yazdanbakhsh 2003, Maizels et al. 2004). In general, TH2 responses are 
considered to be protective by driving a set of type 2 anti-helminth mechanisms, 
including class-switched antibodies, activated swarms of immune cells; disabling 
parasites overall fitness and ability to reproduce, degrading parasite integrity and 
dislodging parasites by making the chosen niche untenable, leading to their destruction 
or expulsion (Maizels, Hewitson and Smith 2012). TH2 responses against helminths 
will be described in more detail in the section 1.4.1. 
Generally, TH1 cells tend to produce immune responses against intracellular 
pathogens, such as bacteria and viruses, by producing interferon (IFN)-g and IL-2 
(O’Garra and Arai 2000). However, there are a few intriguing cases in which TH1 
rather than TH2 cell responses are mounted against helminths. First, it is known that 
different strains of mice produce TH1 or TH2 cell responses against the nematode 
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Trichuris muris, and where TH1 predominates, mice remain chronically infected (Else 
et al. 1994). Secondly, the cercarial stage of schistosomes stimulate TH1 cell responses 
soon after infection is initiated in the mouse model. Subsequently, a TH2 cell response 
is induced by schistosome egg antigens as infection progresses and eggs are released by 
adults in the vasculature (Maizels and Yazdanbakhsh 2003, Pearce and MacDonald 
2002). Finally, the B. malayi microfilarial stage is also a notable exception to the pattern 
of TH2 induction by helminths. In this case, the microfilarial stage of B. malayi 
promotes TH1 cell responses in BALB/c mice, although adult filarial worms, especially 
female worms, exert polarization of the TH2-cell response (Pearlman et al. 1993, 
Lawrence et al. 1994). 
1.2.1  Regulatory  T  cells  in  filarial  infection 
Dating back to 1980, it has been found that suppressor cells can cause specific 
immunologic unresponsiveness to microfilarial antigens in patients with patent Brugian 
filariasis (Piessens et al. 1980). Based on the in vitro study of peripheral blood 
mononuclear cell (PBMC) isolated from microfilaremic individuals in Indonesia, these 
suppressor cells have been discovered to be the regulatory T cells (Tregs) which are 
functional in suppressing proliferation and possibly TH2 cytokine responses to B. 
malayi adult worm antigen, proving Tregs is a key element of TH2 suppression and a 
key feature of filarial infection (Taylor, van der Werf and Maizels 2012, Wammes et al. 
2012).  
In the light of the respective roles of TH1, TH2 and Tregs in infection, it was 
proposed that according to the balance of these subsets, three different outcomes of 
specific immune response could be produced by host upon exposure to helminth 
parasites (Figure 1.5) (Maizels and Yazdanbakhsh 2003). In the first outcome, 
individuals susceptible to long-term infection display “Modified T helper 2 (TH2)-cell 
responses”, with ineffective TH2 cell responses and low levels of TH1 cells, but 
developing strong regulatory T (Treg)-cell activity by expressing high levels of IL-10; 
the antibody response is dominated by IgG4 with little IgE. Secondly, in cases of more 
severe pathology, there is an uncontrolled inflammatory (TH1) response developed 
against parasites, whereas there is a low level of Treg-cell activity (low IgG4 vs. high 
IgE). Thirdly, if individual was resistant to parasite infection, they present with 
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restrained Treg-cell activity and balanced TH1 and TH2 cell responses described as 
“balanced TH1/TH2” (with similar IgG4 and IgE isotypes).  
This model is well illustrated by human cases of filariasis. In lymphatic 
inflammation, there are strong type-1 (and TH17) immune responses comprising both 
IgE and IgG4, which lead to pathological changes such as elephantiasis (Babu et al. 
2009). In contrast, highly infected microfilarial patients have high levels of IgG4, but 
lower levels of IgE (Kurniawan et al. 1993). During filarial infection, the TH2 cells are 
differentiated into a hyporesponsive state that is well demonstrated, the modified TH2 
cell response. In human infection with Onchocerca volvulus, it has been shown that T 
cell  in vitro immune responsiveness could be restored by the addition of exogenous IL-
2 (Gallin et al. 1988).  It has also been shown that significant impairment of both TH1 
and TH2 immune responses identified by diminished corresponding cytokine responses 
of PBMC from filariasis patients to live B. malayi microfilariae or larvae, as further 
evidence for the development of T cell hyporesponsive state (Babu et al. 2006). In 
addition, using the laboratory mouse model of filariasis infection with L. sigmodontis, 
effector CD4+ T cells isolated from the infection site were shown to lose the capacity to 
proliferate and produce TH2 cytokines in response to antigen. In contrast, mice in 
which regulatory T cell activity was ablated by combined antibody treatment against 
CD25 and glucocorticoid-induced TNF receptor family-related gene (GITR), were able 
to reverse hyporesponsiveness and overcome an established infection, leading to 
clearance of filarial parasites (Maizels and Yazdanbakhsh 2003, Taylor et al. 2005). 
However, neutralization of IL-10 receptor or depletion of Foxp3 CD25 Treg cells alone 
wereunable to restore the ability of the immune system to expel parasites (Taylor et al. 
2005, Taylor et al. 2007). Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade in 
human PBMC cultures switches the unresponsive state, increases TH2 cytokine 
production and reduces anergy-inducing factors expression in filariasis patients (Babu 
et al. 2006). Thus, these data suggest that during chronic helminth infection, CD4+ T 
cells develop both intrinsic antigen specific hyporesponsiveness/ tolerance, and 
expanded regulatory T cell activity, in both human and mouse models, thereby 
mediating two levels at which filarial parasites suppress host immunity.  
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Figure 1.5: Immunology of human infections with helminth. From Maizels and 
Yazdanbakhsh, 2003. 
1.2.2  Immune  evolution  of  helminths  parasites 
In order to protect themselves from elimination, long-lived helminth parasites have thus 
proved to be strong selective forces for immune evolution and to be able to (1) modify 
the bystander immune responses and also (2) downregulate the host immune system 
(Maizels and McSorley 2016). 
1.2.2.1  Modifying  the  bystander  immune  responses  
It has been noted since 1968 that autoimmune disorders, such as rheumatoid arthritis, 
are much less frequent in developing countries due to the immunological disturbance 
by parasite infection (Greenwood 1968). It has been shown in the follow-up studies 
that mice and rats infected with rodent malaria were protected from autoimmune 
disease (Greenwood and Voller 1970, Greenwood, Herrick and Voller 1970). More 
recently, children infected with S. haematobium were detected to have lower levels 
of skin reactivity to allergen house-dust mite (HDM) than uninfected children (van 
den Biggelaar et al. 2000). Furthermore, it has been shown in the follow-up study 
that atopic reactivity to HDM increased in those schoolchildren who have reduced 
Ascaris and/or Trichuris infections after taking anthelminthic drugs (van den 
Biggelaar et al. 2004). Exposure to helminth immune modulation can even begin 
before birth, as it was reported that maternal helminth infections during gestation 
reduced infants’ allergen skin prick test reactivity to perennial allergens (Clark et al. 
2016). 
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Cases such as these are consistent with the so-called “Hygiene Hypothesis”, 
which was first postulated in 1989 (Strachan 1989), that increased exposure to 
microorganisms protected children from the development of allergy. Although Strachan 
considered only virus and bacterial infections, many subsequent commentators 
extended the “Hygiene Hypothesis” to postulate that helminth infections in low-income 
countries would reduce the development of allergic and autoimmune diseases (Versini 
et al. 2015). Using the paradigm proposed in the 1990s of opposing TH1 and TH2 
lymphocyte populations in the immune response (Mosmann and Coffman 1989) and 
the recognition that viral and bacterial infections induce a TH1 response, it was first 
thought that early-life exposure to virus and bacterial infections protected younger 
siblings in larger families from developing allergies such as hay fever (Strachan 1989, 
Strachan 2000). Thus, the young immune system may be “educated” away from 
excessive and allergy-promoting IgE mediated TH2 responses (Maizels, McSorley and 
Smyth 2014). It is difficult with this model to explain how helminth infection reduce 
allergy, as helminth infections generally drive the TH2 responses. However, it might be 
an answer that some autoimmune diseases are driven by TH1 responses, or by TH17 
cells, such as Type I diabetes, multiple sclerosis and Crohn’s disease. Following the 
principal that infectious agents can dampen inflammation in the mature immune 
system, helminth therapy is proposed to protect against autoimmune diseases (Maizels 
et al. 2014). Versini et al. 2015 summarized a list of the experimental and clinical 
studies utilizing live parasites or parasite antigen for various autoimmune diseases 
including Crohn’s disease, inflammatory bowel disease (IBD), multiple sclerosis (MS), 
rheumatoid arthritis (RA) and other diseases in either human or mouse (Versini et al. 
2015). For long term research, it may be more effective to identify the specific 
immunosuppressive molecule from these parasites. For example, the filarial-derived 
glycoprotein ES-62 has been characterized to be the most effective molecule in mouse 
models of RA (Pineda et al. 2014). However, such helminth-derived molecules have yet 
been used in RA clinical trials (Versini et al. 2015). 
Parasite helminths also alter immune responses to other agents. To take co-
infections with human filariasis as an example, filariae mediate immunomodulatory 
mechanisms and also change the protective immune responses to other parasites (e.g. 
malaria) and infectious microbes (e.g. tuberculosis) (Taylor et al. 2010). Filarial 
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infections suppress the cytokine response specifically against Plasmodium falciparum, 
reducing resistance to malaria in an IL-10-dependent manner (Metenou et al. 2009), and 
they diminish M. tuberculosis–specific TH1 and TH17 responses (Babu et al. 2009).  In 
addition, intestinal helminth infections are considered to potentially indirectly influence 
the immune response through the effects on the composition of the intestinal 
microbiome (Leung 2013). It has been shown that chronic infection with H. polygyrus 
favors specific types of commensal bacteria, especially members of the 
Lactobacillaceae family (Walk et al. 2010). Furthermore, it has been found interestingly 
that intestinal microbiota provide a platform for T. muris hatching eggs (Hayes et al. 
2010), suggesting intestinal helminths might alter resident microbes (Mishra et al. 
2014). 
In addition, helminth infections compromise disease prevention efforts, as they 
reduce vaccine responses. This has been shown, for example, in maternal parasitic 
infections with schistosomes, filarial worms and malaria during pregnancy can impair 
later immune responses by infants to childhood vaccinations (LaBeaud et al. 2009). 
Mice with S. mansoni infections (Elias et al. 2005) have decreased responses to BCG 
vaccination, humans with schistosomiasis (Sabin et al. 1996) or onchocerciasis (Cooper 
et al. 1998) have impaired tetanus-specific responses following tetanus toxoid 
vaccination.  
1.2.2.2  Downmodulation  of  host  immunity  
It is worth mentioning that helminths have co-evolved with their hosts for centuries; 
their goal is to survive as long as possible by dampening host immunity but not to 
kill their host. To accomplish this, helminths are able to finely down-modulate the 
function of various effector cell populations of host immunity to prevent recognition 
or activation that may lead to their elimination, while not creating too profound an 
immunosuppression which would lead to host death from infection. Currently, 
filarial parasites are thought to interfere in at least three different ways: 
1). Interference with antigen processing: Using the fluorogenic substrate 
preferentially cleaved by asparaginyl endopeptidase (AEP), the recombinant B. malayi 
cysteine protease inhibitor-2 (Bm-CPI-2) was found to inhibit the cysteine proteases 
AEP, which are required for antigen presentation (Manoury et al. 2001). Filarial 
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parasites also interfere with innate cell recognition through toll receptors (Semnani et al. 
2008). 
2). Cytokine mimicry: A homologue of the endogenous immunosuppressive 
cytokine TGF-β was found to be expressed by the filarial nematode B. malayi and was 
the first helminth cytokine discovered to interact functionally with host cytokine 
receptors (Gomez-Escobar, Gregory and Maizels 2000). Another set of helminth 
cytokines are the macrophage-migration inhibitory factors (MIFs). Bm-MIF-2 was 
shown to have extremely similar structure to human MIF, and to induce similar 
responses from mammalian macrophages (Zang et al. 2002, Falcone et al. 2001, Prieto-
Lafuente et al. 2009). A related activity was found with the B. malayi abundant larval 
transcript-2 (ALT-2) protein that is secreted by infective larvae, and shown to activate 
SOCS1 (suppressor of cytokine signaling-1), an inhibitor of IFNγ signalling (Gomez-
Escobar et al. 2005). 
3). Blocking efferent immune mechanisms and effector cells (Figure 1.6): Many 
of the other secreted products of filarial parasites are likely to modulate effector cells 
and their products. For example, it has been shown that the serpin secreted from 
bloodstream microfilariae of B. malayi, SPN-2, inhibits the enzymatic activity of the 
neutrophil proteases elastase and cathepsin G, encoded by the human host (Zang et al. 
1999, Maizels and Yazdanbakhsh 2003). Adult parasites of the same species secrete a 
wide range of proteins that have been identified (Hewitson et al. 2008) including 
galectin and triose phosphate isomerase. 
 
Figure 1.6: Blocking efferent immune mechanisms. From Maizels and Yazdanbakhsh, 2003. 
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1.3  Immune  evasion  genes  in  filarial  nematodes    
Because living nematode parasites do not replicate but are established for many 
months or years, it is presumed that immune evasion is accomplished by products 
which they express on their surface and/or which they release in vivo. Such released 
products may be modelled in vitro by cultivating live parasites and collecting their 
excretory-secretory products. The term “Excretory-Secretory (ES) products” is a 
long-standing parasitological term describing the assortment of molecules that 
parasitic helminths excrete or secrete into their hosts (Lightowlers and Rickard 
1988). The stage- and gender-specific ES products of helminths also include 
components such as digestive enzymes produced from the intestine by adult worms, 
or uterine contents released along with eggs, larvae or microfilariae by female worms. 
In addition, it has recently been established that along with soluble proteins and other 
macromolecules, many parasitic helminths release exosome-like extracellular 
vesicles (EVs) (Buck et al. 2014, Coakley, Maizels and Buck 2015). Extracellular 
vesicles can be released both by the intracellular parasites (either by endocytic 
pathways or are directly released from the plasma membrane), including Leishmania 
spp. and Trypanosoma cruzi (Gonçalves et al. 1991, Silverman et al. 2010), and also 
by extracellular pathogens, which providing a mechanism for the import of parasite 
cargo into host cells, including virulence factors from diverse protozoan parasites, 
such as Trypanosoma brucei and Trichomonas vaginalis (Szempruch et al. 2016, 
Twu et al. 2013). In the case of extracellular parasites, including helminths, the 
vesicles represent a previously unsuspected pathway by which the pathogens can 
influence the intracellular milieu of the host cells to which the vesicles are targeted. 
Each of these products may be associated with immune evasion strategies against the 
corresponding host (Hewitson, Grainger and Maizels 2009).  
Technically, researchers developed simple methods to collect the excretory-
secretory ES products for study, generally using serum-free medium with few 
supplements to avoid introducing extraneous components (such as serum proteins) into 
the preparation.  However, parasites vary dramatically in their ability to survive in such 
simple media, with adult filarial worms living no more than 1 week (Hewitson et al. 
2008). In contrast, it was found the intestinal nematode H. polygyrus survives for at 
least 3 weeks, as maintained in the Maizels laboratory (Johnston et al. 2015).  
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1.3.1  Adult  surface-­associated  proteins   
In 2001, Maizels et al. summarized information on the major surface and secreted 
proteins from different stages the adult, microfilariae and larval of filarial Brugia 
parasites, based on techniques such as surface labelling, molecular cloning and 
antibody immunoprecipitation (Maizels et al. 2001). Subsequently, high-throughput 
research technologies including secretome proteomics, mass spectrometry and 
transcriptome sequencing have been combined to mine potential diagnostic or 
vaccine candidates, as well as immune modulators in Brugia (Hewitson et al. 2008, 
Moreno and Geary 2008, Bennuru et al. 2009). An extensive list of secreted proteins 
has now been revealed for deeper understanding of how these parasites and each of 
their stages survive in their particular host.  
The major surface-associated proteins of adult B. malayi are Bm-GPX-1 
(glutathione peroxidase) and Bm-SOD (superoxide dismutase); both carry out important 
anti-oxidant functions. Bm-GPX-1 is also designated as gp29 because the major 
component is a 29kDa glycoprotein (Maizels et al. 1989). GPX may protect parasite 
lipid by neutralizing reactive oxygen intermediate attack, or modifying and removing 
host immunomodulatory lipids (Bennuru et al. 2009). Bm-GPX-1 was identified in ES 
from both female and male adult worms as well as microfilariae, but was revealed to be 
of much higher abundance in adults compared to the Mf stage, suggesting a more 
important role in adult survival (Moreno and Geary 2008). 
Superoxide dismutase (SOD), which is similarly involved in immune evasion of 
free oxygen radicals, was reported to be present in variable amounts among different 
stages. Moreover, two forms of B. malayi SOD were reported: a cytoplasmic form and 
an extracellular form (Ou et al. 1995). It was found that extracellular protein was 
detected at higher levels in adult male worms, whereas the cytoplasmic form was 
present to a similar degree in all stages. According to the protein fold and the metal 
cofactor, SOD is divided into three major families: the Cu/Zn type (binds both copper 
and zinc), Fe and Mn types (bind either iron or manganese), and the Ni type (binds 
nickel). B. malayi copper/zinc superoxide dismutase (Cu/Zn-SOD), the recombinant 
enzyme of which has 32kDa (Lee et al. 2005), appeared similar abundance in ESP 
among all stages from Moreno and Geary 2008 (Moreno and Geary 2008), whereas a 
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greater abundance was found in microfilariae than adult in Bennuru et al., 2009 
(Bennuru et al. 2009). 
1.3.2  Adult  Excretory-­Secretory  Proteins 
The recent proteomic studies of the ‘secretome’ of adult B. malayi has revealed a wider 
range of potential immunomodulatory molecules. Among these are galectins, triose 
phospate isomerase (TPI), leucine aminopeptidase (LAP) and macrophage migration 
inhibitory factor (MIF).  
Galectins are a family of evolutionarily conserved carbohydrate-binding 
proteins with many potential roles as regulators of immune cell homeostasis and host-
pathogen interactions (Rabinovich et al. 2002a, Rabinovich, Rubinstein and Toscano 
2002b). Bm-GAL-1 (Bm1_24940) was identified as a Galectin (galactoside-binding 
lectin, PF00337) which is one of the most abundant proteins in B. malayi adult 
excretory–secretory products (BES) (Hewitson et al. 2008). Blastp analysis of the Bm-
GAL-1 sequence showed high homologues to Loa loa, O. volvulus and Dirofilaria 
immitis, with 98%, 96% and 97% identity, respectively. It was also found that 89.42%, 
32.56% and 31.95% identity against Toxascaris leonina galectin, human galectin 9 (Hs-
GAL-9) and galectin 4 (Hs-GAL-4), respectively. Hs-GAL-9 was reported to suppress 
the generation of TH17, and promote the induction of regulatory T cells (Seki et al. 
2008). Moreover, Li et al. identified that N- and C-terminal CRD of Gal-9 have 
different functions, Gal-9-C was more potent in inducing T cell death while Gal-9-N 
was more potent in activating DCs, by inducing higher TNF-a and IL-6 
production/greater phosphorylation of p38 and AKT (Li et al. 2011). Zhu et al. 
proposed that murine Gal-9 binds to murine Tim-3 and Gal-9 is the ligand for Tim-3 
(Zhu et al. 2005, Zhu, Anderson and Kuchroo 2011). However, Leitner et al. obtained a 
contrasting conclusion that Gal-9 is NOT the ligand for Tim-3 (Leitner et al. 2013). 
Hewitson et al. found that Bm-GAL-1 is able to bind to host immune cells in a 
carbohydrate dependent manner. Both N- and C- terminal domains bind host cells 
through canonical CRD sites. Monoclonal antibody B37 blocks binding of the N-
terminal domain of Bm-GAL-1. Bm-GAL-1 potentiates TGF-b-dependent induction of 
Foxp3 (unpublished data), which potentially drive regulatory T cells in the host, helping 
parasites avoid the host immune response.  
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The glycolytic enzyme triose phospate isomerase (Bm-TPI, EC 5.3.1.1) has 
been revealed to be the most abundant ES protein of adult B. malayi, predominantly 
from female worms (Hewitson et al. 2008). TPI was also found in moulting L3 larvae 
early in infection by stage specific proteomic sequencing (Bennuru et al. 2009). It has 
been shown that polyclonal sera against TPI results in little inhibition of catalytic 
activity although TPI is a prominent target of the antibody response to infection. The 
follow-up study by Hewitson et al. demonstrated that two of twenty-three anti-TPI 
monoclonal antibodies produced in the laboratory were able to block TPI enzymatic 
activity. It has been further shown that immunization of jirds with Bm-TPI was not able 
to induce neutralising antibodies. However, passive transfer of neutralising mAb to 
mice before adult B. malayi implantation lead to 60-70 % reductions in the number of 
microfilariae produced by female worms, suggesting TPI plays an important role in the 
transmission cycle of B. malayi and is considered to be a potential drug target against 
filarial infections (Hewitson et al. 2014). 
 Leucine aminopeptidase (LAP; also named as ES-62) was identified to be an 
abundant phosphorylcholine containing glycoprotein, secreted by Acanthocheilonema 
viteae adult worms (Harnett et al. 1999). A homolog in B. malayi is detected to be 
secreted by L3s molting to L4s and also by adult worms (Hewitson et al. 2008, Bennuru 
et al. 2009). Interestingly, it has been demonstrated that ES-62 in A. viteae is heavily 
decorated with phosphorylcholine (PC) (Harnett, McInnes and Harnett 2004), while the 
ES-62 homologue in B. malayi is not conjugated to PC. This was demonstrated by 
western blotting with anti-PC monoclonal antibody, the B. malayi molecule was 
designated PC-free ES-62 (Hewitson et al. 2008). PC is a pathogen-associated 
molecular pattern (PAMP) expressed by a wide range of disease-causing agents, 
including bacteria, fungi and protozoa, as well as gastrointestinal and filarial nematodes 
(Harnett and Harnett 1999). Despite the fact that it enables recognition of pathogens by 
the host (via antibodies or C-reactive protein), it can also help pathogen survival by 
modulating host immunity (Harnett, Melendez and Harnett 2010). However, so far, no 
studies have shown PC from Brugia is playing a role in immune evasion. 
 Macrophage migration inhibitory factor (MIF) from filarial parasites has been 
discovered with striking structural similarities to the mammalian cytokine (Maizels et 
al. 2001). In B. malayi the two homologues are Bm-MIF-1 and -2. Bm-MIF-1 is present 
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in all 3 stages of worms and both genders, whereas MIF–2 is detected in the ES of the 
moulting L3 and also in the adult stage (Moreno and Geary 2008, Bennuru et al. 2009).  
1.3.3  Microfilariae  Excretory-­Secretory  Protein   
In two proteomic studies of the microfilarial ES products, endochitinase and serpin 
were both reported to be abundant proteins at this developmental stage (Moreno and 
Geary 2008, Bennuru et al. 2009). Chitinases are essential for chitin degradation during 
moulting of larval filariae and hatching of microfilariae (Moreno and Geary 2008, 
Tachu et al. 2008) and have been suggested as candidate vaccine antigens (Fuhrman et 
al. 1992, Raghavan et al. 1994). The serine protease inhibitor (serpin) Bm-SPN-2 was 
also found to be specifically secreted by the microfilarial stage (Zang et al. 1999, 
Moreno and Geary 2008). Serpins expressed by parasitic nematodes are thought to help 
parasites avoid host immune defenses. Zang and Maizels and Molehin et al. have 
summarized the parasite serpins and smapins (Zang and Maizels 2001, Molehin et al. 
2012) (Table 1.1).  
Moreno and Geary suggested that the function of many microfilariae secreted 
proteins would be to regulate enzyme activity (Moreno and Geary 2008). Notably, 
many Mf secreted proteins are associated with protease inhibition, and in addition Mf 
secrete a different set of protease inhibitors compared to adults. For example, as well as 
SPN-2, Mf secrete more cysteine protease inhibitor-2 (Bm-CPI-2) than adults (Bennuru 
et al. 2009), and this product inhibits activities of multiple cysteine proteases required 
for antigen presentation, found in the endosomes/lysosomes of human B lymphocyte 
lines (Manoury et al. 2001).The release of protease inhibitors may be related to the 
ability of filarial nematodes to dampen host immunity (Hewitson et al. 2008, Hartmann 
and Lucius 2003), and differential expression by life cycle stages is most likely due to 
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 Ascaris suum As-SPN    Human 
antithrombin III 
AW165870 
B.malayi Bm-SPN-1 44kDa Secretory All life cycle 
stages 
Unknown (Yenbutr and Scott 
1995) 
B.malayi Bm-SPN-2 47·5 kDa Secretory Microfilariae Neutrophil 
elastase, 
cathepsin G 
(Zang et al. 1999) 
Zang et al. (1999); 
Zang et al. (2000) 
Haemonchus 
contortus 
Hc-serpin 63 kDa Intracellular Adult/gastrointestinal 






(Yi et al. 2010) 
Onchocerca 
volvulus 
















Ts11−1 42 kDa Intracellular Muscle larvae Trypsin (Nagano et al. 2001) 
Trichostrongylus 
vitrinus 








and Knox 2005) 
Trematode serpins 
 
S. haematobium Sh serpin 46·2 kDa Surface Adult worm 
tegument 
Unknown (Blanton, Licate and 
Aman 1994) 
Li et al. (1995) 
S. mansoni Smpi56 56 kDa  Adult worms Neutrophil and 
pancreatic 
elastase 
(Ghendler, Arnon and 
Fishelson 1994) 
S. mansoni Contrapsin 68 kDa Surface and 
intracellular 
Male adult worms Trypsin (Modha and Doenhoff 
1994) 
S. japonicum Sj serpin 45·2 kDa Surface Intestinal/epithelium 
of adult worms and 
cercariae 
epithelium of 




(Yan et al. 2005) 
S. japonicum SjB6 60 kDa secretory intra-mammalian 
stage of the parasite 
life cycle 
Unknown (Molehin et al. 2014) 
Clonorchis 
sinensis 
CsproSERPIN 42·2 kDa Intracellular Metacercariae Unknown (Yang et al. 2009) 
Clonorchis 
sinensis 
CsSERPIN 44 kDa Intracellular All life cycle 
stages 
Chymotrypsin (Kang et al. 2010) 
Paragonimus 
westermani 





















12 kDa Secretory Protoscoleces 
/germinal layer 













Anisakis Simplex ASPI-1    Elastase (Lu et al. 1998, Nguyen 
et al. 1999) 
Anisakis Simplex ASPI-2    Elastase (Lu et al. 1998, Nguyen 
et al. 1999) 
Ancylostoma 
caninum 
AcAP5    Factor Xa, XIa (Stassens et al. 1996) 
Ancylostoma 
caninum 
AcAP6    Factor Xa (Stassens et al. 1996) 
Ancylostoma 
caninum 
AcAPc2    Factor VIIa/TF (Stassens et al. 1996) 
Ascaris suum ICE1    Chymotrypsin, 
elastase 
(Huang et al. 1994) 
Ascaris suum ICE2-5    Chymotrypsin, 
elastase 
(Huang et al. 1994) 
Ascaris suum ITR1    Trypsin (Grasberger, Clore and 
Gronenborn 1994) 
Ascaris suum ITR2    Trypsin (Grasberger et al. 1994) 
Onchocerca 
volvulus 












(Rhoads et al. 2000a) 
 
Trichuris suis Ts-TCI    Chymotrypsin, 
trypsin  
(Rhoads, Fetterer and 
Hill 2000b) 
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1.4  Type  2  immunity  and  IL-­33  
1.4.1  Helminths  induce  TH2  responses 
Epithelial cells (ECs) provide the very first barrier in the host against environmental 
pathogens, as well as commensal bacteria and inhaled or ingested antigens (Figure 
1.7). ECs can recognize these via a number of different mechanisms. They can 
express pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) 
(Abreu 2010) to respond to not only type-1 associated ligands, but also type-2-cell-
mediated stimuli (Hammad and Lambrecht 2015). Thanks to the expression of 
protease-activated receptors (PARs), they can also recognize proteases produced by 
pathogens to gain entry into host tissues (Chiu et al. 2007, Park et al. 2011). PARs 
belong to a subfamily of G protein-coupled receptors, including four members PAR-
1, PAR-3, and PAR-4 (activated by thrombin) and PAR-2 (activated by trypsin) 
(O'Brien et al. 2001, Macfarlane et al. 2001). It was suggested that PAR2 is a 
recognition receptor for the N. brasiliensis proteases, trypsin and trypsin-like 
enzymes (Devlin, Gasser and Cocks 2007). Experiments with PAR2 deficient mice 
has shown that T. spiralis infection could not evoke TH2 responses characterized by 
markedly low level of TH2 cell-secreted cytokines IL-4, IL-5, and IL-13 (Park et al. 
2011). 
Barrier ECs mount a set of prototypical innate cytokines such as interleukin-1 
(IL-1), IL-25, IL-33, and thymic stromal lymphopoietin (TSLP), as well as the 
danger-associated molecular patterns (DAMPs) or alarmins, uric acid (UA), ATP, 
High Mobility Group Box 1 (HMGB1), and S100 family proteins, that activate a 
range of target cell populations, including dendritic cells (DCs) to promote adaptive 
TH2 cell immunity (Hammad and Lambrecht 2015). 
Type 2 innate lymphoid cells (ILC2s), previously named “nuocytes”, are 
another innate cell population discovered to respond in vivo by expansion after 
administration of IL-25, IL-33, and TSLP (Fallon et al. 2006, Neill et al. 2010, 
Saenz, Noti and Artis 2010, Salimi et al. 2013). ILC2s have been shown to be 
required for the induction of type 2 immune responses, producing IL-5 and IL-13 
long before TH2 cells (Fallon et al. 2006). IL-33 and IL-25 can induce different 
types of ILCs. It has been shown that IL-33 can induce ILC2s while IL-25 prefers to 
elicit multi potent progenitor (MPP) type 2 cells (Saenz et al. 2010). However, ILC2s 
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and TH2 cells interact repeatedly in promoting type 2 immune responses and 
contributing to helminth expulsion, reflecting an ongoing dialogue between the 
innate and adaptive arms of the immune system (Oliphant et al. 2014, Huang et al. 
2015). 
Multiple effects occur subsequently in response to IL-4, IL-5 and IL-13 
produced by ILC2s and TH2 cells (Figure 1.7). In the intestinal and airway smooth 
muscle, IL-33 can cause hyper-contractility of the smooth musculature. In the gut, 
IL-13 promotes goblet cell differentiation and enhance mucin secretion, which is 
crucial for intestinal nematode rejection (Hasnain et al. 2011, Allen and Maizels 
2011). The intestinal epithelium also produces resistin-like molecule-β (RELMβ), 
which is an innate protein with direct anti-helminth activity that impairs the function 
of the worm chemosensory apparatus (Artis et al. 2004).  IL-4 and IL-13 also drive 
the alternative activation of macrophages (AAM) for immunity to parasites as 
demonstrated by their ability to trap tissue larvae of H. polygyrus (Anthony et al. 
2006). In the infected gut, mucosal mast cells expand and release mast cell proteases 
that can degrade tight junctions, increasing fluid flow as part of the “weep and 
sweep” response that aids in parasite expulsion (Allen and Maizels 2011).  
In the non-mucosal tissues, basophils produce high levels of IL-4 and 
significantly amplify type 2 responses during helminth infection (Ohnmacht et al. 
2010). In tissues such as the lung and intestinal lamina propria, IL-4Rα-dependent 
alternative activation of macrophages induces the production of arginase 1, chitinase 
3-like proteins 3 (YM1) and 4 (YM2) and RELMα. While the function of YM-
1/YM-2 and RELMα is less clear, the latter has been reported to mediate a feedback 
inhibition of TH2 responses in vivo (Chen et al. 2016). 
In humoral immunity, TH2 cells and the type 2 cytokines are integral to the 
induction of the antibody class switch to IgG1, IgE and IgG4 (in humans) isotype 
antibodies in B cells (Xu et al. 2012).  
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Figure 1.7: Type 2 immune response induced by helminth.  
Upon helminth infection, the host immune system is activated, alarmin cytokines like IL-33 
induce ILC2s and DCs to initiate TH2 cell differentiation. The type 2 immune response 
activates a range of diverse cell types, including mast cells, eosinophils, basophils, 
neutrophils and macrophages, which differentiate into alternatively activated macrophages. 
In humoral immunity, the class switch of B cells to IgG1, IgG4 or IgE is induced. In addition, 
the airway and intestinal smooth muscle cells and the mucosa are activated to help expulsion 
of parasites. Ig, immunoglobulin; IL, interleukin; ILC2: Type 2 innate lymphoid cell; DC: 
Dendritic Cell; YM-1, chitinase-like secreted protein (adapted from Allen and Maizels, 2011 
and Kemter PhD thesis). 
 
The main function of IgE is immunity against helminth parasites (Erb 2007) 
such as Trichinella spiralis (Watanabe, Bruschi and Korenaga 2005) and Fasciola 
hepatica (Pfister et al. 1983). IgE is able to kill schistosome larval stages via 
antibody-dependent cellular cytotoxicity mechanisms (Fitzsimmons et al. 2007), and 
is involved in vaccine-mediated protection against larval Onchocerca volvulus in 
mice (Abraham et al. 2004). IgE is also utilized during immune responses against a 
few protozoan parasites such as Plasmodium falciparum (Duarte et al. 2007). 
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Moreover, IgE plays an essential role in type I hypersensitivity (Gould et al. 2003), 
which manifests in a wide range of allergic diseases: allergic asthma, food allergies 
and atopic dermatitis and so on. Beside this, IgE also plays an important role in 
responses to allergens. 
1.4.1.1  Mast  cells  
Mast cells originally develop in the bone marrow, then migrate as immature 
precursors to peripheral tissues, especially skin, intestine and airway mucosa where 
they mature. Mast cells are considered to play at least three important roles in host 
defense. First, their location close to body surfaces allows them to recruit swarms of 
cells both pathogen-specific (such as antigen-specific lymphocytes) and nonspecific 
effector cells (such as neutrophils, macrophages, basophils and eosinophils) to sites 
where infectious agents are most likely to enter. Secondly, the flow of lymph (from 
sites of antigen deposition to the regional lymph nodes) is increased by the 
inflammation they cause, activating naive lymphocytes as soon as possible. Thirdly, 
mast cell products are able to trigger muscular contraction, contributing to the 
physical expulsion of pathogens from the lungs or the gut (Murphy and Weaver 
2016). 
Mast cells and IgE can work together and enhance host resistance to parasites 
(Galli and Tsai 2010). It was demonstrated that both mast cells and intact IgE are 
required for better resistance to a secondary infection of the skin of WBB6 F1-W/Wv 
mice with larval Haemaphysalis longicornis ticks (Matsuda et al. 1990). Mast cells 
also play a role in the clearance of intestinal parasites by the accumulation of mast 
cells in the intestine, known as mastocytosis, that accompanies helminth infection. 
The W/Wv mutant mice, which have a profound mast-cell deficiency caused by a 
mutation in the gene c-kit, show impaired clearance of the intestinal nematodes 
Trichinella spiralis (Knight et al. 2000) and Strongyloides species (Abe and Nawa 
1987, Lantz et al. 1998). 
Mouse mast cells, enhanced by TH2 cells, constitutively express ST2 (IL-33 
receptor). Mast cell secreted proteases can cleave human and murine IL-33 into 
mature forms, and this will be discussed in more detail in section 1.4.4. 
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1.4.1.2  Eosinophils    
Eosinophils are enhanced by TH2 cells. During the defense against certain types of 
multicellular parasites, particularly helminths, host immunity is strongly associated 
with IgE production and the presence of many eosinophils (eosinophilia) in blood 
and tissues. Depletion of eosinophils in mice using polyclonal anti-eosinophil serum 
enhances the severity of infection with Schistosoma mansoni (Mahmoud, Warren 
and Peters 1975). In some cases, eosinophils induced by IL-5 play an important role 
in the termination of the parasites too large to be engulfed and seem to be directly 
responsible for helminth expulsion: examination of infected tissues shows 
accumulated and degranulated eosinophils adhering to helminthes larvae (Moqbel 
1980, Lange et al. 1994), and in vitro experiments have shown that “fully activated” 
eosinophils can kill S. mansoni in the presence of anti-schistosome IgG (IgG1 and 
IgG3) antibodies (Khalife et al. 1989). However, eosinophils are suggested to 
preserve parasite growth and survival (e.g. Trichinella spiralis) by promoting 
accumulation of TH2 cells and preventing macrophage and neutrophil induction of 
NO synthase (Gebreselassie et al. 2012). 
1.4.1.3  Neutrophils  with  helminths  infection  
Neutrophils, formed from stem cells in the bone marrow, are the most abundant type 
of granulocytes and the most numerous type of white blood cells, and with a short 
lifespan of only 6–8 hours (L Makepeace et al. 2012). Neutrophils are known to be 
involved in “Type 3” responses characterized by the actions of group 3 ILCs (ILC3), 
TH17 cells, opsonizing IgG isotypes and responding mainly to extracellular bacteria 
and fungi. However, back in 2000, neutrophils were found to mediate worm control 
in murine filariasis and this neutrophil accumulation was IL-5 dependent (Al-Qaoud 
et al. 2000). Recently, two further studies have shown that neutrophils are involved 
in helminth expulsion (Chen et al. 2014, Sutherland et al. 2014). It has also been 
suggested that neutrophils can sense the size of pathogens and could release 
neutrophil extracellular traps (NETs) upon large pathogens, enabling neutrophils to 
help catch and kill them (Branzk et al. 2014). 
1.4.2  IL-­33  Initiates  Type  2  Immune  Responses 
IL-33, is an alarmin cytokine, it is stored in the nucleus of endothelial cells and 
epithelial cells. During programmed cell death (apoptosis), IL-33 is cleaved by 
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caspases into an inactivated form, whereas in contrast it is released as an active full-
length (FL) protein during necrosis. Serine proteases, cathepsin G and elastase 
secreted by recruited neutrophils, are able to cleave FL-IL-33 resulting in a mature 
product with approximately 10-fold higher bioactivity. Mature bioactive IL-33 then 
initiates a type 2 and/or inflammatory response from a range of target cell 
populations expressing the IL-33R (in mice designated as T1/ST2) in Figure 1.8 
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1.4.3  IL-­33 
Interleukin-33 is the latest member of the IL-1 cytokine family, discovered originally 
as a nuclear factor present in endothelial cells, and first designated NF-HEV (nuclear 
factor from high endothelial venules)(Girard et al. 2003). Two years later, it was re-
identified as the extracellular ligand for the prominent orphan IL-1 receptor ST2, and 
named IL-33 (Schmitz et al. 2005). Healthy mice and human share constitutive IL-33 
expression, primarily in nuclei of non-hematopoietic cells (Schmitz et al. 2005), most 
abundant in epithelial and endothelial cells (Moussion, Ortega and Girard 2008, 
Pichery et al. 2012). The major target cells of IL-33 are the innate lymphoid cells 
type 2 (ILC2) which are involved in the initiation of T helper cell 2 (TH2) immune 
responses, but many other immune system cells from macrophages to memory TH2 
cells express ST2 and can respond to IL-33 (Lefrançais and Cayrol 2012). 
1.4.4  IL-­33  Mature  process  by  proteases   
Full-length murine and human IL-33 are transcribed from seven coding exons, which 
express an approximately 32-kDa protein of 266 and 270 amino acids, respectively 
(Molofsky, Savage and Locksley 2015). Exons 1–3 encode the N-terminal domains 
(amino acids 1-109 in mouse; 1-95 in human) required for IL-33 nuclear localization, 
whereas exons 4–7 (amino acids 109–266 in mouse, 95-270 in human) encode the C-
terminal IL-1-like cytokine domain, which binds to the IL-33 receptor ST2, thus 
facilitating recruitment of IL-1RAcP to induce the canonical NF-kB signalling 
pathway(Carriere et al. 2007). 
Other members of the IL-1 family such as IL-1β and IL-18 have to be cleaved 
from their pro-forms by caspases in order to be active and to initiate signalling via IL-
1/IL-18R. Interestingly, IL-33 is a divergent member of the IL-1 family as other 
members are cleaved and activated by caspase-1 while the N-terminal portion of IL-33 
does not require cleavage by caspase 1 for release from the cell nucleus or to bind to 
their receptor (Cayrol and Girard 2009). In contrast, if the C-terminal IL-1- like domain 
of IL-33 is processed by apoptotic caspase-3 and caspase-7, the result is to inactivate 
IL-33, and ablate its ability to bind the ST2 receptor (Cayrol and Girard 2009, Lüthi et 
al. 2009). 
IL-33 is also distinct from other members of the IL-1 family, as it is reported 
that full-length human IL-331-270 is active (unlike IL-1β and IL-18) (Cayrol and Girard 
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2009) but activity is greatly enhanced when cleaved by inflammatory cell neutrophil 
serine proteases cathepsin G and elastase (Lefrançais et al. 2012). Using a combination 
of in vitro and in vivo approaches, Lefrançais et al. demonstrate that full-length human 
IL-331-270 is cleaved into mature forms IL-3395–270, IL-3399–270, and IL-33109–270 
approximately 18 and 21 kDa in size, processed by these two neutrophil serine 
proteases. These forms have a 10-fold higher potency than full-length IL-33 in cellular 
assays or to activate ST2. They found murine neutrophil cathepsin G and elastase can 
also cleave full-length murine IL-33 into mIL-33102-266 with 20kDa, and detected both 
full-length and cleaved endogenous IL-33 in the bronchoalveolar lavage fluid (BAL) in 
an in vivo model of acute lung injury associated with neutrophil infiltration. 
Furthermore, they suggested that independently active full-length IL-33 might act as an 
endogenous danger signal or alarmin to alert cells of the innate immune system to tissue 
damage during trauma or infection (Cayrol and Girard 2009, Lefrançais et al. 2012). 
It is worth noting that the central cleavage domain of IL-33 (amino acids 66–
111) might act as an important functional domain. It has been further studied that serine 
proteases, chymase and tryptase, secreted by activated mast cells cleave central domain 
of IL-33 for potent activation of group-2 innate lymphoid cells. Ex vivo experiments 
demonstrated that the mature forms of IL-33 produced by mast cell proteases were 30-
fold more effective than FL-IL-33 for activation of ILC2s. By characterizing the level 
of IL-5 and IL-13 in vivo, it has been shown that these mature forms of IL-33 induced a 
strong expansion of ILCs and eosinophils. In addition, Lefrançais et al. demonstrated 
that mast cell tryptase also cleaves murine FL-IL-33 and IL-33-dependent allergic 
airway inflammation was reduced by a tryptase inhibitor in vivo (Lefrançais et al. 
2014). Table 2 summarizes, for human and mouse IL-33, the relevant enzymes, their 
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Table 2. Human and mouse IL-33 and their cleavage by different enzymes	  
Full-length 
IL-33 
Enzymes Cleavage fragments Activity  Reference 
Human IL-
33 1-270 
Caspase-1 112-270 Inactivated Schmitz et al. 2005 
Caspase-1 &3 1-178, 179-270 Inactivated Cayrol and Girard,2009; 
Martin and Martin,2016   
Cathepsin G 
(neutrophils) 
95-270 & 109-270 10 fold  Lefrancais et al. 2012 
Elastase 
(neutrophils) 
99-270 10 fold 
Chymase 
(mast cells) 








111-270 Not known 
Mouse IL-33 
1-266 
Caspase-1 &3 176-266 Not known Cayrol and Girard, 2009 
 Neutrophil 
Cathepsin G 
102-266 Not known Lefrancais et al. 2012 
 Neutrophil 
Elastase 
102-266 & 109-266 Not known 
Tryptase 
(mase cells) 
Not known Not known Lefrancais et al. 2014 
 
1.4.5  IL-­33/ST2  signaling   
The IL-33 receptor ST2, expressed by T helper 2 (TH2) cells and mast cells, has two 
forms including a soluble form (sST2) and a longer membrane-bound receptor form 
(ST2L) (Molofsky et al. 2015). IL-33 is a nuclear cytokine in vivo, which is always 
found in the nucleus of cells expressing the protein in both human and mouse tissues 
(Pichery et al. 2012, Moussion et al. 2008, Cayrol and Girard 2014). During cell 
damage or mechanical injury associated with necrosis or necroptosis (a form of 
“programmed necrosis”, a new model of cell death, shown the morphological 
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features of necrosis but highly regulated by an intracellular protein platform like 
apoptosis (Vandenabeele et al. 2010), biologically active full-length IL-33 is released 
from the nucleus into the extracellular environment. Once released into the 
extracellular spaces, full-length IL-33 can be further processed by serine proteases, 
such as neutrophil cathepsin G, elastase and mast cell chymase and tryptase into 
mature bioactive forms. sST2 binds free IL-33, decreases the concentration of IL-33 
and restricts its availability for ST2L binding. Both full-length and cleaved mature 
IL-33 bind to ST2L in combination with the IL-1 receptor accessory protein (IL-
1RAcP) on target cells, to activate NF-kB and mitogen-activated protein kinase 
(MAPK) signalling pathways leading to cellular activation and proliferation (Figure 
1.9). The myeloid differentiation factor 88 (MyD88) and downstream TNF receptor-
associated factor 6 (TRAF-6) are both required for intact IL-33 signaling (Kakkar 




Figure 1.9: IL-33/ST2 signalling. From Molofsky et al, 2015. 
 
1.4.6  IL-­33  and  helminth  infection 
Previous findings show IL-33 is critically involved in developing the initial TH2 
response to helminth infections, and peak expression was observed at early time 
points, indicating that prompt release of the alarmin cytokine IL-33 is a potent signal 
for type 2 response initiation. 
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In the mouse, infection with Nippostrongylus brasiliensis (Moro and Koyasu 
2010), S. mansoni (Townsend et al. 2000) and T. muris (Humphreys et al. 2008) each 
cause IL-33 release and activation of ILC2s and TH2 cytokine production. Using IL13-
eGFP reporter mice in the absence of IL25 and IL33 signaling, nuocytes were unable to 
expand, leading to a defect in expulsion of N. brasiliensis (Neill et al. 2010); In IL-4 
and IL-13 reporter mice, lineage-negative innate cells, which arise during type 2 
immunity or in response to IL-25 and IL-33 in vivo, expand robustly in response to 
exogenous IL-25 or IL-33 and after infection with N. brasiliensis (Price et al. 2010), 
suggesting that IL-33 might cooperate with the parasite-induced TH2 cells or other 
epithelial cytokines, including IL-25, to mediate helminth worm expulsion. ST2 
deficiency but not MyD88 deficiency in mice significantly alter larval burdens in the 
muscle tissue after T. spiralis infection, which suggests IL-33 signaling limited worm 
encystation in muscle (Scalfone et al. 2013).  
Administration of exogenous IL-33 leads to worm expulsion of H. polygyrus 
(Yang et al. 2013), N. brasiliensis (Bouchery et al. 2015), Strongyloides venezuelensis 
(Yasuda et al. 2012), and T. muris (Humphreys et al. 2008). Exogenous IL-33 treated 
mice were successful at expelling worms, expulsion of which was associated with the 
development of a protective TH2 response with increased expression of TH2 cytokines 
IL-4, IL-9, and IL-13, elevated goblet cell numbers, and increased levels of serum IgE 
(Humphreys et al. 2008). 
Further studies utilizing IL-33R-deficient mice supported the role for IL-33 in 
the promotion of TH2 cytokine responses. IL-33R-deficient mice (ST2−/− mice), which 
lack the extracellular domain common to both the soluble sST2, the membrane-bound 
form ST2L and thus lack the IL-33 signaling pathway. 
Townsend et al. demonstrated that ST2−/− mice failed to induce a TH2 
response in vivo and form granulomas after intravenous injection of S. mansoni eggs 
(Townsend et al. 2000). Mice lacking the IL-33 signaling pathway were observed to 
have a defect in the induction of type 2 responses to helminth parasites and are more 
susceptible to infection with L. sigmodontis (Ajendra et al. 2014), N. brasiliensis (Hung 
et al. 2013), and T. spiralis (Scalfone et al. 2013). Using L. sigmodontis infected mice, 
the absence of ST2 was proven to lead to significantly increased levels of peripheral 
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blood microfilariae, the filarial progeny, whereas adult worm burdens were not affected 
(Ajendra et al. 2014). 
Thus the IL-33 signaling pathway is likely to be a primary target for parasitic 
helminth immunomodulation, to allow continuous infection and re-infection. In fact, it 
was recently demonstrated that the excretory/secretory products of H. polygyrus (HES) 
significantly inhibit the IL-33 pathway, both by suppressing IL-33 release (McSorley et 
al. 2014) and by suppressing expression of the IL-33 receptor IL1RL1/ST2 (Buck et al. 
2014) resulting in decreased type 2 cytokine responses and ablated inflammation in a 
mouse model of asthma. Further studies revealed that the functional parasite secreted 
protein Hp-ARI (Alarmin Release Inhibitor) was able to profoundly inhibit IL-33, by 
binding both mouse IL-33 and human IL-33, and tethering it within the cell, preventing 
release (Osbourn et al. 2017). Whether these pathways of immunomodulation are 
common to numerous parasitic helminths, or unique to the chronically infective H. 
polygyrus, remains to be researched (Maizels and McSorley 2016). 
1.5  Hypotheses  and  aim  of  this  thesis    
Can   Bm-­SPN-­2   block   IL-­33   cleavage   processed   by   neutrophil  
cathepsin  G  and  elastase?  
It is mentioned above that full-length human IL-331–270 is cleaved into 10-fold higher 
activity mature forms IL-3395–270, IL-3399–270, and IL-33109–270 processed by 
neutrophil serine proteases cathepsin G and elastase, as well as mouse IL-33. 
Furthermore, independently active full-length IL-33 might act as an endogenous 
danger signal or alarmin to alert cells of the innate immune system to tissue damage 
during trauma or infection (Cayrol and Girard 2009, Lefrançais et al. 2012). 
Based on all of the aforementioned information, the proposed hypothesis is that 
the function of Bm-SPN-2 is to inhibit human and murine full-length IL-33 cleavage 
into mature active IL-33 processed by murine and human neutrophil serine proteases 
(cathespin G and elastase), thereby inhibiting the host alarm signal. 
 
Can  Bm-­SPN-­2  inhibit  TH2  initiation?  
It was reported by two independent laboratories that injecting live Mf intraperitoneally 
into mice first induces a TH1 immune response; splenocytes restimulated with parasite 
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antigen showed enhanced IFN-g production and reduced quantities of the TH2-type 
cytokines IL-4 and IL-5 (Pearlman et al. 1993, Lawrence et al. 1994). Also, a TH1 
response to intravenously administered Mf has been reported ((Lawrence, Allen and 
Gray 2000). On the contrary, a TH2-dominated response elicited when adult parasites 
were implanted. This pattern is unusual as most helminths - including adult B. malayi - 
are the prototypic inducers of TH2 responses (Allen and Maizels 2011).  
As the most abundant protein in ES of Mf, Bm-SPN-2 might play a role in 
boosting the TH1 immune response. The Maizels group revealed that mice infected 
with B. malayi Mf mounted a strong, but short-lived Bm-SPN-2-specific TH1 response 
with significant increases in IFN-γ production, but this was replaced by a TH2-
dominated response to other Mf antigens after 28 days (Zang et al. 1999, Zang et al. 
2000). 
Considering that Bm-SPN-2 drives TH1 responses in mice and IL-33 drives 
TH2 response (Schmitz et al. 2005), we infer that Bm-SPN-2 could inhibit TH2 
initiation by blocking IL-33 cleavage.  
Can  Mf  number  enhance  in  ST2  deficient  mice?  
Using L. sigmodontis infected mice, a recent paper reported that in the absence of ST2, 
the IL-33-specific subunit of the IL-33 receptor, led to significantly increased levels of 
peripheral blood microfilariae, the filarial progeny, whereas adult worm burden was not 
affected (Ajendra et al. 2014).This study demonstrated that ST2 is required to control 
the number of microfilariae but was not essential for the TH2 immune response.  
Considering that ST2 is the receptor for IL-33, it is interesting to repeat this 
experiment using wild type (WT) and IL-33R-deficient mice infected with B. pahangi 
microfilariae instead of L. sigmodontis. The number of microfilariae between WT and 
ST2 deficient mouse groups is counted. It is hypothesized that IL-33R deficiency will 
enhance the number of microfilariae compared to the WT group.  
 
Aim  of  this  thesis  
In this study, we aim to further understanding of the relationship between parasites and 
their host and the mechanisms by which microfilariae avoid host immune responses. 
The ultimate aim of this study is to evaluate if Bm-SPN-2 is a strong candidate for drug 
or vaccine development, on the basis of its immune function. 
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CHAPTER2  
Materials  and  Methods    
2.1  Cell  culture  
Human alveolar basal epithelial cells (A549 cells, a human lung cancer cell line, was 
first established in 1972 by D. J. Giard et al.) (Giard et al. 1973) were kindly 
provided by Henry McSorley, and cultured in Dulbecco's Modified Eagle Medium 
DMEM containing 10% FBS. 
Human embryonic kidney 293T (HEK 293T) cells were obtained from liquid 
nitrogen stocks of the Maizels lab. Cells were maintained in complete Dulbecco's 
Modified Eagle Medium DMEM high glucose containing 10% FBS (Thermo 
Scientific Hyclone No.: 30014.03), 5 ml Pen/Strep (stock 10,000 I.U. Penicillin and 
10,000 mg/ml streptomycin) Thermo Scientific Hyclone No.: SV30010) 5 ml L-
glutamine (stock 200 mM L-Glutamine, final concentration 1 mM) (Thermo 
Scientific Hyclone No.:SH30034.01) 
SP2 cells were also obtained from liquid nitrogen stocks of the Maizels lab, 
originally purchased from The European Collection of Authenticated Cell Cultures 
(ECACC). SP2 cells were growing in complete Roswell Park Memorial Institute 
(cRPMI) 1640.  
cRPMI=500ml RPMI+5ml L-Glutamine+5ml Penicillin/Streptomycin+50ml FBS. 
Hybridoma cells were cultured in complete hybridoma media: 
•500ml RPMI with 20% special FCS (Hyclone Fetalclone 1 SH30080.03) 
• 5ml Penicillin/Streptomycin and 5ml L-Glutamine 
• HAT (hypoxanthine-aminopterin-thymidine medium): Hypoxanthine 6.8 mg; 
Aminopterin 0.088 mg; Thymidine 1.94 mg for 500ml culture media. 
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• OPI Media Supplement Hybri-Max™: 0.15 g oxaloacetate, 0.05 g pyruvate, and 
0.0082 g insulin. Reconstitute contents of vial with 10 mL sterile water. Use 5ml for 
500ml culture media to make a final working concentration: 1 mM oxaloacetate, 0.45 
mM pyruvate, 0.2 U/ml insulin. 
Note: For monoclonal antibody purification from cells grown in flasks, hyclone 
special FCS in the medium was replaced with ultra low IgG fetal bovine serum 
(Thermo Scientific). 
 
The mast cell line MC/9 ATCC (CRL-8306) was kindly provided by 
Lefrançais et al. Cells were grown up in Dulbecco's Modified Eagle's Medium 
DMEM (ATCC 30-2002) with 4 mM L-glutamine adjusted to contain 4.5 g/L 
glucose and 1.5 g/L sodium bicarbonate and supplemented with 2 mM L-glutamine, 
0.05 mM 2-mercaptoethanol, 10% Rat T-STIM (Becton Dickenson Catalog No. 
354115) and 10% fetal bovine serum (FBS 30-2021). 
For mast cell stimulation experiment, cleaved or full-length IL-33 was mixed 
with 1 or 2x105 cells (in 96-wells plates, 200 µl/well) and incubated for 24h at 37°C. 
Supernatant was then harvested for IL-6 ELISA. 
All cells were grown at 37°C with 5% CO2 and 95% humidity. All cells were 
counted on a haemocytometer under Leica DM2000 LED microscope. 
2.2  Parasites  and  Experimental  Animals  
2.2.1  Parasites  
Brugia pahangi microfilariae were kindly provided by Professor Eileen Devaney, 
University of Glasgow. Jirds (Meriones unguiculatus) were infected with 250 Brugia 
pahangi L3; microfilariae (Mf) were recovered from the peritoneal cavity of infected 
jirds 4 months later. Microfilariae were washed extensively in Hanks’ Balanced Salt 
Solution (HBSS). Histopaque-1077 (Sigma) was used to purify Mf from host cells by 
density centrifugation at 1,000 RCF for 15 mins without brake (Osborne 1997).  Mf 
were then resuspended in HBSS and counted.   
2.2.2  Experimental  Animals  
Wild-type BALB/c mice and Sprague/Dawley rats were bred in house at the 
University of Edinburgh and accommodated according to Home Office regulations. 
Eight-week-old female BALB/c mice were utilized for the Alternaria airway allergy 
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model (see Section 2.3.1). Two male Sprague/Dawley Rats and two female BALB/c 
mice were immunized with Bm-SPN2 protein to generate polyclonal and monoclonal 
antibodies, respectively.  
T1/ST2 (IL-33 receptor, abbreviated to ST2) deficient mice (Townsend et al. 
2000) were bred and maintained at the University of Edinburgh animal facilities, 
kindly provided by Henry McSorley, University of Edinburgh. ST2-deficient mice 
and BALB/c mice were used for Brugia pahangi microfilariae infection experiments. 
2.3  In  vivo  procedures  
2.3.1  Alternaria  Airway  allergy  model  
: To test the effects of Bm-SPN-2 on allergy, in vivo experiments delivered 
Alternaria alternatus antigen (Greer) with or without Bm-SPN-2 by the intranasal 
route. 
Mice were lightly anaesthetised using isoflurane. 50 µl PBS containing 40 µg LPS-
depleted Bm-SPN-2 protein or 50 µl PBS alone was administered intranasally 0.5 
hour prior to PBS containing 50 µg Alternaria or 50 µl PBS alone (Figure 5.5A). 1 
hour later, mice were culled by cervical dislocation, and lungs were taken for further 
experimentation, including release of IL-33 measured by ELISA (section 2.8) and 
anti-IL-33 western blotting (section 2.5.3). 
2.3.2  Microfilariae  infection  experiment  
ST2-deficient and BALB/c mice were injected intraperitoneally (i.p.) with 150,000 
Brugia pahangi microfilariae (Mff). Uninfected ST2–/– and BALB/c mice were set as 
controls. Mice infected with microfilariae were sacrificed by terminal anaesthesia 
with CO2 on day 1 and day 6 post infection, uninfected mice were culled on day 6 
(the experimental plan is shown in Figure 5.8A). Peritoneal lavage of each mouse 
was performed by injecting 5 ml 4°C HBSS immediately after cull, the first three 
5ml peritoneal lavage were harvested for the Mff counting and ELISA analysis. 
Mesenteric lymph nodes (mLN) were collected into 1 ml RNAlater (Qiagen) and 
spleens were weighed, followed by cytokine ELISA of peritoneal lavage, real-time 
PCR of mLN and comparison of spleen weight. Microfilariae were harvested, 
purified and counted from peritoneal lavage to assess the effect of ST2 receptor 
deficiency on Mff infection. An in-house made glass chamber was used to count live 
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microfilariae from 20 µl samples. 
2.3.3  Polyclonal  and  monoclonal  antibody  production  against  Bm-­
SPN-­2  
2.3.3.1  Polyclonal  antibody  preparation  
Two rats were each immunized with 100 µg of Bm-SPN-2 in alum by intraperitoneal 
(i.p.) injection. In order to prepare antigen in Alum, 15ml Falcon was used. An 
amount of 200 µg Bm-SPN-2 was added into 1ml PBS. Step by step, 1ml of 9% alum 
and 2 drops of phenol red were added and mixed. Next, drops of 1M NaOH were 
added and mix well by vortex each time until colour is pretty luminous pink. The 
whole mix sample was placed onto a rotating mixer at room temperature for 30 
minutes. Finally, sample mix in 15ml falcon tube was centrifuged at 3000 x g for 10 
minutes and washed three times with PBS. The pellet was made up to 1ml with PBS, 
0.5ml mixture was injected per rat by i.p. Rats were boosted with 20 µg Bm-SPN-2 in 
alum i.p. 28 days later. A second boost was given with 20µg Bm-SPN-2 in alum i.p. 
one week later. Rats were bled out after another week. Blood was left in fridge 
overnight and allowed to coagulate. Sera was taken by directly collecting the fluid 
phase from the coagulated blood and stored at -80°C until use. 
2.3.3.2  Monoclonal  antibody  screening  
Two BALB/c mice were immunized by i.p. injection with 200 µl PBS containing 50 
µg of Bm-SPN-2 in Alum prepared as above. After 6 weeks, mice were boosted with 
Bm-SPN-2 without adjuvant by intravenously injection (i.v.) for 3 consecutive days 
with 200 µl PBS containing 1 µg Bm-SPN-2. Two days after the final injection, 
brachial bleeds were taken for polyclonal antisera and following euthanasia, spleens 
were recovered (workflow of injection is shown in Figure 5.1A). Immediately, 
spleens were mashed through a 70µm cell strainer using the plunger of a 1ml syringe 
and washed through with 10mls of culture media. Culture media contains: 500ml 
Roswell Park Memorial Institute RPMI (Gibco) 50ml FCS Gibco) 5ml L-glutamine 
Gibco) 5ml Pen-strep (Gibco) 50µl β-mercaptethanol (500mM stock). Cells were 
washed three times in 50 ml RPMI-1640 media with 0.5ml Penicillin-Streptomycin 
(P/S) at 350xg for 8mins each time. Cells were resuspended in 2mls of red blood cell 
lysis buffer (Sigma, #11814389001) and left to lyse for 3-5 minutes at RT. Cells were 
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then washed again with 50 ml RPMI, resuspended in 10ml RPMI and counted on a 
haemocytometer. 
In parallel, the mouse myeloma cell line Sp2/0-Ag14 (ATCC® CRL-1581™) 
(SP2) was cultured in cRPMI media; cells from T75 flasks were centrifuged at 350xg 
for 8mins and resuspended in 20 ml cRPMI and counted on a haemocytometer. For 
the fusion, immunized spleen cells and SP2 cells were mixed in 1:1 ratio, with 4x107 
of each. A traditional method of making hybridoma cells was applied, the whole 
strategy and workflow is shown in Figure 5.1. Polyethylene glycol (PEG) was added 
for cell fusion. 1ml of warmed 50% PEG 1500(w/v) PEG was added drop-wisely 
over a period 1 min whilst turning tube by vortex to achieve thorough mixing. Then 
1ml of RPMI was added by the same way. The total volume was brought up to 20ml 
with RPMI. Fused cells were centrifuged for 5 min at 500 xg. Cells were resuspended 
with 200ml complete hybridoma media (See section 2.1) 20% FBS and HAT 
selection medium and plate 150 µl of cell suspension to ten 96-well plates. Multiple 
hybridoma colonies were then incubated in 96-well plate at 37°C with 5% CO2. After 
10–14 d postfusion, hybridoma colonies can be observed in the 96-well plates. Wells 
may contain a single hybridoma colony or multiple hybridoma colonies derived from 
different independently fused B-lymphocyte/myeloma cells. ELISA screen against r 
Bm-SPN-2 was performed to select the desired well from the 96 wells, and limiting 
dilution desired wells with complete hybridoma media was followed to obtain clonal 
population x2 (takes ~2 weeks each). Another two ELISA screens against rBm-SPN-2 
were performed to select the final desired well. mAb isotype was determined by 
ELISA. ELISA was performed by coating rBm-SPN-2 and using mAb candidate as 
primary antibody and different secondary antibody IgG1-HRP, IgG2a-HRP, IgM-HRP, 
IgA-HRP or IgE-HRP, with sera from naïve mice as negative control and polyclonal 
antibody sera as positive control. 
2.3.3.3  IgG  monoclonal  antibody  purification  
Hybridoma cell lines which secreted ELISA-positive monoclonal antibodies were 
expanded into larger cultures in cRPMI (complete Roswell Park Memorial Institute 
1640 =500ml RPMI+5ml L-glutamine+5ml penicillin/streptomycin+50ml ultra low 
IgG foetal bovine serum) containing ultra low IgG foetal bovine serum (Thermo 
Scientific) in T175 flasks. Supernatants were harvested, filtered using a Thermo 
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ScientificTM NalgeneTM Rapid-FlowTM 75mm Filter Unit (0.2µm) and 1:1 diluted 
into 2x PBS binding buffer. A total of 250ml supernatant was loaded onto a HiTrap 
Protein G HP 5ml column (GE Healthcare) using a Minipuls 2 peristaltic pump 
(Anachem). 2ml fractions were eluted with 100% 0.1M glycine Elution buffer and 
collected into the neutralization buffer 1M Tris base pH9.0 using an AKTA Prime (GE 
Healthcare, Wisconsin, USA) together with the UNICORN software. Monoclonal 
antibody purification was confirmed by SDS-PAGE using NuPAGE® 4-12% Bis-Tris 
Gels and NuPAGE® MES SDS running buffer (Novex®, Life Technologies) and 
visualized by InstantBlue™ (expedeon). In addition, Mff extract and Bm-SPN-2 were 
loaded on a gel and transferred onto blot, the western blotting was then visualized by 
mAb candidates as primary antibody and polyclonal antibody sera as positive with 
1:2000 dilution and also anti-mouse immunoglobulins (P0260 by Dako) as secondary 
antibody.  
2.4  Gene  cloning  and  recombinant  protein  expression    
2.4.1  Bacteria  expression    
2.4.1.1  Expression  of  Bm-­SPN-­2  and  Bm-­SPN2-­mCherry  
 Bm-SPN-2 was expressed in (plasmid – pET29) that had been inserted with 
restriction enzymes NdeI and XhoI; for the work in this thesis Zang’s original 
protocol and plasmid were used (Zang et al. 1999). This construct used the initiator 
ATG of the NdeI site and omitted the signal peptide sequence of Bm-SPN-2 (Amino 
acid sequence and the structure of Bm-SPN-2 is shown in Figure 4.2A). 
mCherry-labelled Bm-SPN-2: Signal peptide depleted Bm-SPN-2 and 
mCherry were connected with three restriction enzymes NdeI at N-terminal, NotI 
and XhoI. Sequence was codon optimized for expression in Escherichia coli (E. coli) 
and synthesized by GeneArt (See Figure 4.4A). Inserts were reacquired by restriction 
enzyme double digestion using corresponding restriction enzymes according to the 
following protocol at 37°C over night.  
                        NdeI and XhoI Digest 
dH2O 14 µl 
DNA 1 µg or 10 µl 
CutSmart Buffer 3 µl 
restriction enzymes 1.5 µl each 
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The expression vectors pET29T, pET29c and pET29a vector (Invitrogen) are 
each linked to six histidine residues for nickel column purification and a kanamycin 
resistance gene for selection, was digested using the same protocol. Digested insert 
and vector were purified by DNA gel electrophoresis and the QIAquick® Gel 
Extraction Kit, and ligated by T4 DNA ligase (NEB) over night at 16 °C. 
E. coli bacterial cell line JM109 cells (Agilent Technologies) were 
transformed with the above corresponding plasmids by heat shocking 42°C for 45 
seconds before adding plasmid, and grown for one hour at 37 °C in 0.9 ml of S.O.C 
medium (Invitrogen). Colonies were grown overnight on LB agar containing 50 
µg/ml of kanamycin, then were expanded into 10ml LB containing the same 
concentration of antibiotic at 37°C. Plasmid purification was performed by Qiagen 
miniprep kit, primers for vector T7 promoter and T7 terminator (T7 promoter primer 
and T7 terminator primer are pET29a vector primer. The sequence of T7 promoter 
primer: 5’TAATACGACTCACTATAGGG3’; the sequence of T7 terminator reverse 
primer: 5’GCTAGTTATTGCTCAGCGG3’) were used for insert sequencing by The 
Gene pool, Universtiy of Edinburgh (http://genepool.bio.ed.ac.uk) and eurofins 
( http://www.eurofins.com ).  
BL21(DE3) E. coli (Novagen®) were then transformed with these plasmids in 
the above method. Colonies were grown overnight on kanamycin agar plates before 
expansion into 500 ml LB medium. To determine bacterial growth was in the 
exponential phase, regular OD600 readings were measured from 1 ml samples of the 
culture using a photometer (BioPhotometer Eppendorf, Hamburg, Germany). 0.5 ml 
of 1M inducer IPTG (isopropyl-1--D-galactopyranoside; Melford laboratories, 
Ipswich, UK) was added when OD600 reached 0.6. Bacterial cultures were then 
grown for three hours at 37 °C until further experiment. 
2.4.1.2  Purification  of  recombinant  protein    
Large culture pellets were resuspended in BugBusterTM Protein Extraction Reagent 
(Novagen). Cells were resuspended in 5 ml BugBuster per gram of wet cell paste. 
Resuspended cells were incubated on a rotating mixer for 20 min at room 
temperature. Supernatants were harvested by centrifugation 16,000 xg for 20 min at 
4°C, filtered and then loaded onto a 1ml HiTrapTM Chelating HP column (GE 
Healthcare) by a Minipuls 2 peristaltic pump (Anachem). The protein was eluted 
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with 100% His elution buffer using Akta Prime. The protein contents of each 1ml 
eluted fraction were determined by SDS-PAGE (section 2.3.3.3). One gel was 
directly stained by InstantBlueTM (expedeon) for 1 hour at room temperature. The 
other gel was then used to transfer separated proteins onto a nitrocellulose membrane 
(Bio-Rad) with NuPAGE® Transfer Buffer (20X), then the membrane was blocked 
with blocking reagent (Qiagen) and protein detected using anti-Penta-His HRP 
Conjugate (Qiagen). Bands were visualized with a FluorChemTM SP (Alpha 
Innotech) and PXi/PXi Touch Fluorescent & Chemiluminescent Imaging System 
from SYNGENE. Fractions containing protein of interest with little contamination 
were selected and and dialysed in 5 L PBS using Slide-A-Lyzer Dialysis Cassettes 
(Thermo Scientific) for 48 hours. The solution was then sterile filtered and 
concentration determined using the Bradford assay (section 2.4.3.1) and NanoDrop 
2000 (Thermo Scientific). More dilute fractions (<100 µg/ml) were concentrated 
using Vivaspin columns (5 kDa molecular weight cut-off; Sartorius Stedim Biotech, 
Aubagne, France). 
2.4.1.3  Depletion  of  endotoxin  from  E.  coli  expressed  protein    
Endotoxin was depleted using Triton X-114 as previously described (Liu et al. 1997). 
Briefly, 5 µl Triton X-114 was added to 500 µl protein solution at a final 
concentration of 1%, and the sample rotated for 45 minutes at 4°C to allow Triton 
binding to LPS. Samples were then heated to 37°C for 10 minutes to allow formation 
of Triton-LPS micelles. The aqueous layer was then harvested after centrifugation at 
13,000 xg at room temperature, and the whole procedure repeated another 2 times to 
further deplete LPS. The final protein concentration was determined also by the 
Bradford assay and Nanodrop. The Limulus Amebocyte Lysate (LAL) assay was 
used to measure the remaining endotoxin level. 
2.4.2  Mammalian  gene  expression  system  
2.4.2.1  Cloning  of  WT  hIL-­33,  mutant  hIL-­33  and  mIL-­33    
The coding sequences for the target proteins were acquired from the human and 
mouse database NCBI (https://www.ncbi.nlm.nih.gov). Primers were designed for 
human wild type IL-33 (Primer position is shown in Figure 3.2A):  
Forward primer (nt 1-30, starting at Gly-1, AscI GGCGCGCC was added at 
the 5 end) 5’-GGCGCGCCAAGCCTAAAATGAAGTATTC-3’ and Reverse primer 
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(nt 821-797, starting at Gly-273, ApaI GGGCCC was added at the 5 end) 5’-
GGGCCCAGTTTCAGAGAGCTTAAAC-3’. The A549 cell line was cultured for a 
substrate for mRNA to amplify the IL-33 coding sequence.  
To make mutant human and mouse IL-33, chromatin binding site amino acids 
L47, R48, S49 (‘LRS’) were each mutated to alanine residues (‘AAA’). The entire 
coding sequences were codon optimized for expression in mammalian system, 
flanked with restriction sites, using the GeneArt GeneOptimizer® tool 
(ThermoFisher Scientific) and synthesized by GeneArt. Inserts were extracted by 
restriction enzyme double digests using AscI and ApaI. 
 
              AscI and ApaI Digest 
dH2O 14 µl 
DNA 1 µg or 10 µl 
CutSmart Buffer 3 µl 
restriction enzymes 1.5 µl each 
 
The mammalian expression plasmid vector pSecTag2a with ampicillin 
resistance was digested also by AscI and ApaI; digestion products were purified and 
ligated at 16℃ overnight, catalyzed by NEB T4 DNA ligase (M0202). JM109 cells 
were transformed (section 2.4.1.1) with recombinant plasmid and selected by 
overnight culture on ampicillin agar plates, followed by colony screen PCR using T7 
promoter primer and BGH reverse primer (T7 promoter primer and BGH primer are 
pSectag vector primer. The sequence of T7 promoter primer: 
5’TAATACGACTCACTATAGGG3’; the sequence of BGH reverse primer: 
5’TAGAAGGCACAGTCGAGG3’). Positive colonies were subjected to DNA 
extraction and sequencing of insert. Clones of the verified insert were grown up in 
100 ml LB medium containing ampicillin and plasmid DNA extracted using the 
QIAfilterTM Plasmid Midi Kit (Qiagen), and stored at -20°C until HEK-293 cell 
transfection. 
2.4.2.2  Transfection  into  HEK-­293  cells  
The day before transfection, HEK-293T cells were counted and plated out at 8x105 
cells per tissue culture dish (100 mm) in 10 ml complete growth medium (complete 
Dulbecco's Modified Eagle Medium DMEM High Glucose containing 10% FBS 
(Thermo Scientific Hyclone No.: 30014.03), 5 ml Pen/Strep (stock 10,000 I.U. 
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Penicillin and 10,000 mg/ml streptomycin) Thermo Scientific Hyclone No.: 
SV30010) 5 ml L-Glutamine (stock 200 mM L-Glutamine, final concentration 1 
mM) (Thermo Scientific Hyclone No.:SH30034.01). Three hours before transfection, 
spent media was replaced. Five plates of cells were prepared for transfecting each 
construct. For each 100 mm plate, 20 µg DNA was first mixed well with dH2O (the 
volume of dH2O differs because different concentration of DNA batches), then 62 µl 
2M CaCl2 was added to a total volume of 500µl, and mixed again. In a tissue culture 
hood, this mixture was drop-wise added to 500 µl 2x HEPES-buffered saline (Sigma) 
while vortexing gently. After 30min incubation at room temperature, the transfection 
solution was vortexed briefly and the 1 ml volume distributed drop-wise across each 
plate. Plates were then returned at 37°C CO2 incubator for 24 hours before rinsing 
them twice and replacing with fresh complete growth medium. 72 hours after 
transfection, cells were transferred into tissue culture T25 flasks with selective 
medium (10% FBS DMEM containing 100 µg/ml ZeocinTM (Invitrogen)). Stable 
cells that were successfully transfected were selected for 1 month, with biweekly 
medium exchange, after which cells were cultured in serum-free medium to produce 
recombinant proteins. Supernatants of stably transfected HEK 293T cells in serum-
free medium were harvested and dialysed with 1x PBS three times for 24 hours. 
Next, 45-60ml of supernatant was loaded onto a HiTrap column after applying 1x 
binding buffer (more details see section 2.4.1.2). 
2.4.3  Protein  concentration  measurement  
2.4.3.1  Bradford  assay    
The Bradford protein assay, a spectroscopic analytical procedure, based on an 
absorbance shift of the dye Coomassie Brilliant Blue G-250, used to measure the 
concentration of protein in a solution. Serial doubling dilutions of bovine serum 
albumin (BSA) were made and 10 µl of each added to 190 µl of Coomassie Plus 
Protein Assay Reagent (Thermo Scientific), providing a standard curve. 10 µl of 
sample was similarly added to Coomassie Plus. After 5-10 minutes, ELISA plates 
were then read using an Emax precision microplate reader (Molecular Devices) 
under 595nm and concentrations calculated using the SoftMax®Pro software 
(Molecular Devices). 
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2.4.3.2  Qubit®  Protein  Assay  Kit  (Life  technologies)  
Compared to the Bradford assay, the Qubit® Protein Assay Kit could quantitate 
samples ranging from 12.5 µg⁄ml to 5 mg⁄ml and exhibits low protein to protein 
variation by using between 1 and 20 µl of sample. Qubit® working solution was 
prepared by diluting the Qubit® protein reagent 1:200 in Qubit® protein Buffer. 
Assay tubes were prepared as the following table. The mixture was vortexed for 2-3 
seconds and incubated at room temperature for 15 min. A Qubit® 2.0 Fluorometer 
was used to calibrate with standards and read the samples. 
 
Volume Standards Samples 
Working solution 190 µl 190 µl 
Standard (from kit) 10 µl -- 
Sample -- 10 µl 
  
2.5  Western  blotting  
2.5.1  Anti-­His  western  blotting    
To detect proteins bearing the hexa-histidine tag, 20 µl of protein mixed with 5µl of 
4x loading buffer was loaded on the SDS-PAGE gel using NuPAGE® 4-12% Bis-
Tris Gels and MES SDS Running Buffer (Novex®, Life Technologies). Gel-
separated proteins were transferred onto nitrocellulose membrane in NuPAGE® 
transfer buffer (25X) at 35 Volts for 80 min. The membrane was blocked with 
blocking reagent (directly provided in the kit, Qiagen) before incubating with 50pg 
anti-Penta-His HRP Conjugate in prepared solution at RT for 1hour (Qiagen), a 
sensitive detection of recombinant proteins carrying His tags without the need for 
secondary antibodies, and proceeding to detect proteins by addition of ECL 2 
Western Blotting Substrate A:B (1:40) at RT for 5 min (Thermo Scientific™ 
Pierce™, 80196). 
2.5.2  Anti-­Bm-­SPN-­2  western  blotting  
To verify monoclonal antibody candidates against Bm-SPN-2, recombinant serpin 
protein or Mff or adult extract was loaded onto SDS-PAGE gel. Following transfer to 
nitrocellulose as described above, the membrane was visualized by mAb candidates 
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as primary antibody and polyclonal antibody sera as positive with 1:2000 dilution 
4°C over night and also anti-Mouse Immunoglobulins (P0260 by Dako) as secondary 
antibody at RT for 1 hour. 
2.5.3  Anti-­IL-­33  western  blotting  
In order to measure the IL-33 from bronchoalveolar lavage after Alternaria 
intranasal administration by WB, 20 µl of the BAL sample with 5µl of the loading 
buffer 4x was loaded on the gel. Gel was transferred onto nitrocellulose membrane 
(Amersham GEHealthcare Life Science) in NuPAGE® transfer buffer (25X) at 
35Volts for 80 min. The membrane was then blocked with 5% non-fat milk diluted 
in TBST (TBS-Tween 0.1%), for 30 min at RT. Blot was revealed by primary 
antibody goat anti-mouse IL-33 (R&D systems AF3626) 4°C over night and 
secondary antibody Donkey anti-goat-HRP V8051 (Promega A16005) at RT for 1 
hour. 
2.6  IL-­33  cleavage  experiment    
Human and murine full-length IL-33 proteins, produced in rabbit reticulocyte lysate 
(RRL), were kindly provided by Corinne Cayrol, the French National Center for 
Scientific Research.  
On ice, 5 µl RRL (HsIL-331-270 or MmIL-331-266) was mixed with Elastase 
(0.01 mU/µl) or Cathepsin G (Calbiochem®, 0.25 mU/µl). The volume was made up 
to 15 µl with PBS (containing Ca2+/ Mg2+). The mixtures of full-length IL-33 were 
incubated for 30 min for Elastase and 1 h for Cathepsin G at 37°C (workflow see 
Figure 4.5A and 4.6A).  
At the end of this incubation, 5µl of 4x loading buffer (containing 5% b-
mercaptoethanol) was added, heated 5 min at 95°C, and loaded onto the SDS-gels 
immediately (to avoid excess cleavage even after boiling). In order to clearly see the 
2 bands resulting from Cathepsin G cleavage of full-length IL-33, 13.5% SDS 
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Separating gel  8 ml 4% Stacking gel 
 
5 ml 
ddH2O 3.1ml ddH2O 3.1ml 
1.5M Tris PH8.8 2ml 0.5M Tris PH6.8 1.25ml 
40% Acrylamide 2.7ml 40% Acrylamide 0.5ml 
10% SDS 80µl 10% SDS 50µl 
10% APS 80µl 10% APS 50µl 
TEMED 8µl TEMED 5µl 
 
As migration control, 1µl of the HsIL-3395-270 and HsIL-33109-270 was 
comigrated for the human blot, and MmIL-33102-266 for the mouse blot. Samples were 
run into the 4% stacking gel at 35mA for 30 min and then the separating gel at 45mA 
for 40 min. Gel was transferred onto nitrocellulose membrane (Amersham 
GEHealthcare Life Science) in NuPAGE® transfer buffer (25X) at 35 Volts for 80 
min. The membrane was then blocked with 5% non-fat milk diluted in TBST (TBS-
Tween 0.1%), for 30 min at RT. Then the membrane was incubated with the primary 
antibody (anti HsIL-33 305B from Adipogen, diluted 1/1500 in TBST 2% milk or 
goat anti-mouse IL-33, R&D systems AF3626, diluted 1/750 in TBST 2% milk) 
overnight at 4°C. The membrane was washed 6 times 5 min with TBST, at RT, and 
then incubated with the secondary antibody (“anti mouse-HRP” diluted 1/10,000 in 
2% TBST for the human blot and Donkey anti-goat-HRP V8051, Promega A16005, 
diluted 1/5000 in 2% TBST for the mouse blot) for 1 hour at RT. The membrane was 
washed 6 times 5 min with TBST, at RT.  Antibody-bound proteins were then 
detected by adding ECL 2 Western Blotting Substrate (Thermo Scientific™ 
Pierce™, 80196). 
To test the inhibitory function of Bm-SPN-2 to neutrophil proteases, different 
concentrations of Bm-SPN-2 were pre-incubated with the neutrophil elastase and 
CatG at 37°C for 10 min. Then the above IL-33 cleavage experiment was continued 
with Bm-SPN-2 incubated proteases. The workflow of investigating Bm-SPN-2 acts 
on human and murine IL-33 cleavage is shown in Figure 4.7A and 4.8A, 
respectively. 
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2.7  Enzyme  activity  assays  
To further verify the ability of Bm-SPN-2 to inhibit cathepsin G, cathepsin G activity 
colorimetric assay kit (K146-100, BioVision) was employed according to each 
manufacturer's instructions. Briefly, neutrophil elastase, cathepsin G was pre-
incubated with Bm-SPN-2 at 37°C for 20 min. Cathepsin G with or without pre-
incubation with Bm-SPN-2, were mixed with corresponding enzyme substrates. The 
substrate can be cleaved by the cathepsin G into a colorimetric product. As 
appropritae, absorbance (at 405nm) was measured in kinetic mode at 37 °C every 
one minute for 60 min. Each sample reading was then converted according to 
standard curves prepared at the same time. 
2.8  Enzyme-­linked  immunosorbent  assay  (ELISA)  
To measure different cytokines present in the peritoneal lavage after microfilariae 
infection of ST2-deficient and BALB/c mice, enzyme-linked immunosorbent assay 
(ELISA) of IFN-g, IL-4, IL-5, IL-13, IL-33 and Relma was performed. To compare 
mast cell stimulation by full-length and cleaved IL-33, IL-6 secretion from mast cell 
supernatants was measured by ELISA. Also to select monoclonal antibodies against 
Bm-SPN-2, an ELISA screen was performed.  
In each assay, 96-well flat bottomed plates (NUNC Maxisorp) were coated 
with 50 µl/well capture antibody in carbonate buffer at corresponding working 
dilution (see Table 2.1 for concentrations) overnight at 4°C. For Bm-SPN-2 
monoclonal antibody ELISA screen, 1µg/ml of rBm-SPN-2 was made for coating. 
The next day, plates were washed 4 times with ELISA wash buffer (0.05% TBS-T) 
and blocked with 150 µl/well of ELISA blocking buffer (1% BSA in ELISA wash 
buffer) and incubated for 2 hours at 37°C. After removing the blocking buffer, 
relevant wells were incubated with standards and samples overnight at 4°C. On day 
2, plates were emptied, washed 4 times with wash buffer and incubated 1 hour at 
37°C with 50 µl/well biotinylated detection antibodies at the optimal concentration 
(concentrations see Table 2.1). The plates were then washed another 4 times before 
adding extravidin alkaline phosphatase (1/10,000) in 50 µl blocking buffer per well, 
followed by 4 further washes with wash buffer, twice with distilled water and 
incubation with 100 µl p-Nitrophenyl phosphate (Sigma) made up from tablets 
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according to the manufacturer’s instructions, until colour development allowed 
measurement to take place. For the ELISA screen for monoclonal antibody, wells 
were incubated with polyclonal rabbit anti-mouse immunoglobulins HRP (P0260, 
Dako) 1:4000, followed by incubation with 50 µl detection reagent ABTS® 
Peroxidase Substrate System until reading. ELISA plates were then read using an 
Emax precision microplate reader (Molecular Devices) under 405nm and 
concentrations calculated using the SoftMax®Pro software (Molecular Devices). 
Table 2.1: Antibodies used for ELISA 
Specificity Clone Capture  Standard  detection 
IL-4 BD 1/1000  1/250 1/8000 
IL-5 BD 1/4000 1/500 1/1000 
IL-6 BD 1/250 1/200 1/1000 
IFN-g BD 1/1000 1/200 1/250 
IL-13 BD 1/125 1/500 1/1000 
IL-33 BD 1/125 1/32.5 1/60 
Relma BD 1/400 1/100 1/400 
extravidin alkaline phosphatase BD   1/10000 
anti-mouse immunoglobulins HRP Dako   1/4000 
2.9  Gene  expression  analysis  
2.9.1  RNA  extraction  
RNA was extracted from mesenteric lymph nodes of ST2-deficient and BALB/c 
mice at day 1 and day 6 post-microfilariae infection as well as uninfected mice. 
mLNs were collected in 1 ml RNA later (Qiagen) until being transferred into new 
tissue lysis Eppendorf tubes, with a steel ball in 700 µl Qiazol, then disrupted in 
Tissue Lyser for 1min at a frequency of 25. In the meantime, gradient centrifugation 
of peritoneal lavage cells was performed using Histopaque, the white cell layer was 
collected and resuspended in 700 µl Qiazol. After transfer into an RNase-free 2ml 
tube, 140 µl chloroform was added and the mixture shaken vigorously for 15s and 
incubated 5 min at room temperature. Following centrifugation (12,000 x g, 15 min, 
4°C), the aqueous phase was transferred into a new RNase-free 1.5ml tube, and 
mixed thoroughly with 1.5 volumes of 100% ethanol. To get rid of any contaminated 
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DNA, RNA was then cleaned further using DNase 1 (Qiagen) and the RNeasy® Mini 
Kit (Qiagen), a developed kit for fast purification of high-quality RNA. 
 
2.9.2  cDNA  preparation  
RNA concentration was measured by determination of optical density at 260 nm 
(OD260) using a NanoDrop 2000 (Thermo Scientific). For reverse transcription, 1 µl 
qScript RT reverse transcriptase (20x) was added to 250 ng RNA in 15 µl RNase-
free water, followed by addition of 4 µl of qScript Reaction Mix (5x) (Quanta qScript 
cDNA kit). The reaction was performed in a thermocycler with the following 
program. 
1 cycle 22°C 5 min 
1 cycle 42°C 30 min 
1 cycle 85°C 5 min 
 4°C hold 
 
Note: In order to clone human WT IL-33, this protocol was also used for RNA extraction 
and cDNA preparation from A549 cells.  
2.9.3  Real  time  PCR  
To perform RT-PCR, cDNA was diluted 1/5 and a 1-5 µl of each sample pooled for 
use as top standard. Standards were serially diluted 1/5 to obtain six standard 
concentrations. 3 µl of sample or standard and 9.5 µl of master mix (see below) were 
added to each well. Samples and standards were used in triplicate for each primer; 
experiments were performed using 384-well plates and the QuantStudio™ 7 Flex 
(Thermo Scientific) using the following cycling conditions. 
PCR products was analyzed by agarose gel electrophoresis and results analysed 
using delta CT method. 
 
Master mix for 384 well PCR plates 
6.25µΙ Perfecta SYBR Green SuperMix, Low ROX (2X) 
0.25µl forward primer 
0.25µl reverse primer 
2.75µl Nuclease free water  
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Template 3µl 
Final volume 12.5µl 
 
Cycling conditions 
95°C 2:30 minute 
40 cycles  
95°C 15 seconds (Denature) 
60°C 45 seconds (Anneal) 
 
Mouse gene expression primer list 
GAPDH forward 5’ ATG ACA TCA AGA AGG TGG TG 3’ 
GAPDH Reverse 5’ CAT ACC AGG AAA TGA GCT TG 3’ 
RPL13a Forward 5’ CCC TCC ACC CTA TGA CAA GA 3’ 
RPL13a Reverse 5’ GCC CCA GGT AAG CAA ACT T 3’ 
IL-4 Forward 5’ GAG AGA TCA TCG GCA TTT TGA 3’ 
IL-4 Reverse 5’ TCT GTG GTG TTC TTC GTT GC 3’ 
IFN-γ 5’ TGA ACG CTA CACACT GCA TCT TGG 3’ 
IFN-γ 5’ CGA CTC CTT TTC CGCTTC CTG AG 3’ 
IL-33 Forward 5’ GAC ACA TTG AGC ATC CAA GG 3’ 
IL-33 Reverse 5’ AAC AGA TTG GTC ATT GTA TGT ACT CAG 3’ 
Arginase 1 Forward 5’ GTC TGT GGG GAA AGC CAA T 3’ 
Arginase 1 Reverse 5’ GCT TCC AAC TGC CAG ACT GT 3’ 
Relma Forward 5’ TAT GAA CAG ATG GGC CTC CT 3’ 
Relma Reverse 5’ GGC AGT TGC AAG TAT CTC CAC 3’ 
 
2.10  Parasite  extract  preparation  
Microfilarae and adult worms of both B. malayi and B. pahangi were obtained from 
liquid nitrogen stocks of the Maizels lab and Eileen group, respectively. 500µl cold 
PBS was added to parasites, then 50 µl protease inhibitor cocktail solution was 
added. The protease inhibitor cocktail solution was prepared by dissolving one tablet 
of cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail (Cat.No.04693159001, 
Roche) into 1ml PBS. After mixing, adult worm samples were transferred to a glass 
homogenizer (Jencons H103/32/423 with a ground glass barrel), and repeated strokes 
used to break up macroparasites. Sonication using a Soniprep 150 (MSE) was 
performed on microparasites (microfilariae) for 3 min at 6 µm on ice, keeping the 
samples cold at all times. Suspensions were then placed on ice for 60 min, agitating 
occasionally. Centrifugation was performed at 10,000 g, 30 min, 4 °C. Supernatants 
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were harvested and then passed through a Millex 0.2 µm filter. Protein 
concentrations were measured and stored at -80 °C until use. 
2.11  Accession  numbers  
The accession number of Bm-SPN-2 is AF009825. 
To make human fl-IL-33, the primers were designed based on the Homo sapiens (Hs) 
IL-33 mRNA with the accession number of NM_0033439.2.  
 
2.12  Software  and  statistics  
Statistical analysis was performed using GraphPad Prism 8. Depending on the data 
set, multiple t-tests, one or two-way ANOVAs were used, with significance 
thresholds of: *: p ≤ 0.05; ** : p ≤ 0.01; *** : p ≤ 0.001. 
2.13  Media  and  buffers    
His-tag Binding buffer (8x) (mM: milli molar) 
40 mM Imidazole                        2.72 g 
4 M NaCl 233.76 g 
160 mM Tris-HCl  25.22 g 
pH7.9                                             1 Litre 
His-tag Elute buffer (8x)   
4 M Imidazole                          272.3 g 
2 M NaCl 116.8 g 
80 mM Tris-HCl 12.61 g 
pH 7.9 1 Litre 
His-tag Charge buffer (8x) 
400 mM Nickel sulphate NiSO4    105.12g/L 
His-tag Strip buffer (8x) 
400mM EDTA 37.22g 
2M NaCl 29.22g                        
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80mM Tris HCL 3.15g  
pH 7.9  250 mL   
Carbonate coating buffer 
Buffer A 8.5 g NaHCO3 in 100 ml H20 (1M)   
Buffer B 10.6 g Na2CO3 in 100 ml (1M)   
Add 45.3 ml of A to 18.2 ml of B and 936.5 ml H2O 
pH to 9.6  
10µl 10% sodium azide  
cRPMI 
500 ml RPMI (Gibco) 
5ml L-Glutamine (Gibco) 
5ml Penicillin/Streptomycin (Gibco) 
50 ml FCS (Gibco) 
ELISA wash buffer (TBS-T) 
5 L TBS  
2.5 ml Tween® 20 
ELISA blocking buffer: 1% BSA in ELISA wash buffer 
Protein G column purification buffers 
Binding buffer 2 x PBS 20mM Sodium phosphate pH7.0 
Elution buffer 0.1M Glycine-HCl pH2.7 
Neutralisation buffer 1M Tris HCl pH9.0 
[13.5% SDS PAGE gel] 
1.5M Tris PH8.8 
Tris base  90.82g 
HCL                                adjust to pH 8.8 
 Up to 500 ml 
0.5M Tris PH6.8 
Tris base 30.27g 
HCL adjust to pH 6.8 
 Up to 500 ml 
10% SDS  
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SDS 5.0g/50ml 
10% Ammonium persulphate (APS)  
Ammonium persulphate 0.1g/ml 
Western Blot washing buffer 
1L TBS   
1ml Tween® 20 
Silver Stain Developing 
6.25g Sodium carbonate 
0.05ml Formaldehyde (37%) 
fill up to 250ml with dH2O 
Silver Stain Fixation 
100ml Ethanol  
25ml Acetic acid 
fill up to 250ml with dH2O 
Silver Stain Sensitizing 
75ml Ethanol 
0.5g Sodium thiosulfate 
17g Sodium acetate 
fill up to 250ml with dH2O 
Silver Stain silver reaction reagent 
0.1g Silver nitrate  
40ml d H2O 
Silver Stain Stop solution 
3.65g EDTA Na2.2H2O 
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CHAPTER3  
Human  and  murine  IL-­33:  preparation  
mutation  and  testing  on  mast  cells  
ABSTRACT 
 
The most abundant secreted product from the Brugia malayi microfilarial stage, 
serine protease inhibitor-2 (Bm-SPN-2), was found to specifically inhibit the 
enzymatic activity of human neutrophil elastase and cathepsin G in a dose-dependent 
manner. More recently, these two enzymes have been linked to the activation of a 
major innate cytokine IL-33, which is stored as a full-length 270-aa protein in the 
cell nucleus, and released as an active C-terminal domain upon stimulation. In order 
to verify the hypothesis that Bm-SPN-2 blocks full-length (FL) IL-33 cleavage by 
inhibiting neutrophil elastase or cathepsin G, FL-IL-33 is required for this study. It 
was found that only C-terminal human and murine IL-33, and not FL IL-33 from 
either species are commercially available. In addition, recombinant wild-type FL-IL-
33 was unable to be secreted directly into the supernatant of transfected HEK 293T 
cells. It was possible, however, to produce soluble murine and human FL-IL-33 in 
HEK 293T cells, following mutation of the nuclear binding motif. In this form, IL-33 
is no longer retained in the nucleus and can be purified as a soluble protein. 
Furthermore, it was confirmed that once cleaved, but not by caspase, human IL-33 
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3.1  Introduction  
Many parasites have evolved to release products that interfere with host defence 
mechanisms such as enzymatic activation pathways in the mammalian host, in order 
to promote and sustain their survival. The human filarial nematode Brugia malayi 
produces larval microfilariae, which circulate in the blood stream. Their most 
abundant secreted product is a serine protease inhibitor with sequence homology to 
mammalian serpins, termed Bm-SPN-2 (Hewitson et al. 2008). Serine protease 
inhibitors are reported to be involved in how nematodes avoid host immune 
defences, and in the case of Bm-SPN-2, the protein was found to specifically inhibit 
the enzymatic activity of human neutrophil elastase and cathepsin G in a dose-
dependent manner (Zang et al. 1999). More recently, it was reported that these two 
enzymes are also linked to the activation of a major innate ‘alarmin’ cytokine IL-33, 
which is stored as a full-length 270-aa protein in the cell nucleus, and released as an 
active C-terminal domain upon stimulation (Lefrançais et al. 2012).  
A role for IL‑33 in parasitic infection was first suggested by the discovery 
that Leishmania major-infected BALB/c mice showed a switch in T cell response 
polarity from TH2 cell response to a protective TH1‑type response, upon the 
administration of an ST2 (IL-33 receptor)-specific blocking antibody (Xu et al. 
1998). As summarized in the general introduction (Chapter 1.4.6) it is now 
recognised that IL-33 is critically involved in developing the initial TH2 response to 
helminth infections, including Nippostrongylus brasiliensis (Moro and Koyasu 
2010), Schistosoma mansoni (Townsend et al. 2000) and Trichuris muris 
(Humphreys et al. 2008). Furthermore, peak IL-33 expression was observed at early 
time points (Humphreys et al. 2008), indicating that prompt release of this alarmin 
cytokine is a potent signal for type 2 response initiation.  
Based on the above information, as Brugia malayi is a human filarial parasite, 
the hypothesis is proposed that the function of Bm-SPN-2 is to inhibit the cleavage of 
human full-length IL-33 into the mature active form processed by human and 
neutrophil serine proteases (cathespin G and elastase). Such an effect would directly 
inhibit the host alarm signal, and could be key to understanding both the host and 
parasite relationship and the parasite immune evasion strategy. As human and mouse 
IL-33 are 55% identical at the amino acid level (Schmitz et al. 2005), this hypothesis 
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may also be extended to infections in mice as well.  
In order to verify this hypothesis, human and murine full-length IL-33 are 
required. As commercial sources proved to only provide the cleaved, activated C-
terminal form, it was necessary to produce full-length IL-33 in our own laboratory.  
In previous work, it has been demonstrated using real-time PCR by Schmitz 
et al. that human and murine IL-33 mRNA are expressed in a wide range of tissues 
and cell types (Schmitz et al. 2005). In mice, IL-33 mRNA is expressed in activated 
macrophages, epithelial cells and purified dendritic cells and it was also confirmed 
that its expression was much higher in stomach, lung, brain, spinal cord and skin 
tissues. However, human IL-33 mRNA expression follows a somewhat different 
pattern is found in activated dermal fibroblasts, bronchial smooth muscle cells and 
small airway epithelial cells, various resting epithelial cells and pulmonary artery 
smooth muscle cells (Schmitz et al. 2005). Thus, with the sequences of full length 
cytokines from both human (IL-331-270) and murine (IL-331-266) available from 
NCBI, it was feasible to produce human and murine recombinant full-length IL-33 in 
the laboratory, as described in this section. 
Most recently, it was also reported that the processing of IL-33 into mature 
bioactive IL-33 can also be mediated by mast cell serine proteases, namely chymase 
and tryptase (Lefrançais et al. 2014). As discussed in the General Introduction 
(Chapter 1.4.1.1), mast cells are involved in many instances of parasite expulsion 
(Murphy and Weaver 2016). Upon infection with Strongyloides species, the TH2 
cytokines, IL-3 and IL-9, stimulate mast cell growth and degranulation, increasing 
smooth muscle contraction (Maizels and Holland 1998). For example, athymic nude 
mice, which have no thymus-dependent T cells, expel Strongyloides ratti following 
repetitive administration of IL-3 (mast cell growth factor) (Abe et al. 1992). In 
addition, IL-3-deficient mice show delayed expulsion of Strongyloides venezuelensis 
(Lantz et al. 1998). Overproduction of IL-9, which functionally activates mast cells 
and augments IgE and IgG1 production, enables mice to rapidly expel T. spiralis. 
Using antibodies against c-kit receptor, which normally acts to promote mast cell 
maturation, impedes mouse mucosal mastocytosis and parasite expulsion (Faulkner 
et al. 1997). In the intestinal setting, mast cell products are thought to promote fluid 
egress through relaxing tight junctions, and to trigger muscular contraction, hence 
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underpinning the “weep-and-sweep” response. For instance, upon infection with 
gastrointestinal helminths (H. polygyrus bakeri and Trichuris muris), mast cell-
deficient mice had dramatically reduced TH2 cytokine production and increased 
parasite burdens (Hepworth et al. 2012a). In the tissues and skin, mast cells work 
together with IgE to cause rejection of parasites including ticks and helminths. 
Notably, it has been shown that IL-33 is a potent activator of mast cells and can 
induce their degranulation, maturation, and production of pro-inflammatory 
cytokines, like IL-6 (Allakhverdi et al. 2007, Iikura et al. 2007). IL-9 can stimulate 
IL-6 production, which is considered to be a crucial cytokine for mast cell maturation 
(Conti et al. 2002), from certain mast cell lines and also promote the expression of 
mast cell proteases (Hültner et al. 1990, Faulkner et al. 1997). Very recently, it was 
shown by Shimokawa et al., 2017 that mast cells are a potent source of IL-33, crucial 
for ILC induction and clearance of H. polygyrus (Shimokawa et al. 2017). Thus, it is 
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3.2  Results    
3.2.1  Preparation  of  human  wild  type  full-­length  IL-­33    
In initial experiments to determine the optimal amount of IL-33 for antibody 
detection on Western blots, Western blotting was performed with a range of amounts 
(100ng, 10ng, 1ng, 0.1ng) of rIL-33 purchased from a commercial supplier (R&D). 
Although the antibody used in these experiments successfully detected the target 
cytokine, it was found that the size of detected IL-33 was ~20-kDa, representing the 
proteolytically cleaved form of IL-33 (Figure 3.1). It thus transpired that the IL-33 
protein sold by R&D was actually the cleaved form, which although having 10 times 
greater biological activity than FL-IL-33, was not suitable for experiments testing 
inhibition of cleavage. However, the result did clearly indicate that the amount of IL-
33 needed for Western blotting detection was in the order of 10ng.  
In order to test the hypothesis that Bm-SPN-2 inhibits the cleavage of full-
length IL-33 by neutrophil cathepsin G or elastase, another strategy was required to 
obtain human and murine FL-IL-33 It was therefore necessary to produce full-length 
IL-33 in our laboratory, starting from a template of cDNA for IL-33 obtained from 
human and mouse cells.  
 A number of reports indicated potential sources for IL-33 mRNA. For example, 
both transcript and protein for human IL-33 have been reported to be widely 
expressed in various cell types such as adipocytes, bronchial, dendritic cells, 
endothelial cells, fibroblasts, intestinal epithelial cells, macrophages, osteoblast and 
smooth muscle cells (Schmitz et al. 2005). Also, it was reported that IL-33 is 
expressed in primary human monocytes (Nile et al. 2010). To amplify the 
corresponding cDNA, the human IL-33 sequence was first obtained from Genbank as 
Reference Sequence NM_033439.3. Using an online Eurofins oligo analysis tool, 
primers were then designed for human full-length IL-33 as detailed in Figure 3.2B. 
In the previous attempt to amplify IL-33, human peripheral blood 
mononuclear cells were isolated from a volunteer’s blood. Unfortunately, under the 
conditions used in this study, IL-33 cDNA was not able to be amplified from the 
isolated human PBMCs. 
As it was reported by Moussion et al., that IL-33 is constitutively expressed 
in epithelial cells (Moussion et al. 2008), it was then decided to isolate IL-33 cDNA 
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from human alveolar basal epithelial cells (A549 cell line). In this instance, IL-33 
cDNA was successfully amplified from the A549 cell line (Figure 3.3A). The PCR 
product containing IL-33 cDNA was ligated into pGEMT holding vector, sequenced 
and verified to be error-free. The insert was then excised with restriction enzymes 
AscI and ApaI to be ligated into the pSecTag expression vector (Figure 3.3B and 
3.3C), followed by HEK293T cell transfection.  
Although cells were successfully transfected with the IL-33-pSecTag 
construct, no IL-33 was detected in the HEK cell supernatant by western blotting, 
after transfection of IL-33 into HEK cells (data not shown). According to the 
manufacturer's instruction, cell lysates of stable IL-33-transfected HEK293T cell 
lines were then prepared with mammalian cell lysis buffer (Cat.# G9381, promega) 
and the cell lysate supernatant was harvested. Subsequently, both anti-His and anti-
IL-33 Western blotting of the cell lysate supernatant were carried out (Figure 3.4). 
The anti-His Western blot revealed a strong band around 60-kDa, which may be 
fetuin within the Foetal Calf Serum (FCS) added to the cell growth media (Figure 
3.4A). However, specific anti-IL-33 Western blotting showed an approximately 40-
kDa band, consistent with the expected size of human full-length IL-33 (Figure 
3.4B). 
Unfortunately, efforts to purify wild-type FL-huIL-33 protein by nickel-
chelating AKTA column purification were not satisfactory (protein purification trace 
was shown in Figure 3.5A). Although by anti-IL-33 Western blotting, a band of ~40-
kDa corresponding to human full-length IL-33 was clearly visible in fractions 15-18 
(Figure 3.5C), multiple other proteins were detected in these fractions by silver staining 
(Figure 3.5B). The high level of contamination with other proteins rendered these 
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Figure 3.1: Western blotting of a range of quantities of rIL-33. Recombinant IL-33 
(R&D) with the stock concentration of 100µg/ml were used to prepare the range of 
quantities of rIL-33, 1/10 serial dilution from 100ng, 10ng and 1ng to 0.1ng, then loaded 
onto the gel. IL-33 biotinylated antibody (R&D) with the working concentration of 
0.2µg/ml, was prepared from the stock concentration of 36µg/ml. ExtrAvidin HRP (1:4000) 
and ECL Plus Western blotting substrate (Cat. #PI80196) were used for detection. The bands 
and the marker were captured individually by FluorChem®SP Superior Performance 
Imaging System, this image was the merged version (The images of the bands and marker 
were taken separately, and were merged together). “M” stands for marker: SeeBlue® Plus2 
Pre-stained Protein Standard. 100ng and 10ng of IL-33 were detected in western blotting. 
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Figure 3.2: Primer design and construct design for human full-length IL-33.  
(A) Schematic of the proteins produced, with vector sequences in red and restriction sites 
used indicated. AscI (GGCGCGCC) shown in purple and ApaI (GGGCCC) shown in green. 
The start codon (ATG) and the stop codon (TAG) were deleted when the primer was 
designed. The forward and reverse primer for human IL-33 are shown at the beginning and 
the end of the IL-33 insert, respectively. A total of 821 bp should be the size of the PCR 
product.  
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Figure 3.3: IL-33 cDNA cloning from A549 cell line and ligation into pSecTag.  
(A) Agarose gel of IL-33 PCR product with the size of 821bp from A549 cell line cDNA 
using the primers shown in figure 3.2B.  
(B) Digestion products from pGEMT holding vector with IL-33 following digestion with 
Apa1/Asc1 restriction enzymes; gel extraction of the shortest band (IL-33 insert) was 
followed by ligation into the pre-cut pSecTag expression vector. 
(C)  T7 promoter primer (primer for pSectag vector, sequence is shown in Section 2.4.2.1) 
and IL-33 specific reverse primer were used to perform colony screens, colonies 1-4 were 
first chosen for sequencing and proved to contain correct sequences. “M” stands for marker: 
GeneRulerTM 1 kb DNA Ladder. 
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Figure 3.4: Anti-His-tag and anti-IL-33 detection of products in IL-33 transfected HEK 
cell lysates. CL-1 and CL-2 were sample replicates of IL-33 transfected HEK293 T cell 
lysate. 20 µl of cell lysate were loaded into each lane. “M” stands for marker: SeeBlue® 
Plus2 Pre-stained Protein Standard. The blots were visualised by FluorChem®SP Superior 
Performance Imaging System, ladder and bands were captured individually, then were 
emerged together.  
(A) Anti-His western blotting. “PC1” was NSP-4, a His-tagged protein transfected in 
HEK293 T cells made in our laboratory, as the positive control for anti-His western blotting. 
Pink arrow with blue frame shows the band of the positive control. Blue arrow points out the 
band about 60kDa might be the fetuin within the Foetal Calf Serum added to the cell growth 
media. Red arrow directs the weak band of IL-33 around 40kDa. 
(B) Anti-IL-33 western blotting. “PC2” stands for positive control for IL-33 western blotting, 
was the cell lysate which proved to have IL-33 during the previous experiment. Red arrow 
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3.2.2  Retention  of  WT  IL-­33  within  HEK  cells   
The retention of IL-33 within the cell body, and the inability to export it into the 
supernatant of HEK293T cells, can be attributed to an important biological feature of 
this alarmin.  Previously, Carriere et al. defined a non-conserved domain, in IL-33, 
absent from other IL-1 family members, aa 1-65, which was identified as a 
chromatin and mitotic chromosome association domain (Carriere et al. 2007). 
Further, using deletion mutagenesis, Roussel et al. have demonstrated that IL-33 
residues 40–58 are sufficient to tether N- or C-terminal green fluorescent protein 
(GFP) to mitotic chromatin in living human embryonic kidney (HEK) 293T cells 
(Roussel et al. 2008). Using alanine scanning mutagenesis, human IL-33 residues 43-
54 were individually mutated to alanine (A) within the IL-33 chromatin binding 
motif (CBM). Six of these residues were found to be essential for chromatin binding: 
M45, L47, R48, S49, G50 and I53. The same authors further verified that a triple 
alanine mutation within the IL-33 CBM, IL-3340–58 (47AAA49) abrogated 
chromosome association. It was confirmed in the context of full-length IL-33 (IL-
33FL) that GFP-IL-33FL(47AAA49) and GFP-IL-33FL(R48A) mutants were found 
not to associate with chromatin. It was also shown that the IL-33 CBM is conserved 
in murine IL-33 (Roussel et al. 2008), as shown in the sequence alignment between 
human and murine IL-33 and its chromatin binding motif in Figure 3.6. 
3.2.3  Producing  mutant  human  and  murine  FL-­IL-­33 
To produce a soluble, secreted form of FL-IL-33 which would not be retained within 
the cell by chromatin binding, the cDNAs for human and mouse IL-33 were mutated 
to alanine ‘AAA’ at positions 47-49, in accordance with the previous finding 
(Roussel et al. 2008). Mutant human and murine FL-IL-33 gene sequences were 
synthesized and inserted into the pMA-T vector, flanked with AscI and ApaI 
restriction endonuclease sites, by GeneArt (Gene synthesis details see appendix 1A 
and 1B). The amino acid alignment of mutant and WT human and murine FL-IL-33 
are shown in Figure 3.7.  
The synthesized mutant human and murine FL-IL-33 were excised from the 
pMA-T vector by double digestion with restriction enzymes AscI and ApaI, then 
ligated into the pSectag expression vector. The sequential steps of gel extraction of 
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hIL-33, mIL-33 and pSectag2a products used for the ligation are shown in Figure 
3.8A. Following transformation of E. coli colonies were screened (Figure 3.8B) and 
sequenced (sequence results are shown in Appendix 2), followed by transfection of 
HEK293T cells with the verified plasmids. 
From culture of these transfected cells in serum-free media, it was possible to 
purify secreted mutant human and murine full-length IL-33, with sizes of 34.1kDa 
and 33.3kDa, respectively. As both human and murine FL-IL-33 were predicted to 
have N-glycosylation sites, the sizes of the proteins were somewhat greater than 
expected (see Figure 3.9C and 3.10C). The schematic of the proteins produced is 
shown in Figure 3.9A, the human mutant IL-33 inset with the size of 821bp was 
flanked with the restriction enzymes AscI and ApaI. The UV trace, anti-IL-33 
western blotting and silver staining of the purified fractions of human IL-33 are 
shown in Figure 3.9B, 3.9C and 3.9D. The insert of murine mutant IL-33 is 809bp. 
Similar results of murine mutant IL-33 are shown in Figure 3.10 A, B, C and D.  
Figure 3.9 C and D shown the purified fraction B4 of human mutant IL-33, 
according to the IL-33 western blotting, there is a band for IL-33 at a mol wt of 40 
kDa, whereas the silver staining shows a predominant band of a smaller size in this 
fraction. In order to ascertain the purity of these five fractions, they were sent for 
analysis by mass spectrometry (MS). The MS result shows that there are many other 
peptides in these fractions. However, MS result has shown that human IL-33 amino 
acid was detected in the Fraction 4 and Fraction 5. The amino acid sequences 
detected by MS were “VDSSENLCTENILFK”, 
“VLLSYYESQHPSNESGDGVDGK” and 
“CEKPLPDQAFFVLHNMHSNCVSFECK” in fraction 4; whereas 
“TDPGVFIGVK” in the fraction 5 (the alignment with human mutant IL-33 is 
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Figure 3.5: AKTA purification fractions of WT human FL-IL-33 transfected HEK293T 
cell lysate. “M” stands for marker: SeeBlue® Plus2 Pre-stained Protein Standard. “6-23” 
stand for “Fractions 6-23”. 
(A) Purification trace of the purified fractions. 0%-100% gradient of the Elution buffer was 
used to elute the protein. Fractions are collected in Eppendorf tubes. Red arrows indicate each 
fraction 1, 3, …, 17 etc. 
(B) Silver staining of purified fractions 6-23. 
(C) Anti-IL-33 western blotting of purified fractions 6-23. Fraction 11-13 shows a band 
about 60kDa (black arrow) might be the fetuin within the Foetal Calf Serum added to the cell 
growth media. Fraction 15-18 shows a band of about 40kDa (red arrow) which is likely to be 
the FL-IL-33. 
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Figure 3.6: Sequence alignment between human and murine IL-33 and their chromatin 
binding motif (CBM). CBM was located close to the N-terminal domain. Red = residues 
required for chromatin binding; Brown = region which binds to (and inhibits) NF-kappa-B; 
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Figure 3.7: The amino acid alignment of wild type and mutant human and murine full-
length IL-33. The site of the triple mutation from LRS to AAA is shown in red. The 
flanking sequences showing in Blue are the pSectag vector sequence. Six hexahistidine-tags 
are shown in Green. 
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Figure 3.8. Mutant human and mouse IL-33 insert into pSectag2a vector.  
(A) Human and mouse mutant IL-33 as well as pSecTag2a vector were double digested with 
Apa1/Asc1, gel extraction was followed (the areas cut for gel extraction are visible on the 
image).  
(B) and (C) T7 promoter primer and BGH reverse primer (vector primers for pSectag) were 
used to screen colonies; colonies 3 and 4 in blue frame were chosen for human mutant IL-33 
sequencing, whereas colonies 4 and 5 in pink frame were chosen for mouse mutant IL-33. 
“M” means marker, GeneRulerTM 1 kb DNA Ladder. “DD” stands for Double digested by 
AscI and ApaI. “hmuIL-33” refers to human mutant IL-33. “mmuIL-33” means mouse 
mutant IL-33. 
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Figure 3.9: Human mutant full-length IL-33 purification from transfected HEK293T 
cell supernatant by AKTA FPLC. 
(A) Schematic of the proteins produced, with vector sequences in red and restriction sites 
used indicated. The insert is 821bp. 
(B) The UV trace of purified fractions from human mutant IL-33 (black arrow indicates the 
purified IL-33). The elution gradient of imidazole is indicated on each trace with a gradient 
from 0% to 100% of Elution buffer. Fractions are collected by 96 wells plates, then fractions 
order are shown as A1, A2,...,A12; B1,B2…B12 and C1,…C12. 
(C) Anti-human IL-33 Western blotting of purified fractions following chelating column 
chromatography of supernatants of HEK cells expressing human mutant IL-33.  (D) Silver 
staining of purified fractions of human mutant IL-33. Red arrow points to an unknown band 
in purified fraction 4. “uSup” is the un-purified supernatant, “FT” stands for flow through. 
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Figure 3.10: Mouse mutant full-length IL-33 purification from transfected HEK293T 
cell supernatant by AKTA FPLC. 
 (A) Schematic of the proteins produced, with vector sequences in red and restriction sites 
used indicated. The insert is 809bp. 
(B) The UV trace of purified fractions from mouse mutant IL-33. The elution gradient of 
imidazole is indicated on each trace with a gradient from 0% to 100% of Elution buffer. 
Fractions are collected by 96 wells plates, same way as human mutant IL-33. 
(C) Anti-mouse IL-33 Western blotting of purified fractions following chelating column 
chromatography of supernatants of HEK cells expressing mouse mutant IL-33 (Black arrow 
indicates the purified murine full-length IL-33; red arrow shows the cleaved IL-33).  (D) 
Silver staining of purified fractions of mouse mutant IL-33. “uSup” is the un-purified 
supernatant, “FT” stands for flow through. 
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Figure 3.11: Mass spectrometry result of human mutant IL-33 purified fractions, 
aligned with mutant IL-33. 
Amino acid sequence showing in blue are the pSectag vector sequence. 6 His tags present in 
green at the end of the vector. “AAA” showing in red are the mutant DNA binding motif of 
IL-33. Sequences in purple are the detected amino acid from the purified fraction 4, whereas 
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3.2.4  Stimulation  of  mast  cells  with  human  and  murine  full  length  
and  cleaved  IL-­33 
It has been reported previously that full-length IL-33 significantly induced IL-6 
secretion by cells of the MC/9 mast cell line, whereas following degradation by 
caspase-1, there was no effect (Cayrol and Girard 2009). In contrast, it was also 
shown that incubation of full-length IL-33 with neutrophil elastase and cathepsin G 
resulted in a more potent induction of IL-6 secretion by mast cells, compared with 
cells treated with full-length IL-33 alone (Lefrançais et al. 2012).  
To better understand how IL-33 interacts with mast cells, a collaborative 
experiment was undertaken with the group of Cayrol et al. MC/9 cells were grown 
up and cultured with rabbit reticulate lysate full-length and Cathepsin-G cleaved IL-
33, 24 hours prior to assaying cell supernatants for IL-6 release by ELISA (Figure 
3.12A). It was confirmed that human cleaved IL-3395-270 significantly increased IL-6 
secretion by mast cells, compared with cells treated with human full-length IL-331-270 
alone (Figure 3.12B). 
In further experiments, a similar result was obtained with mouse IL-33; Here 
was a modest induction  of IL-6 from mast cells with full length IL-33 compared to 
very significantly increased IL-6 from mast cells stimulated with cleaved mouse IL-
33106-266 (Figure 3.12C). Hence the same relationship between IL-33 and mast cells 
was found for both the human and mouse cytokines, and also that the murine mast 
cell line MC/9 is a sensitive readout for human IL-33 bioactivity. As very limited 
quantities of murine cleaved IL-33 were available to us, the murine IL-33 stimulation 
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Figure 3.12: IL-6 induction by human and murine IL-33 stimulation of mast cells.  
(A) Experimental protocol for mast cell incubation and stimulation.  
(B) IL-6 secretion after human full-length IL-331-270 and cleaved IL-33109-270 stimulation of 
the MC/9 murine mast cell line. Cleaved human IL-33109-270 significantly increased IL-6 
secretion.  
(C) Mouse full-length IL-331-266 and cleaved IL-33106-266 stimulation of MC/9 cells, using 106 
mast cells/well. Cleaved murine IL-33106-266 shows significantly increasing IL-6. 2µl of IL-33 
rabbit reticulocyte lysate RRL was added to each well. IL-6 was measured by ELISA after 
24 hours incubation. Human IL-33 stimulation was repeated twice, whereas murine IL-33 
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3.3  Discussion    
At the outset of this study, neither human nor mouse full-length IL-33 was available, 
as it transpired that the commercial products were the cleaved bioactive IL-33 form. 
It was therefore apparent that the only way of obtaining full-length IL-33 was to 
produce recombinant IL-33 in the laboratory. 
In carrying out this work, results were not consistent with the previous 
finding that IL-33 messenger RNA is expressed in human monocytes (Nile et al. 
2010). Although IL-33 cDNA could not be cloned from human isolated PBMCs, it 
was possible to take advantage of gene expression data from the first screening of IL-
33 expression among various tissue and cell types (Schmitz et al. 2005). It had been 
observed that there was abundant expression of the endogenous IL-33 protein in 
epithelial cells from tissues exposed to the environment, and in fibroblastic reticular 
cells (FRCs) of lymphoid organs (Moussion et al. 2008, Pichery et al. 2012). 
Furthermore, IL-33 cDNA has been cloned from adenocarcinomic human alveolar 
basal epithelial cells (A549 cell line). Hence, after an initial setback, full length 
human IL-33 was successfully cloned. 
In addition, it was confirmed that both human and murine wild type IL-33 are 
not secreted into the supernatant of transfected HEK293T cell cultures, as they are 
retained in the cell nucleus through the chromatin binding motif located in the N-
terminal sequence of the IL-33 full-length protein (Roussel et al. 2008). Several 
reports suggest that IL-33 is a nuclear cytokine in vivo, which is always found in the 
nucleus of cells expressing the protein in both human and mouse tissues, with no 
evidence for cytoplasmic or extracellular localization (Moussion et al. 2008, Pichery 
et al. 2012, Cayrol and Girard 2014). It was summarized by Cayrol and Girard 2014 
that (i), in the homeostatic state, IL-33 localizes in the nucleus of epithelial cells, 
with no ST2-dependent cytokine activity and inflammation; and (ii), during the 
programmed cell death, cleavage of IL-33 within the IL-1-like cytokine domain by 
caspases 3 and 7, abolishes its cytokine activity and consequent inflammation. It was 
concluded that IL-33 is thought to function as an 'alarmin', which is released 
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following cell necrosis to alert the immune system to tissue damage or stress (Miller 
2011). Cayrol and Girard also proposed that during cell damage or mechanical injury 
associated with during necrosis or necroptosis (a form of “programmed necrosis”, a 
new model of cell death, showing the morphological features of necrosis but highly 
regulated by an intracellular protein platform like apoptosis) (Vandenabeele et al. 
2010), biologically active full-length IL-33 (the IL-1-like cytokine domain) is 
released from the nucleus into the extracellular environment followed by the 
cleavage of IL-33 in the central domain (Molofsky et al. 2015). This somewhat 
explains the reason for retention of full-length IL-33 in cells. 
So far, the nuclear role(s) of IL-33 remains unclear. However, IL-33 can be 
involved with chromatin by tethering to histones H2A/H2B, via a short chromatin-
binding motif, located in its N-terminal nuclear domain (Carriere et al. 2007, Roussel 
et al. 2008). It has recently been shown that deletion of this chromatin-binding 
nuclear domain result in constitutive extracellular release of the protein, ST2-
dependent multi-organ inflammation and death of the organism (Bessa et al. 2014). 
Thus, nuclear localization (retention) is a fundamental property of IL-33, which is 
crucial for regulation of its cytokine activity (Cayrol and Girard 2014).  
Notably, after mutating residues 47-49 of chromatin binding motif of both 
human and mouse full-length IL-33, soluble human and mouse FL-IL-33 were 
successfully purified from the supernatant of the transfected HEK293T cells, with 
the theoretical size of 34.1kDa and 33.3kDa, respectively. Because of both of human 
and murine FL-IL-33 are predicted to be N-glycosylated, the actual band size in 
Figure 3.9C and Figure 3.10C is greater than the computational size. 
Although it is understood that a human full-length IL-33 protein was 
commercially available in the year of 2017 by Abnova (Cat No. H00090865-P01), it 
is a recombinant protein expressed in vitro in a wheat germ extract system, and has a 
size of 57.2kDa. However, in the construct reported here, the chromatin-binding 
motif-mutated human full-length IL-33 is codon optimized to this mammalian 
expression system and expressed in human embryonic kidney cells 293 (HEK293T 
cells) with 34.1kDa, indicating a lower degree of post-translational modification and 
arguably providing a final product closer to the natural human protein. 
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Mast cells (MCs) belong to the white blood cell lineage, however, they reside 
in peripheral tissues and are well situated to respond immediately to invasive agents 
(Anthony et al. 2007). MCs are involved in many instances of parasite expulsion 
(Murphy and Weaver 2016). Upon infection with Strongyloides species, the TH2 
cytokines, IL-3 and IL-9, stimulate mast cell growth and degranulation, increasing 
smooth muscle contraction (Maizels and Holland 1998). Antibodies against c-kit 
receptor, which normally acts to promote mast cell maturation, impedes mouse 
mucosal mastocytosis and parasite expulsion (Faulkner et al. 1997). Previously, a 
role for mast cells in helminth immunity had also been shown in Trichinella spiralis, 
in which it was reported, using W/Wv mice or stem-cell factor (SCF)-specific 
antibodies that impair mast-cell function, that SCF is required for mucosal 
mastocytosis and effective helminth expulsion (Grencis et al. 1993, Newlands et al. 
1995). Interestingly, it was shown that mouse mast cell protease 1 (mMCP-1; also 
known as Mcpt1 and β-chymase)-deficient mice are unable to expel T. spiralis; 
however, mMCP-1 deficiency has little effect on N. brasiliensis host resistance 
(Knight et al. 2000, Anthony et al. 2007). Furthermore, it was inferred by Anthony et 
al. 2007 that mMCP-1 might function to impair epithelial-cell barriers by degrading 
the tight junction protein occluding, increasing luminal fluid flow (McDermott et al. 
2003, Pennock and Grencis 2006). In the intestinal setting, mast cell products are 
thought to promote fluid egress through relaxing tight junctions, and to trigger 
muscular contraction, hence underpinning the “weep-and-sweep” response. For 
instance, upon infection with gastrointestinal helminths (H. polygyrus bakeri and 
Trichuris muris), mast cell-deficient mice had dramatically reduced TH2 cytokine 
production and increased parasite burdens (Hepworth, Maurer and Hartmann 2012b), 
demonstrating a novel role for gastrointestinal mast cells in the early events that lead 
to the generation of TH2 immunity to helminth infection (Hepworth et al. 2012b). 
However, MCs do not appear to have a key role in schistosomiasis, although they 
might contribute to the immune response at early stages of infection when the 
cercariae penetrate the skin (Gerken, Vaz and Mota-Santos 1990). Thus, it would be 
interesting to know whether MCs play a role in adult or microfilariae Brugia malayi 
infection, as the adult of this species live in the lymphatics whereas the microfilariae 
live in the blood stream of the host, like the schistosomes.  
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As mentioned in the introduction, mast cells work together with IgE to cause 
rejection of parasites including ticks and helminths in the tissues and skin (Murphy 
and Weaver 2016). Notably, it has been shown that IL-33 is a potent activator of 
mast cells and can induce their degranulation, maturation, and production of pro-
inflammatory cytokines, like IL-6 (Allakhverdi et al. 2007, Iikura et al. 2007). Most 
recently, it was also reported that the processing of IL-33 into mature bioactive IL-33 
can also be mediated by mast cell serine proteases, namely chymase and tryptase 
(Lefrançais et al. 2014). Very recently, it was shown by Shimokawa et al., 2017 that 
mast cells are a potent source of IL-33, crucial for ILC induction and clearance of H. 
polygyrus (Shimokawa et al. 2017). However, the important question remains of 
whether mast cells are important in protecting non-intestinal nematodes, and is 
subject to ongoing investigation. 
Another clear finding was that cleaved human IL-3395-270 significantly 
increased IL-6 secretion by mast cells compared to the full-length protein. Cleavage 
of the full-length IL-33 can either inactivate the cytokine (Schmitz, et al. 2005 and 
Cayrol and Girard, 2009), or generate a C-terminal fragment of greater activity. Thus 
caspase-1 cleaves FL-IL-33 into two different bands IL-33179-270 and IL-331-178, 
neither of which retain biological activity (Cayrol and Girard 2009). In contrast, a 
number of proteases can cleave human full-length IL-33 into a more active form. In 
addition to neutrophil elastase and cathepsin G which cleave human full-length IL-
331-270 into IL-3395-270 and IL-33109-270 (Lefrançais et al. 2012), the mast cell 
proteases, tryptase and chymase, cleave FL-IL-33 into IL-3395–270, IL-33107–270, and 
IL-33109–270, which were 30-fold more potent than full-length human IL-331–270 for 
activation of ILC2s ex vivo (Lefrançais et al. 2014).  
Thus, based on current knowledge, at least four enzymes including neutrophil 
elastase, cathepsin G, mast cell chymase and tryptase can cleave human full-length 
IL-331–270 into active fragments such as IL-3395-270. It is then inferred that the full-
length human IL-331-270 is firstly cleaved by neutrophil cathepsin G and elastase into 
cleaved human IL-3395-270, IL-3395-270 then enhances IL-6 secretion by mast cells. As 
IL-6 release represents mast cell activation, more proteases could then be secreted 
from mast cells, in particular chymase and tryptase. To amplify the cycle, these 
proteases then could cleave more full-length IL-33 into mature active IL-3395-270, to 
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maximise the TH2 immune response stimulated in the host. This is consistent with 
the very recent finding that mast cells play a role as a crucial source of IL-33, which 
can activate ILC2 responsible for parasite expulsion in the early phase, following 
infection with the intestinal helminth, H. polygyrus ((Bouchery and Harris 2017, 
Shimokawa et al. 2017).  
There have been a couple of reports suggesting that IL-6 plays an important 
role in helminth infection. It was demonstrated using IL-6 deficient mice that IL-6 
promotes host susceptibility following helminth infection (H. polygyrus) by 
impeding TH2 responsiveness and altering regulatory T (Treg) cell phenotype 
(characterized by lower expression of Foxp3, Helios and GATA3, and increased 
production of IL-2 and IL-17). Moreover, restoration of normal Treg cell function 
decreased the TH2 cell response to H. polygyrus. This suggests that IL-6 stabilizes 
Treg cells during helminth infection (Smith and Maizels 2014). As described earlier, 
IL-6 release also triggers mast cell activation, and it would therefore be important to 
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CHAPTER4  
Functional  analysis  of  Bm-­SPN-­2,  
Brugia  malayi  microfilariae  major  
secreted  product    
ABSTRACT 
 
The most abundant secreted product from Brugia malayi microfilaria stage, serine 
protease inhibitor-2 (Bm-SPN-2) was found to specifically inhibit the enzymatic 
activity of human neutrophil elastase and cathepsin G in a dose-dependent manner. 
Subsequently, however, another group had reported that Bm-SPN-2 is a non-
inhibitory member of the serpin family. More recently, these two neutrophil enzymes 
have been linked to the activation of the major innate cytokine IL-33 and its release 
as an active C-terminal domain following stimulation. Thus, the hypothesis was 
proposed that Bm-SPN-2 blocks full-length (FL) IL-33 cleavage by inhibiting 
neutrophil elastase or cathepsin G. Here, recombinant Bm-SPN-2 was expressed into 
E. coli and soluble Bm-SPN-2 was purified. Furthermore, using western blotting, it 
was confirmed that human neutrophil cathepsin G cleaves human full-length IL-33 
into two major bands Hs IL-3395-270 and Hs IL-33109-270, whereas neutrophil elastase 
cleaves human full-length IL-33 into one major product IL-3399-270. It was also 
shown that neutrophil CG cleaves murine full-length IL-331-266 into a major band 
mIL-33102-266, whereas neutrophil elastase cleaves mIL-331-266 into two different 
products mIL-33102-266 and mIL-33109-266. It was then found that using a commercial 
enzyme activity assay, Bm-SPN-2 did not show any inhibitory function against 
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human neutrophil cathepsin G. However, utilizing Western blotting, it was 
demonstrated that Bm-SPN-2 could inhibit human IL-33 cleavage by inhibiting this 
enzyme in a dose-dependent manner. Finally, Bm-SPN-2-mCherry construct was 
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4.1  Introduction  
4.1.1  Serine  protease  inhibitors  
The term ‘serpin’ (serine proteinase inhibitor) was originally coined as a superfamily of 
structurally conserved proteins (Pfam No. PF00079) (Huntington, Read and Carrell 
2000). They are typically 350–500 amino acids in size (Silverman et al. 2001) with 
corresponding molecular weights of 40-60 kDa (van Gent et al. 2003), and those with 
inhibitory activity employ a suicide substrate-like mechanism: The structure of the 
reactive centre loop (RCL) is a critical feature for serpin to undergo the conformational 
change, including the permanent loss of 37% of the structure and overall distortion of 
the protease, necessary for inhibitory activity (Huntington et al. 2000, Irving et al. 2000, 
van Gent et al. 2003). It was shown by Huntington et al. (2000) that the permanent loss 
of the protease structure is a direct consequence of the limited length of the serpin RCL, 
which causes the ‘plucking away’ of the protease ester-linked serine from its catalytic 
partners, hence the name ‘suicide’ substrate inhibitors (Molehin et al. 2012, Huntington 
et al. 2000). Over 1000 serpins have now been identified in species as diverse as 
bacteria, fungi, viruses, plants, insects, birds, and mammals. In humans, serpins have 
evolved to be a predominant family of protease inhibitors with 36 recognised members 
(Huntington et al. 2000). 
Smapins (small serine protease inhibitors) are small proteins distinct from 
serpins and comprise no more than 100 amino acid residues. These inhibitors appear to  
be unique to nematodes, with no recognizable relatives from any other organism 
(Molehin et al. 2012, Zang and Maizels 2001). 
In mammals, serpins play an important role in the regulation of many 
fundamental processes, including blood coagulation, complement activation, cell 
development and inflammation (Potempa, Korzus and Travis 1994, Knox 2007). Some 
serpins are uniquely involved in more diverse functions such as the control of 
chromatin folding and Toll signalling (Grigoryev, Bednar and Woodcock 1999, 
Levashina et al. 1999). 
Serpins are also expressed by parasitic nematodes, and thought to help parasites 
avoid host immune defences (Molehin et al. 2012). The likely nematode serpin and 
smapin genes have been summarized in Zang and Maizels, 2001 and Molehin et al. 
2012, with eight serpin genes (Ce-SPN-1, …Ce-SPN-8) being identified in the model 
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organism, Caenorhabditis elegans, and four in a range of parasitic nematode species, 
including Ascaris suum, B. malayi, Onchocerca volvulus and Trichostrongylus vitrines, 
as well as in trematode Schistosoma spp. and the cestodes Echinococcus multilocularis 
and E. granulosus. In addition, nematode smapins have been identified in Anisakis 
simplex (Kobayashi et al. 2007), A. suum (Grasberger et al. 1994), Ancylostoma 
caninum (Duggan, Dyson and Wright 1999), O. volvulus (Ford et al. 2005) and 
Trichuris suis (Rhoads et al. 2000b, Rhoads et al. 2000a) (Table 1.1).  
The metastable conformation of serpins is required for their inhibitory activity 
(Zang and Maizels 2001). The serpins consist of a conserved tertiary structure 
comprising nine alpha helices and three beta sheets A, B and C (Silverman et al. 2001). 
Key features include a serpin motif, a reactive site loop (the functional domain near the 
C-terminus) and a serpin signature sequence (Knox 2007). The functional domain 
‘reactive site loop’ is exposed on the surface and contains a scissile bond which acts as 
a cleavable bait to trap the target proteinase, inducing a profound change in its 
conformation and thus inhibiting proteases (Huntington et al. 2000). 
A total of 14 serpins have been predicted in the B. malayi genome, but only two 
- Bm-SPN-1 and Bm-SPN-2 - have been characterized to be secretory (Zang et al. 1999, 
Molehin et al. 2012, Ballesteros et al. 2016). Phylogenetic analysis shows that Bm-
SPN-1 and -2 have low homology and are not closely related, sharing only 27.8% 
identity (110/395) at the amino acid level but showing conserved ‘motif’ and 
‘signature’ sequences (Zang and Maizels 2001). Bm-SPN-1 is detected in all life cycle 
stages, but little is known about its target protease(s) (Yenbutr and Scott 1995). Neither 
Bm-SPN-1 nor any of the other serpins appear to be secreted from adult worms, as no 
serpin was detected in adult B. malayi “excretory-secretory” (BES) proteins (Hewitson 
et al. 2008). Bm-SPN-2 was subsequently confirmed as specific for the microfilarial 
stage, by both proteomic analysis and transcriptome sequencing (Moreno and Geary 
2008, Bennuru et al. 2009, Li et al. 2012, Ballesteros et al. 2016). Bm-SPN-2 will be 
described in the following section. 
4.1.2  Bm-­SPN-­2  discovery  and  disputed  functions  
In order to identify prominent antigens from bloodstream B. malayi microfilariae 
(Mf) proteins that might be recognized by the host immune system’s T lymphocytes, 
previous research in the Maizels lab isolated a fraction from Mf proteins of 35-55 
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kDa which potently stimulated antigen-specific T-cell proliferation and cytokine 
production (Zang et al. 1999). A clone encoding a native serine proteinase inhibitor 
protein, with a molecular mass of 47.5 kDa, was then identified as a major T cell 
antigen and isolated by immunoscreening of an Mf cDNA library (Zang et al. 1999). 
It was designated as Bm-SPN-2 because of the similarity to the previously described 
Bm-SPN-1 by Yenbutr and Scott (1995) (Yenbutr and Scott 1995).   
Through the following studies, Bm-SPN-2 was demonstrated to be the most 
abundant protein only secreted by the B. malayi microfilarial stage. Using first-strand 
cDNA from a range of B. malayi stages (L3, adult female, adult male, Mf) as templates, 
transcription of Bm-SPN-2 by 2 gene-specific primers was only detected in blood-
dwelling microfilariae. As stated above, no serpin was detected from B. malayi 
“excretory-secretory” (BES) proteins from adult worms (Hewitson et al. 2008). Bm-
SPN-2 was further confirmed as specific and one of the most abundant proteins for the 
microfilarial stage by proteomic analyses and transcriptome sequencing in independent 
laboratories (Moreno and Geary 2008, Bennuru et al. 2009, Li et al. 2012, Ballesteros et 
al. 2016). 
In the original studies, the open reading frame encoding Bm-SPN-2 lacking the 
signal peptide was subcloned into the pET-29 E. coli expression vector, permitting 
expression of recombinant Bm-SPN-2 as a fusion protein containing a C-terminal 
hexahistidine-tag for affinity purification, with molecular weight of 52 kDa (Zang et al. 
1999). 
When tested for its ability to inhibit a panel of mammalian serine proteases with 
differing substrate specificity and function, Bm-SPN-2 protein was found to specifically 
inhibit the enzymatic activity of human neutrophil elastase and cathepsin G in a dose-
dependent and highly specific manner (Zang et al. 1999). In that study, human 
neutrophil cathepsin G or elastase was incubated with Bm-SPN-2. After 10 minutes of 
incubation at room temperature, a corresponding peptidyl-p-nitroanilide substrate 
solution was added to the mixture, and the residual enzyme activity was measured by 
monitoring the absorbance change at 405nm with time. The enzymes and their 
substrates used in the tests were human neutrophil cathepsin G (1 µg/µL, Athens 
Research & Techology, Inc) and N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (Sigma); 
human neutrophil elastase (1 µg/µL, Athens Research & Techology, Inc) and N-
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succinyl-Ala-Ala-Pro-Leu-p-nitroanilide (Sigma) (Zang et al. 1999, Jiang and Kanost. 
1997).  This specificity of inhibition was confirmed by the fact that Bm-SPN-2 showed 
no inhibitory activity with bovine pancreatic α-chymotrypsin or porcine pancreatic 
elastase, two enzymes which hydrolyze the same substrates as human neutrophil 
cathepsin G and elastase, respectively (Zang et al. 1999, Molehin et al. 2012).  
However, Stanley and Stein disputed this result by analyses which concluded 
that Bm-SPN-2 is a non-inhibitory serpin, which has no effect on the activity of 
neutrophil cathepsin G or elastase (Stanley and Stein 2003). This group also expressed 
the Bm-SPN-2 protein in E. coli, and characterized its structural and functional 
properties. Comprehensive sequence alignment, phylogenetic analysis, and 
susceptibility to cleavage by proteases suggested that the Bm-SPN-2 shared the 
conserved tertiary structure of the serpin family, including a reactive centre loop (Irving 
et al. 2000). However, they found that the protein had no effect on the activity of 
neutrophil cathepsin G or elastase and did not undergo the characteristic stressed to 
relaxed transition required for protease inhibition by serpins. As in the study by Zang et 
al., Stanley and Stein determined proteinase inhibition by measuring the release of p-
nitroanilide at 405 nm at 37°C, using a different substrate N-methoxysuccinyl-Ala-Ala-
Pro-Val-p-nitroanilide for elastase, but the same substrate N-succinyl-Ala-Ala-Pro-Phe-
p-nitroanilide for cathepsin G. The absorbance was measured on a Shimadzu UV-1601 
spectrophotometer at 405 nm at 25 °C (Stanley and Stein 2003). These authors 
concluded that Bm-SPN-2 was a new non-inhibitory serpin. Therefore, it was thought 
worthwhile to re-assess the previous conclusion about the function of Bm-SPN-2 and its 
ability to inhibit the neutrophil cathepsin G and elastase. 
A further question is whether Bm-SPN-2 influences the host-parasite 
relationship in vivo.  Mice infected with B. malayi microfilariae mount a strong but 
short-lived Bm-SPN-2-specific TH1 response with significant increases in IFN-γ 
production (Zang et al. 1999, Zang et al. 2000). Human filariasis patients displayed a 
potent humoral response to Bm-SPN-2 but primarily in both IgG1 and IgG4 antibody 
subclasses, which are promoted by TH2 cytokines, hence if there is also a TH1 
response to Bm-SPN-2 in humans, it may also be short-lived (Zang et al. 2000). 
Overall, Bm-SPN-2 was suggested to play an important role in neutralizing the 
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immunostimulatory properties of the host neutrophils proteases and contributing to the 
longevity of Mf in the host bloodstream (Molehin et al. 2012). 
It is interesting now to ask whether Bm-SPN-2 interacts with the IL-33 pathway. 
Analysis of tissue mRNA isolated from mice treated with IL-33 each day by Schmitz et 
al. demonstrates that IL-33 drives the TH2 immune response by inducing the 
expression of IL-4, IL-5, and IL-13, as measured by quantitative PCR, and leads to 
severe pathological changes in mucosal organs (Schmitz et al. 2005). More recently, it 
was reported by Corinne et al. that both full-length human and murine IL-33 are 
processed into mature bioactive IL-33 by the two human neutrophil proteases, cathepsin 
G and elastase (Lefrançais et al. 2012), that Zang et al found to be targeted by Bm-SPN-
2 (Zang et al. 1999).   
Based on these findings, we hypothesized that Bm-SPN-2, as the most abundant 
product secreted specifically from microfilariae stage, could impede IL-33 cleavage 
into mature bioactive forms by inhibiting the activity of these two enzymes, then block 
TH2 initiation, helping microfilariae avoid the protective arm of the host immune 
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4.2  Results  
4.2.1  Bm-­SPN-­2  expression  and  purification  
To express recombinant Bm-SPN-2, the plasmid pET29-Bm-SPN-2-His, previously 
constructed by Zang et al. (Zang et al. 1999), was used for transformation of JM109 
E. coli cells. The Mini-Prep product of pET29-Bm-SPN-2-His was sequenced to 
verify the nucleotide sequence of the insert, with the result presented in Appendix 3. 
To determine the optimal conditions of Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) induction, four groups were designed for expression as set out in Figure 
4.1A, with the results presented in Figure 4.1B. Notably, clear expression of the 
recombinant protein was found in all protocols, with the best induction condition for 
protein expression found to be 0.1mM IPTG for 3 hours. Bm-SPN-2 with the size of 
about 52kDa was purified on a chelating Nickel Column on the AKTA Prime 
machine. The original Bm-SPN-2 was encoded by 428-aa, (the protein structure of 
recombinant Bm-SPN-2 is shown in Figure 4.2A,) with the signal peptide deleted and 
restriction enzymes NdeI and XhoI added at the both end of the insert. The trace of 
purified fractions is shown in Figure 4.2B, and the coomassie blue staining of the 
purified fractions in Figure 4.2C. Protein concentrations are estimated based on OD 
280 using a Nanodrop ND-1000 Spectrophotometer or using Bradford assay. After 
purification, we obtained a total of 9.778 mg Bm-SPN-2 protein with the 
concentration of 1.8mg/ml, which was stored at -80°C until use.  
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Figure 4.1: Different conditions of IPTG Induction for Bm-SPN-2 expression.  
(A) Table of different conditions tested for IPTG induction of Bm-SPN-2 protein expression. 
(B) Coomassie blue staining of SDS-PAGE gel from each IPTG induction group. “kDa” 
means “molecular weight in kilodaltons”. “G1-un-“ stands for “Group 1 un-induced”, “G1-
1hr” “G1-2hr” and “G1-3hr” represent “Group 1 post-induced 1 hour”, “Group 1 post-
induced 2 hours” and “Group 1 post-induced 3 hours”. “1mM” and “0.1mM” are the 
concentration of IPTG. Group 1 and 2 were incubated at 37°C, while Group 3 and 4 were 
incubated at 20°C.  
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Figure 4.2: Recombinant Bm-SPN-2 structure and purification. 
(A) Schematic of the Bm-SPN-2 produced, with vector sequences in red and restriction sites 
used indicated. Signal peptide of Bm-SPN-2 was deleted. NdeI (CATATG) in purple and XhoI 
(CTCGAG) in brown were placed either side of the Bm-SPN-2 insert and a 6-Histidine tag 
inserted at the C-terminal end.  The insert has a total size of 1236 bp and 412aa. 
(B) The UV trace of purified fractions from Bm-SPN-2. The elution gradient is indicated on 
each trace with a gradient from 0% to 50% of Elution buffer with 4M imidazole. Fractions 
were collected in Eppendorf tubes. Blue and purple arrows direct fraction 8 and 9, and 
fractions 10-15, respectively. 
(C) SDS-PAGE of the purified fractions of Bm-SPN-2 by Coomassie Blue Staining. “M” 
stands for marker: SeeBlue® Plus2 Pre-stained Protein Standard. Fractions 10-12 have a 
clean and strong band about 52kDa, fractions 13-15 also have a clear band (purple arrow).  
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4.2.2  Full-­length  IL-­33  cleavage  by  neutrophil  cathepsin  G  and  
elastase  
Previously, Lefrançais et al., demonstrated that neutrophil serine proteases cathepsin 
G and elastase can cleave full-length human IL-331-270 and generate mature forms IL-
3395-270 and IL-33109-270, and IL-3399-270, respectively. Murine full-length IL-33 is 
also cleaved by these two enzymes (Lefrançais et al. 2012). In order to verify 
whether Bm-SPN-2 blocks IL-33 cleavage via western blotting, it was first confirmed 
that neutrophil cathepsin G and elastase can cleave full-length human and mouse IL-
33 into cleaved forms in our own laboratory.  
Using human and murine full-length IL-33 provided by Cayrol et al and 
commercial human neutrophil cathepsin G (Calbiochem®, Cat: 219373-100MIU) 
and elastase (Calbiochem®, Cat: 324681-50UG), these collaborative experiments 
were undertaken with the group of Cayrol et al. 
For human IL-33 cleavage, 2µl of full-length IL-331-270 was incubated with 
human neutrophil Cathepsin G (0.025mU/µl) for 1 hour at 37℃ or for 30 minutes 
with human neutrophil Elastase (0.01mU/µl). Following incubation, proteases were 
inactivated by heating 95℃ 5 minute and samples loaded immediately onto SDS-
PAGE gel. Western blotting was then performed with anti-human IL-33, using Hs IL-
33 (305B) monoclonal antibody from Adipogen as primary antibody and anti-mouse 
HRP from Promega as secondary antibody (the workflow of human IL-33 cleavage 
experiment is shown in Figure 4.3A). As the western blotting shown in Figure 4.3B, 
human neutrophil Cathepsin G (0.025mU/µl) cleaves human full-length IL-331-270 
into two major products: Hs IL-3395-270 of about 21kDa and Hs IL-33109-270 of around 
18kDa. In addition, human neutrophil elastase (0.01mU/µl) less efficiently cleaves 
human full-length IL-331-270 into one major product Hs IL-3399-270 with the size of 
∼20 kDa (in the right-hand panel of Figure 4.3B), which is consistent with the 
previous finding of Lefrançais et al, although it was not showing relatively weak 
cleavage (Lefrançais et al. 2012), suggesting higher concentration of neutrophil 
elastase is needed. Proteins were comigrated on SDS-PAGE with 1µl in vitro-
translated Hs IL-3395-270 and Hs IL-33109-270. 
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For murine full-length IL-33 cleavage experiment, a similar procedure was 
performed as human IL-33, followed by anti-mouse IL-33 western blotting and 
revealed by primary antibody goat anti-mouse IL-33 (R&D systems AF3626) and 
secondary antibody donkey anti-goat-HRP V8051 (Promega A16005) (the workflow 
of mouse IL-33 cleavage experiment is shown in Figure 4.4A). It is shown in Figure 
4.4B that compared to the concentration of 0.005mU/µl, 0.025mU/µl of neutrophil 
Cathepsin G could completely cleave 2µl murine IL-331-266 into a major cleavage 
product: Mm IL-33102–266 with the size of ∼20 kDa, whereas 0.05mU/µl of neutrophil 
Elastase could fully cleave murine IL-331-266  into a similar major cleavage product 
Mm IL-33102–266 and a second minor product Mm IL-33109–266 (∼18 kDa), which is 
also consistent with the previous findings of Lefrançais et al (Lefrançais et al. 2012).	  
Proteins were comigrated on SDS-PAGE with 1µl in vitro-translated murine IL-
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Figure 4.3: Human neutrophil cathepsin G (CG) or neutrophil elastase (NE) cleaves 
human full-length IL-33 into cleaved forms. 
(A) Workflow of human IL-33 cleavage experiment by CG or NE. 
(B) PBS, CG (0.025mU/µl) or NE (0.01mU/µl) were incubated with 2µl human full-length 
IL-331-270. Human FL-IL-33 (yellow arrow) was cleaved into two major bands by CG: Hs 
IL-3395-270 (red arrow at the left) and Hs IL-33109-270 (blue arrow at the left), whereas one 
major band Hs IL-3399-270 was observed after cleavage by NE. Proteins were comigrated on 
SDS-PAGE with in vitro-translated Hs IL-3395-270 (red arrow at the right) and Hs IL-33109-270 
(blue arrow at the right) and revealed by western blot with primary antibody Hs IL-33 (305B) 
monoclonal antibody from Adipogen and secondary antibody mouse HRP from Promega. 
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Figure 4.4: Murine full-length IL-33 cleavage processed by human neutrophil 
cathepsin G (CG) and elastase (NE). 
(A) Workflow of murine IL-33 cleavage experiment by CG or NE. 
(B) PBS, CG (0.025mU/µl and 0.005mU/µl) or NE (0.05mU/µl and 0.005mU/µl) were 
incubated with 2µl murine full-length IL-331-266. Proteins were comigrated on SDS-PAGE 
with 1 µl in vitro-translated murine IL-33102–266 (~20kDa) and revealed by western blot with 
primary antibody goat anti-mouse IL-33 (R&D systems AF3626) and secondary antibody 
Donkey anti-goat-HRP V8051 (Promega A16005).  Mouse FL-IL-33 was cleaved into one 
major band by human neutrophil CG: Mm IL-33102-266 (purple arrow) with the size of about 
20kDa, whereas one major band Mm IL-33102-266 and a second minor band MmIL-33109-266 
(blue arrow) were observed after cleavage by human neutrophil NE.   
  
 
                                                                 Chapter 4. Functional analysis of Bm-SPN-2 
	  	   97	  
 
4.2.3  Investigating  the  effects  of  Bm-­SPN-­2  on  IL-­33  cleavage    
4.2.3.1  Testing  Bm-­SPN-­2  for  its  ability  to  block  IL-­33  cleavage    
In order to verify whether Bm-SPN-2 blocks human and murine full-length IL-33 
cleavage by inhibiting the enzyme activity of human neutrophil cathepsin G or 
elastase, different concentrations of Bm-SPN-2 were pre-incubated with human 
neutrophil Cathepsin G (0.025mU/µl) or elastase (0.01mU/µl) for 10 minutes at 37℃, 
prior to adding 1 or 2µl of human or murine full-length IL-33. Similar steps were 
then performed as in the IL-33 cleavage experiments above, followed by anti-human 
or murine IL-33 western blotting, respectively (the workflow is shown in Figure 
4.5A).  
To test whether Bm-SPN-2 blocks human IL-33 cleavage, as shown in Figure 
4.5B, 0, 1, 2, 3 and 4 µg/µl of Bm-SPN-2 was pre-incubated with 0.025mU/µl 
cathepsin G or heat treated (95℃ 5 minutes) CG prior to adding 2µl of full-length 
human IL-33 protein produced in rabbit reticulocyte lysate (RRL). (kindly provided 
by the group of Cayrol et al.) In order to reveal the expected cleaved bands of human 
IL-33, a 13.5% SDS-PAGE gel was made for western blotting. Proteins were 
comigrated on SDS-PAGE with 1µl in vitro-translated human IL-3395–270 and Hs IL-
33109–270. In addition to visualising protein migration on the gel (Figure 4.5B), the 
band intensities were of human full-length and cleaved IL-33 were quantified as in 
Figure 4.5C. The results showed that with increasing concentrations of Bm-SPN-2, 
the band signal of full-length IL-33 increased correspondingly, whereas the band 
signal of lower band of cleaved IL-33 (109-270) decreased.  However, in this 
experiment Bm-SPN-2 was not able to fully block the cleavage of IL-33. 
An additional experiment was then conducted, to evaluate increasing the 
concentration of Bm-SPN-2 up to 6µg/µl while reducing the full-length IL-33 down 
to 1µl, directly using the human RRL IL-33 from the previous paper of Lefrançais et 
al., (Lefrançais et al. 2012) without measuring the concentration of IL-33. According 
to this paper, Lefrançais et al. mapped the cathepsin G cleavage sites at F94 and 
L108 in the human IL-33 sequence. Surprisingly, the upper band of cleaved IL-3395–
270 but not the lower band of cleaved IL-33109–270 were detected after western blotting. 
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This finding might be due to there being very little FL-IL-33 and a higher amount of 
Bm-SPN-2 protein blocking the CG cleavage site L108 of the FL-IL-33. It was also 
found that inhibition is significantly increased at 6µg/µl of Bm-SPN-2, which can 
almost completely block the cleavage of the human IL-33 (Figure 4.5D). The 
quantification of the band intensity of full-length and cleaved IL-33 were analysed in 
Figure 4.5E, showing that there is almost no signal for the cleaved IL-33 when using 
6µg/µl of Bm-SPN-2. However, it was not possible to obtain any evidence that Bm-
SPN-2 blocks the cleavage of human IL-33 by human neutrophil elastase. 
To test whether Bm-SPN-2 also blocks murine IL-33 cleavage by inhibiting 
these two enzymes, a similar workflow was performed as shown in Figure 4.6A. It 
was demonstrated that Bm-SPN-2 does show some ability to block mouse IL-33 
cleavage by inhibiting neutrophil elastase in a dose-dependent manner (see Figure 
4.6B). However, even the highest concentration of Bm-SPN-2 (6µg/µl) could not 
completely inhibit the function of neutrophil elastase to cleave mouse full-length IL-
33. In contrast, heat-treated neutrophil elastase could no longer cleave murine full-
length IL-33. Unfortunately, unlike the human IL-33 cleavage experiment (Figure 
4.5), it was not possible to analyse western blotting of mouse IL-33 cleavage (Figure 
4.6) accurately on the LI-COR® Image Studio Lite software, due to resolution and 
background problems. However, interestingly, Bm-SPN-2 shows slight inhibitory 
function against Cathepsin G cleavage of mouse IL-33 but did not to do so in a dose-
dependent manner (see Figure 4.6C). As each of the Western blotting experiments 
with both human and murine full-length IL-33 were performed only once (due to the 
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Figure 4.5 Bm-SPN-2 inhibits human full-length IL-33 cleavage by human neutrophil 
CG in a dose-dependent manner.  
(A) Workflow of human IL-33 cleavage inhibition test by Bm-SPN-2.  
(B) Western blotting of human IL-33 following cleavage by human neutrophil cathepsin G 
in the presence of Bm-SPN-2. 0, 1, 2, 3, 4 µg/µl of Bm-SPN-2 were pre-incubated with 
0.025mU/µl CG or heat treated (HT) CG. 2µl of human full-length IL-33 protein produced in 
rabbit reticulocyte lysate (RRL) was used. 13.5% SDS-PAGE gels were used to reveal 
cleaved bands. Proteins were comigrated on SDS-PAGE with in vitro-translated Hs IL-3395-
270 and Hs IL-33109-270 and revealed by western blot with primary antibody Hs IL-33 (305B) 
monoclonal antibody from Adipogen and secondary antibody mouse HRP from Promega.  
(C) Quantification of the human full-length and lower mol.wt cleaved IL-33 bands from the 
western blot shown in Panel B.   
                                                                 Chapter 4. Functional analysis of Bm-SPN-2 
	  	  100	  
(D) Western blotting of human IL-33 following cleavage by neutrophil cathepsin G in the 
presence of higher concentrations of Bm-SPN-2. 1, 3, 6 µg/µl of Bm-SPN-2 were pre-
incubated with 0.025mU/µl CG or heat treated (HT) CG. 1µl of human full-length IL-33 
proteins produced in rabbit reticulocyte lysate (RRL) was used here. 
(E) Quantification of the human full-length and cleaved IL-33 bands from the western blot 
shown in Panel D. Western blotting of different amounts of human FL-IL-33 was only 
performed once, as the sample of FL-IL-33 is very limited. Western blot quantification was 
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Figure 4.6: Inhibitory functional test of Bm-SPN-2 in a murine IL-33 cleavage 
experiment with neutrophil cathepsin G or elastase.  
(A) Workflow of murine IL-33 cleavage inhibition test by Bm-SPN-2.  
(B) Bm-SPN-2 inhibitory function test on murine IL-33 cleavage by neutrophil elastase.  1, 3, 
6 µg/µl of Bm-SPN-2 were pre-incubated with 0.05mU/µl NE prior to adding 2µl murine 
full-length IL-33.  “HT NE” stands for heated treated neutrophil elastase. Heat treated NE 
can no longer cleave IL-33.  
(C) Bm-SPN-2 inhibitory function test through murine IL-33 cleavage by neutrophil CG.  0, 
1, 3, 6 µg/µl of Bm-SPN-2 were pre-incubated with 0.025mU/µl CG prior to adding 2µl 
murine full-length IL-33. Blue arrow indicates the murine full-length IL-33, green arrow 
shows the murine IL-33 (102-266) and red arrow indicates the murine IL-33 (109-266) 
fragment. Western blotting with the murine FL-IL-33 was performed only once, as the 
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4.2.3.2  Testing  Bm-­SPN-­2  inhibitory  function  by  enzyme  activity  assay  
Based on the previous result that Bm-SPN-2 blocks human IL-33 cleavage by 
inhibiting human neutrophil Cathepsin G in a dose-dependent manner, it was decided 
to verify this inhibitory function utilizing a commercial enzyme activity assay kit. 
Thus, the Cathepsin G activity colorimetric assay kit purchased from BioVision (Cat 
No. K146) was used to perform this experiment. In this assay kit, Cathepsin G 
cleaves the substrate and releases the dye group, pNA (4-Nitroaniline), which can be 
detected in the visible wavelengths at 405 nm. 
A range of different concentrations of Bm-SPN-2, as well as the 
corresponding concentrations of bovine serum albumin (BSA) as controls, cathepsin 
G inhibitor or phosphate-buffered saline (PBS) were incubated with human 
neutrophil cathepsin G for 20 minutes at 37℃. Next, the pre-incubated samples were 
directly diluted into the Assay Buffer, to take volumes up to 50 µl/well in a 96-well 
plate. Background controls added 10 µl Assay Buffer alone to one test sample, and 
10 µl diluted Cathepsin G inhibitor to another. Next, substrate solution was added to 
each sample well and mixed. Finally, absorbance was measured at 405nm at 37℃ at 
time zero and 1 hour later on an ELISA plate reader (the workflow of the cathepsin 
G activity assay kit is shown in Figure 4.7A).  
As shown in Figure 4.7B and 4.7C, however. no inhibitory activity could be 
detected. This was determined with two independent batches (A and B) of different 
concentration (1, 2.5 and 5µg/µl) of Bm-SPN-2, with no conditions showing 
inhibitory function against neutrophil cathepsin G, whereas CG inhibitor could 
inhibit the activity of Cathepsin G. Although the OD values of samples including 
Bm-SPN-2 were higher than those with CG alone, this may be accounted for a low 
level of intrinsic absorbance by Bm-SPN-2 itself (as shown in Figure 4.7C). 
In parallel, a fluorometric neutrophil elastase activity assay kit (Cat No. K383 
by Biovision) was also used to test the inhibitory function of Bm-SPN-2 against 
elastase. However, it proved unsuccessful to obtain a clear result due to problems 
with variability with the standard curve stable (data not shown). 
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Figure 4.7: Testing the inhibitory function of Bm-SPN-2 by enzyme activity assay kit of 
Cathepsin G. 
(A) Workflow of investigating the inhibitory function of Bm-SPN-2 by Cathepsin G Activity 
Colorimetric Assay Kit. 
(B) 1, 2.5 and 5µg/µl of Bm-SPN-2 batch A (pink round solid) or BSA (blue square), or 
cathepsin G inhibitor (Green triangle) was incubated with 0.5mU/µl of human neutrophil 
cathepsin G, or CG only (Brown triangle).  
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4.2.4  Production  of  mCherry-­labelled  Bm-­SPN-­2  
mCherry is a fluorescent protein used in biotechnology as a tracer to follow the flow 
of fluids, or as a marker for specific molecules and cell components. mCherry, 
derived from a protein isolated from Discosoma sp., is a monomeric fluorescent 
construct with peak absorption/emission at 587 nm and 610 nm, respectively. It is 
resistant to photobleaching and is relatively stable (Shaner et al. 2004). 
In Brugia malayi, two serpin proteins have been described, Bm-SPN-1 
(Yenbutr and Scott 1995) and Bm-SPN-2 (Zang et al. 1999). Although both Bm-
SPN-1 and Bm-SPN-2 were characterized to be secretory (Zang et al. 1999, Molehin 
et al. 2012), Bm-SPN-2 (GenBank: AF009825.1) shows very low similarity (53.4%, 
197/369) and identity (27.9%, 103/369) to the previously described Bm-SPN-1 
(GenBank: U04206.1) at the amino acid level; however conserved ‘motif’ and 
‘signature’ sequences can be recognized (Zang and Maizels 2001) (Figure 4.8). After 
mapping the protein sequence of Bm-SPN-2 against WormBase ParaSite website, it 
was shown to have 99.8 % identity with B. timori serpin and 96.7% identity with B. 
pahangi serpin (Figure 4.9). As reported by Zang et al. compared to homologues 
from other species such as Caenorhabditis elegans, Bm-SPN-2 has not only acquired 
a signal peptide but also an extra N-terminal tract (Figure 4.10) (Zang et al. 1999), 
which might be the crucial for interacting with host cells. In order to investigate any 
potential binding or uptake of Bm-SPN-2 with host cells such as human neutrophils 
to carry out its potential inhibitory function detected by the Western blotting, it was 
necessary to develop an m-Cherry labelled construct of Bm-SPN-2. Considering that 
we already had Bm-SPN-2 construct in pET29 vector, the first strategy was to insert 
the mCherry open reading frame into the previous construct at the site of restriction 
enzyme “XhoI”, at the 3' end of the Bm-SPN-2 coding sequence as shown in 
Appendix 4.1. An insert encoding mCherry was designed with XhoI and NotI 
restriction sites at the both ends and codon optimized for E. coli for gene synthesis in 
the pMK vector (bacterial resistance against kanamycin) by GeneArt®, as shown in 
Appendix 4.1.  Terminal NotI sites were included to allow the insert a more flexible 
use for any subsequent construct in the lab.  
As this strategy necessitated insertion into a single site in the coding 
sequence, it was not directional and equally the synthesized mCherry insert 
                                                                 Chapter 4. Functional analysis of Bm-SPN-2 
	  	   105	  
contained the same restriction enzymes at both ends. Hence, there would be only a 
50% chance of insertion in the correct orientation of mCherry sequence into the 
existing Bm-SPN-2 construct pET29T vector. Because the cut Bm-SPN-2 plasmid 
could reanneal at the single XhoI restriction site, calf-intestinal alkaline phosphatase 
(CIP) was applied to the XhoI digested Bm-SPN-2 construct to catalyze the removal 
of phosphate groups from the 5’ end of DNA strands (Sambrook, Fritsch and 
Maniatis 1989), thereby preventing recircularization of linearized vector DNA, and 
this step was expected to improve the yield of vector containing the appropriate 
insert (Ullrich et al. 1991). As the insert is relatively short (737 bp) compared to the 
XhoI-digested vector (6558bp), a range of different ratios of vector and insert were 
applied 1:5, 1:10, 1:20, 1:50 etc. Unfortunately, using these materials and the 
methods to hand, and despite a number of attempts, inserting the mCherry into the 
previous construct Bm-SPN-2 was not successful.  
An alternative strategy was then adopted to express full-length Bm-SPN--
mCherry fusion protein in the pET29 vector. The full nucleotide sequence of the 
desired Bm-SPN-2-mCherry protein was codon optimized for E. coli and gene 
synthesised by Invitrogen “GeneArt” Thermo Fisher Scientific; the insert was 
provided cloned into in pMA-T vector (containing an ampicillin resistance gene) 
with the structure shown in Figure 4.11A (Gene synthesis documents see Appendix 
4.2). As the pET29a vector encodes resistance against kanamycin, the vector and 
synthesized Bm-SPN-2-mCherry pMA-T were transformed into JM109 cells onto 
kanamycin and ampicillin agar plates, respectively. Plasmid minipreps of both insert 
and vector were double digested with restriction enzymes NdeI and XhoI, with an 
additional CIP treatment of the vector in case of incomplete cleavage permitting 
recircularization. The NdeI/XhoI digestion products from pET29a and Bm-SPN-2-
mCherry in pMA-T were analyzed by DNA gel (Figure 4.11B).  
Gel extraction of the lower mol wt band depicted in pink (Bm-SPN-2-
mCherry insert) was followed by ligation into the pre-cut pET29a (in blue frame) 
expression vector (Figure 4.11B). In order to maximise the chance of a large 
insertion (1953bp) into the pre-cut vector, very low amounts (down to 15.5ng) of 
vector and a range of different insert: vector ratios (such as 10:1; 20:1 and 50:1) were 
used for the ligation at 16℃ overnight, catalyzed by NEB T4 DNA ligase (M0202). 
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Following the ligation, transformation and plating of bacterial cells, new colonies 
were screened. The T7 promoter primer and T7 terminator reverse primer (specific 
primers for pET29a vector, primer sequences see section 2.4.2.1) were used to 
perform colony screens, colonies A, D, F, K, M and S were first chosen for 
sequencing and colony F proved to contain correct sequence (See Figure 4.11C, 
sequencing result see appendix 4.3).  
Next, the plasmid from the validated colony F was used to express the Bm-
SPN-2-mCherry fusion protein in E. coli. Purified plasmid was used to transform 
BL21 (DE3) chemically competent E. coli cells, which were then grown in 500ml 
cultures in the presence of 1mM IPTG for protein expression. Following 3 hours 
induction, bacteria were centrifuged and the BugBuster® protein Extraction Reagent 
was then used for extracting proteins into a soluble supernatant. The schematic of the 
proteins produced is shown in Figure 4.12A, showing the Bm-SPN-2-mCherry insert 
with the size of 1953bp being flanked with sites for the restriction enzymes NdeI and 
XhoI, and as a fusion protein containing a C-terminal hexahistidine-tag for affinity 
purification.  
Bm-SPN-2-mCherry protein was then purified by nickel chelating 
chromatography. The UV trace of purification is shown in Figure 4.12B, with 
material starting to elute from the fraction A8 and ending at fraction B5. It was 
striking to see that these fractions are visibly pink in colour, reflecting the presence 
of the mCherry component of the fusion protein.  
SDS-PAGE and anti-His western blotting of the purified fractions of Bm-
SPN-2-mCherry were then carried out, as shown in Figure 4.12C, 4.12D and 4.12E. 
By protein staining, a faint band can be observed with the molecular weight of Bm-
SPN-2-mCherry of about 75 kDa (Figure 4.12C). Western blotting with anti-His 
antibodies confirms the presence of the recombinant protein at this position, as 
pointed out in Fig 4.12D by a pink arrow. A lower mol.wt band around 26kDa is also 
observed (blue arrow), which corresponds to the mCherry portion of the protein 
resulting from cleavage during heating prior to gel analysis. In this instance, proteins 
were heated to 62℃ for 5 minutes, rather than 95℃ which would cause more 
extensive breakdown and release of mCherry (data not shown). Anti-His western 
blotting of purified fractions A8-B3 can also be captured by Alexa Fluor 488 at 
                                                                 Chapter 4. Functional analysis of Bm-SPN-2 
	  	   107	  
610nm using PXi/PXi Touch Fluorescent & Chemiluminescent Imaging System 
from SYNGENE (see Figure 4.12E), with similar results, confirming that mCherry is 




Figure 4.8: Bm-SPN-1 and Bm-SPN-2 alignment.  
Bm-SPN-1 and 2 stands for Brugia malayi serine protease inhibitor 1 and 2. Bm-SPN-1 
refers to GenBank: U04206.1 whereas Bm-SPN-2 refers to GenBank: AF009825.1. Serpin 
motif, reactive-site loop and serpin signature were labelled with three different colour. 
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Figure 4.9: Bm-SPN-2 mapping against Brugia pahangi (PRJEB497) via the parasite 
wormbase.  
 Bm-SPN-2 stands for Brugia malayi serine protease inhibitor 2. Red frame shows the 
unmatched amino acids.  
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Figure 4.10: Bm-SPN-2 and Ce-SPN alignment. N-terminal signal peptide is shown in the 
blue box, and the red box shows the additional N-terminal sequence unique to Bm-SPN-2. 
Ce-SPN is serpin from Caenorhabditis elegans, GenBank: CCD68323.1. 
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Figure 4.11: mCherry labelling Bm-SPN-2 synthesis, ligation and sequencing. 
(A) Structure of gene synthesized to express Bm-SPN-2-mCherry fusion protein. 
(B) Digestion products from pET29a vector and mCherry Bm-SPN-2 in pMA-T vector and 
following digestion with NdeI/XhoI restriction enzymes; gel extraction of the shorter band 
indicated with a pink arrow (mCherry Bm-SPN-2 insert of 1953bp) was followed by ligation 
into the pre-cut pET29a expression vector (blue box). 
(C)  T7 promoter primer (primer for pET29a vector, sequence is shown in Section 2.4.2.1) 
and T7 terminator reverse primer were used to perform colony screens, colonies A, D, F, K, 
M and S were first chosen for sequencing and colony F was proven to contain correct 
sequences. The GeneRulerTM 1 kb DNA Ladder was used. "Control" is plasmid from the 
previously constructed Bm-SPN-2. 
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Figure 4.12: Bm-SPN-2-mCherry fusion protein expression and purification. 
 (A) Schematic of the Bm-SPN-2-mCherry produced, with vector sequences in red and 
restriction sites used indicated. Sites for NdeI (CATATG) in purple and XhoI (CTCGAG) in 
brown. The sequence of Bm-SPN-2 in blue and the sequence of mCherry in pink, connected by 
a NotI (GCGGCCGC) site in yellow. A total of 1953 bp should be the size of the PCR product.  
(B) The UV trace of purified fractions from mCherry labelled Bm-SPN-2. The elution 
gradient of imidazole is indicated on each trace with a gradient from 0% to 100% of Elution 
buffer. Fractions are collected by 96 wells plates, then fractions order are shown as A1, 
A2, ..., A12; B1, B2…B12 and C1,…, C12. 
(C) SDS-PAGE of the purified fractions A8-B3 visualized by instant blue. Samples were 
pre-heated to 62℃ 5mins. 
(D)Anti-His western blotting of purified fractions A8-B3 recovered from the chelating 
chromatography column. Pink arrows point out the Bm-SPN-2-mCherry with the size of 
about 76kDa, the lower band (blue arrow) is an mCherry cleavage product with the size of 
about 26kDa.  
(E) The same anti-His western blotting of purified fractions A8-B3 as (D), photo was 
captured by Alexa Fluor 488 at 610nm using PXi/PXi Touch Fluorescent & 
Chemiluminescent Imaging System from SYNGENE. 
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4.3  Discussion  
As recombinant Bm-SPN-2 had been previously constructed by Zang et al. (Zang et 
al. 1999) in the Maizels laboratory, this plasmid was used as the starting point of the 
project. First, its identity was verified by sequencing a single new colony which was 
then used for expression of soluble recombinant Bm-SPN-2. Following nickel 
chelating chromatography, the purified Bm-SPN-2 fractions appeared to be well-
expressed and relatively pure, providing ample protein for the studies described in 
this and accompanying chapters.  
A notable point is that Bm-SPN-1 and Bm-SPN-2 share very low similarity 
(53.4%, 197/369) and identity (27.9%, 103/369) at the amino acid level. The reason 
for this might be the very different living environments of the different stages. Bm-
SPN-1 is secreted by late-vector-stage larvae of Brugia malayi from the mosquito 
(Yenbutr and Scott 1995) whereas Bm-SPN-2 is only secreted by the microfilarial 
stage in the bloodstream of the host (Zang et al. 1999). 
Interestingly, a very close homologue is present in the related filarial 
nematode species Brugia pahangi (PRJEB497). Using sequence data available 
through WormBase ParaSite (http://parasite.wormbase.org/ index.html) it was found 
that Bm-SPN-2 has very high similarity (99.1%) and identity (96.7%) to B. pahangi 
Bp-SPN. However, no information yet exists that Bp-SPN is, like Bm-SPN-2, 
expressed solely by the blood-borne microfilarial stage.   
Considering that Bm-SPN-2 has, compared to both C. elegans serpins and 
Bm-SPN-1, gained a short N-terminal extension, and in light of IL-33 cleavage being 
likely to be an intracellular event, the possibility is raised that Bm-SPN-2 may be 
taken up or otherwise enter target cells (e.g. human neutrophils) to carry out its effect, 
for example, inhibiting the enzymes activity of neutrophil elastase or cathepsin G. In 
order to pursue this possibility, it was decided to produce a fusion protein in which 
the fluorescent protein mCherry is conjugated onto Bm-SPN-2. Thus, the coding 
sequence for mCherry was added at the C-terminus of the Bm-SPN-2 pET29 
construct. In the first instance, the mCherry sequence was synthesized and flanked 
with the same restriction enzyme (XhoI) at both ends, giving a 50% probability that 
the mCherry insert is ligated in the correct orientation. However, after trying a wide 
range of different ratios between insert and vector, no success was found at inserting 
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mCherry into the rBm-SPN-2 construct. Several reasons might explain this difficulty, 
for example that single restriction enzyme was not efficient, or that the vector 
digested by only one restriction enzyme religates too readily.  
As a further approach, the whole Bm-SPN-2-mCherry coding sequence, 
flanked with two different restriction enzymes (NdeI and XhoI) was synthesized, to 
be inserted directly into the pET29 vector. In this construct, a NotI site was placed 
between the Bm-SPN-2 and mCherry sequences so that either could be removed or 
replaced in future work. 
Compared to the vector (~6.5kb), the insert of 1953bp is relatively large and 
it was decided to increase the ratio of insert to vector as high as 50:1 to complete the 
ligation successfully. This was accomplished and recombinant fusion protein 
expressed and purified. After purification, it was interesting to note that following 
the normal SDS-PAGE protocol of subjecting samples to 95℃ heat inactivation 
caused the fusion protein with the mCherry fragment to separate from the Bm-SPN-2, 
as was also established by the laboratory of Henry McSorley (personal 
communication). To minimise this, the Bm-SPN-2-mCherry protein was treated at a 
reduced temperature of 62 ℃. After Western blotting either visualized by anti-His 
(Figure 4.4D) or Alexa Fluor 488 (Figure 4.4E), it was shown that compared to 95℃ 
heat shock, only two bands were detected: a more intense band (~76kDa) and a lower 
mol.wt band with the size of 26kDa representing the mCherry itself.  These findings 
were consistent with the previous work that the cleavage problem could be solved by 
removing the N-terminal residues 11 amino acids of mCherry, thereby generating a 
cleavage-resistant fluorescent variant (Huang et al. 2014). At this stage, the newly 
produced Bm-SPN-2-mCherry fusion protein can be used for further research into 
uptake or entry of Bm-SPN-2, and/or Bm-SPN-2 at any potential binding site on host 
cells. In order to investigate whether the N-terminal extension plays such a role, 
making Bm-SPN-2-mCherry fusion proteins with or without this N-terminal 
sequence would be an important comparison. As Bm-SPN-2-mCherry was 
successfully constructed with the N-terminal, the first ongoing experiment should be 
tested whether Bm-SPN-2-mCherry binds to any human cells such as neutrophils. 
Next, it would be interesting to test the binding ability of proteins in which there is 
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truncation of the N-terminal of Bm-SPN2-mCherry. Finally, it is worth investigating 
whether either of them also bind to mouse cells. 
A major objective of this chapter was to test the inhibitory function of Bm-
SPN-2 in the context of IL-33 cleavage. This was done using IL-33 cleavage 
experiments assayed by western blotting with both human and murine full-length IL-
33. Experiments reported in the literature were repeated successfully, for human IL-
33, which was processed by human neutrophil cathepsin G (0.025mU/µl), cleaving 
full-length IL-331-270 into two major bands bands: Hs IL-3395-270 with mol.wt ~ 
21kDa and Hs IL-33109-270 with mol.wt ~ 18kDa. It was also confirmed that human 
neutrophil elastase (0.01mU/µl) could cleave full-length IL-331-270 into a major 
product Hs IL-3399-270 with the size of ∼20 kDa. These results are fully consistent 
with the previous report from Lefrançais et al. (Lefrançais et al. 2012). Murine IL-
33, was shown to be digested by 0.025mU/µl of neutrophil Cathepsin G, cleaving 
murine full-length IL-331-266 into a major cleavage product: Mm IL-33102–266 with the 
size of ∼20 kDa. Similarly, 0.05mU/µl of neutrophil elastase processed full-length 
murine IL-331-266 into a major cleavage product Mm IL-33102–266 and a second minor 
product Mm IL-33109–266, which is also consistent with the previous finding from 
Lefrançais et al. (Lefrançais et al. 2012). 
With this sensitive assay, it was then shown via western blotting that Bm-
SPN-2 is able to block human IL-33 cleavage by inhibiting human neutrophil 
cathepsin G in a dose-dependent manner, which is consistent with the previous 
finding by Zang et al. (Zang et al. 1999). Notably, however, relatively high 
concentrations of Bm-SPN-2 were required to observe this effect. In addition, as the 
only a limited quantity of both human and murine full-length IL-33 was available for 
the cleavage experiment, the Western blotting of different amount of FL-IL-33 was 
only performed once. Thus, repeat testing the inhibitory function of Bm-SPN-2 via 
Western blotting is an important priority for the future.    
 Bm-SPN-2 is serine protease inhibitor-2 secreted only from Brugia malayi 
microfilariae stage (Zang et al. 1999), as the major and specific secreted product 
from microfilariae (Hewitson et al. 2008). Mature cleaved IL-33 as an alarmin 
cytokine could initiate the Type 2 response including TH2 cell, macrophages and 
innate lymphoid cell recruitment upon helminth infection. It was reported that ILC2s 
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and TH2 cells interact repeatedly in promoting type 2 immune responses and 
contributing to helminth expulsion, reflecting an ongoing dialogue between the 
innate and adaptive arms of the immune system (Oliphant et al. 2014, Huang et al. 
2015). Considering that microfilariae live in the bloodstream of the human host and 
neutrophils are the most numerous type of white blood cells, interaction between 
these players mediated by Bm-SPN-2 represents an attractive model for parasite 
evasion of host immunity. The major secreted product from Brugia malayi 
microfilariae Bm-SPN-2 blocks IL-33 cleavage by inhibiting the enzyme activity of 
the human neutrophil enzymes cathepsin G and elastase. This results in reduced 
mature IL-33 production, and blocks initiation of the Type 2 response and parasite 
killing. Thus, Bm-SPN-2, which has the potential for modifying host defense 
responses, may play an important role in parasite survival during the microfilariae 
development.  
Finally, it is important to note that Bm-SPN-2 did not completely inhibit 
human neutrophil cathepsin G using murine IL-33 cleavage experiment. The reason 
might be that human neutrophil cathepsin G is specific for cleaving the human full-
length IL-33 or that there are subtle differences in the cleavage sites for neutrophil 
cathepsin G cleaving human and murine full-length IL-33 (Lefrançais et al. 2012). In 
addition, Bm-SPN-2 was also shown to inhibit human neutrophil elastase using 
murine IL-33 cleavage experiment in a dose dependent manner, but not completely.  
Surprisingly, it was not possible to verify the inhibitory function of Bm-SPN-
2 against human neutrophil cathepsin G by using enzyme activity assay kit with 
small-molecule chromogenic substrates, which were similarly used by another 
laboratory (Stanley and Stein 2003). However, the cathepsin G activity colorimetric 
assay kit used in this study did not reveal the expected substrate. According to the 
manufacturer, cathepsin G should cleave the substrate and release the dye, pNA (4-
Nitroaniline), which is the same dye of the previous two studies (Zang et al. 1999, 
Stanley and Stein 2003) for cathepsin G, as the substrate was N-succinyl-Ala-Ala-
Pro-Phe-p-nitroanilide. This group also expressed the Bm-SPN-2 protein in E. coli, 
and characterized its structural and functional properties. While these authors 
confirmed that Bm-SPN-2 shared the conserved tertiary structure of the serpin family, 
including a reactive centre loop (Irving et al. 2000) they found that the protein had no 
                                                                 Chapter 4. Functional analysis of Bm-SPN-2 
	  	   117	  
effect on the activity of neutrophil cathepsin G on small molecule substrates and did 
not undergo the characteristic stressed to relaxed transition required for protease 
inhibition by serpins. 
Hence these results remain controversial because it was shown in our hands 
that Bm-SPN-2 could block IL-33 cleavage in a dose dependent manner by inhibiting 
the activity of human neutrophil cathepsin G. However, it cannot be verified via 
conventional chromogenic enzyme activity assays, suggesting that Bm-SPN-2 may 
have a significantly different mode of inhibition and/or be closely adapted to 
interfering with the cleavage of IL-33. As cathepsin G cleaves the human full-length 
IL-33 at sites F94 and L108 into 95-270 and 109-270 (Lefrancais and Cayrol, 2012), 
it can be supposed that Bm-SPN-2 might block the IL-33 cleavage sites, not giving 
access to cathepsin G to its enzymatic sites. Thus, it will be meaningful to analyse 
the structure of Bm-SPN-2 and important to further verify this inhibitory function of 
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CHAPTER5  
In  vivo  studies  of  the  roles  of  IL-­33  
and  Bm-­SPN-­2  in  responses  to  
microfilariae  and  allergen  challenge    
ABSTRACT 
Based on the result of the previous chapter, Bm-SPN-2 was shown to block human 
full-length IL-33 cleavage by inhibiting human neutrophil Cathepsin G in a dose-
dependent manner, supporting the hypothesis that Bm-SPN-2 may act in vivo to 
prevent IL-33 activation and the promotion of the TH2 immune response. Here, 
several parallel approaches were taken to test this hypothesis in vivo in mouse model. 
Firstly, to directly assess the function of Bm-SPN-2 in vivo, it was administered to 
mice in an intranasal allergy model elicited by the Alternaria alternata fungal 
allergen. In this setting, however, eosinophilia and IL-33 production was not affected 
by Bm-SPN-2 intranasal administration. Secondly, the requirement for IL-33 
signalling in elimination of filarial parasites was tested.  Unexpectedly, it was found 
that IL-33R (ST2) gene deficiency did not enhance the survival of B. malayi 
microfilariae. Furthermore, in the absence of IL-33R, murine immune responses to 
microfilariae were not significantly altered compared to wild-type BALB/c mice, 
other than in a significant increase in IL-33 expression. Finally, an IgG1 monoclonal 
antibody against Bm-SPN-2 was successfully made by fusing myeloma SP2 cells 
with mouse spleen cells immunized with Bm-SPN-2 antigen. The mAb was purified 
by Protein G affinity chromatography and is available for future experiments to 
neutralise Bm-SPN-2 in vivo. In conclusion, while Bm-SPN-2 can act in vitro to 
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forestall one of the key events in TH2 induction, this has not yet been shown to be 
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5.1  Introduction  
Bm-SPN-2, as the major secreted product specifically from Brugia malayi microfilariae, 
is also the main component from this stage of the parasite to elicit a strong TH1 
response (Zang et al. 2000). This was observed by detecting the high concentration of 
IFNγ cytokine secretion, as well as IL-4 at 14 days post-infection with 300,000 Mf. 
However, this response may be short-lived, as Kazura’s group reported that the initial 
TH1 response was followed by a mixed TH1/TH2 response from day 21 and obtained 
contrasting results when Mf were repeatedly injected into the footpad. In this setting of 
immunization, no IFNg was produced by lymph node cells when restimulated on day 10 
(Pearlman et al. 1993, Pearlman et al. 1995). More recently, the TH2 response has been 
closely linked to IL-33, with, for example, the in vivo data of Schmitz et al. 
demonstrating that IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to 
severe pathological changes in mucosal organs (Schmitz et al. 2005).  
Considering that Bm-SPN-2 drives TH1 responses in mice (Zang et al. 2000) 
and IL-33 drives TH2 responses (Schmitz et al. 2005), we inferred the possibility that 
Bm-SPN-2 could inhibit TH2 initiation via IL-33 neutralisation. One means to test this 
would be to investigate whether blockade of Bm-SPN-2 could shift the TH1 response to 
a TH2 profile, and for this purpose a monoclonal antibody against Bm-SPN-2 was 
prepared.  
Considering the results of Chapter 4, there remains some controversy whether 
Bm-SPN-2 could inhibit mature IL-33 release requiring cleavage of full-length IL-33. 
It was concluded from the previous chapter that Bm-SPN-2 could indeed impede IL-
33 cleavage by inhibiting the enzyme activity of human neutrophil cathepsin G in a 
dose-dependent manner. However, the inhibitory function of Bm-SPN-2 against 
human neutrophil cathepsin G could not be verified with the Cathepsin G enzyme 
activity assay kit. It was therefore decided that in vivo experiments would be a more 
direct way to verify this inhibitory function.  
In the Maizels lab, a conventional allergic inflammation model has been set 
up successfully to investigate whether helminths or their soluble products suppress 
allergy. For example, H. polygyrus excretory-secretory products (HES) was shown to 
inhibit the type 2 innate molecules arginase-1 and RELM-α, as well as eosinophilia 
and ILC2 activation (McSorley et al. 2012). In particular, it was further reported by 
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McSorley et al. that HES coadministration with Alternaria/OVA suppressed IL-33 
release in the first 24 hours of exposure (McSorley et al. 2014). Following 
fractionation and screening of HES, a novel component responsible for inhibiting IL-
33, was identified, initially named Hp42 for its size of 42kDa, and now named Hp-
Alarmin Release Inhibitor (Hp-ARI) because IL-33 is recognised as a key innate 
immune system alarmin (H J McSorley, personal communication).  
In addition, it has recently been established that along with soluble proteins 
and other macromolecules, many parasitic helminths release exosome-like 
extracellular vesicles (EVs) (Coakley et al. 2015). Notably, it was also reported that 
EVs are involved in suppression of the IL-33 pathway. Thus, cells exposed to EVs 
show suppressed levels of ST2 (the IL-33 receptor) protein and mRNA (il1rl1) 
(Buck et al. 2014, Coakley et al. 2017). Thus, as the Alternaria allergy system is 
dependent upon IL-33 and sensitive to suppression by HES, it offers an ideal set up 
for investigating the inhibitory function of Bm-SPN-2 in vivo in the context of IL-33 
activation. 
The relationship between IL-33 and helminth infection was summarized in 
Chapter 1.5.6 that IL-33, shows that this alarmin cytokine plays an important role in 
developing the initial TH2 response to helminth infections. It was shown that mouse 
infection with Nippostrongylus brasiliensis (Moro and Koyasu 2010), Schistosoma 
mansoni (Townsend et al. 2000) and Trichuris muris (Humphreys et al. 2008) each 
cause IL-33 release and activation of ILC2s and TH2 cytokine production. Utilizing 
IL-33R-deficient mice (ST2 deficient mice), further studies supported the role for IL-
33 in the promotion of TH2 cytokine responses. It was demonstrated that ST2−/− 
mice failed to induce a TH2 response in vivo and form granulomas after intravenous 
injection of S. mansoni eggs (Townsend et al. 2000). Mice lacking the IL-33 
signalling pathway were observed to have a defect in the induction of type 2 
responses to helminth parasites and are more susceptible to infection with 
Litomosoides sigmodontis (Ajendra et al. 2014), N. brasiliensis (Hung et al. 2013), 
and T. spiralis (Scalfone et al. 2013). Using L. sigmodontis infected mice, the 
absence of ST2 was proven to lead to significantly increased levels of peripheral 
blood microfilariae, the filarial progeny, whereas adult worm burdens were not 
affected (Ajendra et al. 2014).  
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Based on these findings, in order to further investigate the function of Bm-SPN-
2 in vivo, it would be informative to establish a microfilariae infection model and 
compare wild type (WT) and IL-33R-deficient mice in our laboratory. For logistical 
reasons, it was decided to explore this relationship with the parasite Brugia pahangi, a 
closely related filarial nematode that is naturally found in cats, and may also cause 
clinical infection of humans manifesting as lymphatic filariasis (Tan et al. 2011). The 
genome of B. pahangi was found to have a high similarity to B. malayi, with extensive 
synteny and few genes specific only for one species (Lau et al. 2015). In addition, the 
life cycle of B. pahangi is very similar to B. malayi as shown in Figure 1.4. Both B. 
pahangi and B. malayi share the same vector mosquito species and can infect the same 
rodent Meriones unguiculatus (the Mongolian jird) in the laboratory (Ash and Riley 
1970a, Ash and Riley 1970b). Finally, as stated in Chapter 4, the amino acid alignment 
between Bm-SPN-2 and Bp-SPN reveals a very high similarity (99.1%) and identity 
(96.7%) between the proteins from the two species. Based on this, it is reasonable to 
utilize B. pahangi to study the closely related species B. malayi. This enabled the 
experiments to be undertaken as the life cycle of B. pahangi is maintained in Professor 
Eileen Devaney’s laboratory at the University of Glasgow, while IL-33R deficient mice 
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5.2  Results    
5.2.1  Making  polyclonal  and  monoclonal  antibody  against  Bm-­
SPN-­2    
Following the initial finding that mice infected with B. malayi microfilariae 
mount a strong but short-lived Bm-SPN-2-specifc TH1 response (Zang et al. 2000), 
Bm-SPN-2 was also suggested to play an essential role in neutralizing the 
immunostimulatory properties of host neutrophil proteases thereby contributing to 
the longevity of Mf in host bloodstream (Molehin et al. 2012). In order to further 
understand the in vivo function of Bm-SPN-2, it may be possible to employ 
monoclonal antibody blockade to shift the TH1 response to a TH2 response, for 
which generation of monoclonal antibodies against Bm-SPN-2 is necessary.  
Prior to administering recombinant protein to mice for the in vivo 
experiments, it was decided to remove any contamination with bacterial 
Lipopolysaccharide (LPS), as rBm-SPN-2 was expressed by E. coli. From 1.5ml of 
Bm-SPN-2, 750µl LPS-depleted Bm-SPN-2 (dBm-SPN-2) was obtained with the 
concentration of 0.79mg/ml. Using the Limulus Amebocyte Lysate (LAL) assay, 
only 0.023U/ml of LPS was detected in 1µg/ml dBm-SPN-2.  
To provide a positive control for the monoclonal antibody screens, polyclonal 
antiserum was generated followed by the method see section 2.3.3.1. The schedule of 
antigen injection for making monoclonal antibody is summarized in Figure 5.1A. 
In parallel, the mouse myeloma cell line Sp2/0-Ag14 (ATCC® CRL-1581™) 
(SP2) was cultured for 3 days. For the fusion, immunized spleen cells and SP2 cells 
were combined at a 1:1 ratio and 1 ml polyethylene glycol (PEG) was added. Cells 
were then distributed across 96-well plates and supernatants tested 14 days later by 
an ELISA screen using recombinant Bm-SPN-2 ELISA (Results of ELISA screening 
see Appendix 5.1) and secondary antibody to mouse IgG. Positive wells were re-
cultured by two rounds of limiting dilution to select the monoclonal antibody 
(Procedure of ELISA screen and limiting dilution is shown in Figure 5.1B and details 
are shown in Section 2.3.3.2).   
A total of nine mAb candidates against Bm-SPN-2 were chosen from the final 
ELISA screen, and the isotype of the nine mAb candidates was next determined by 
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ELISA as IgG1 in all cases by testing with different secondary antibody IgG1-HRP, 
IgG2a-HRP, IgM-HRP, IgA-HRP or IgE-HRP, with sera from naïve mice as 
negative control and polyclonal antibody sera as positive control (see Figure 5.2A).  
As the rBm-SPN-2 construct is tagged by a six-histidine C-terminal tail (His-
tag), it was necessary to make sure that the mAb candidate reacts specifically against 
Bm-SPN-2 and not the His-tag. For this purpose, two other proteins in our laboratory 
(Hp1552 and Hp148) that also include the His-tag were probed by ELISA. ELISA 
plates coated with either Hp1552 or Hp148 (1µg/ml) and as shown in Figure 5.2B, 
the mAb candidates were found to be negative against His-tag. 
In order to make sure the mAb candidates react specifically against Bm-SPN-
2, western blotting was performed with rBm-SPN-2 together with the mouse 
polyclonal antibody as positive control and anti-mouse immunoglobulins (P0260 by 
Dako) as secondary antibody. The western blotting result Figure 5.3A shows that all 
candidates are positive against Bm-SPN-2. In parallel, reactivity of the polyclonal rat 
antibody sera was verified by western blotting (Figure 5.3B). Next, western blotting 
was performed on soluble extracts of microfilariae (Mfs) and adult worms that had 
been stored at -80°C in the Maizels lab. B. malayi microfilariae and adult worms 
extract were prepared, followed the protocol in Section 2.10. and 0.5µg of each 
extract was loaded onto to SDS-PAGE gel. The western blotting was then performed 
and shows that mAb candidates only specifically react against Mf extract (Figure 
5.3C) and not adult extract (Figure 5.3D). The two bands in Figure 5.3C and three 
bands in Figure 5.3D seen in the Mf extract may be attributed to some degradation 
during long term storage prior to the preparation of the extract.  
As all mAb candidates were determined to be IgG1 isotype, they were 
purified using a Protein G column Complete RPMI1640 (cRPMI) medium 
containing ultra low IgG fetal bovine serum was used to cultivate the hybridoma 
cells and supernatants harvested when cells were fully confluent. Typically, a total 
volume 250ml of supernatant was loaded onto a 5ml Protein G column and eluted 
either manually or using an Akta Prime FPLC. The trace of the purified fractions of 
mAb candidate 1 is shown in Figure 5.4A. The trace graphs of the rest of the mAb 
candidates are shown in Appendix 5.2. Measuring the MAb concentrations by 
Nanodrop, very high concentrations up to 6.221mg/ml were obtained after dialysis, 
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and the quality of the purification assessed by SDS-PAGE gel. In this analysis, each 
sample was incubated with or without 2-mercaptoethanol reducing agent to break 
down into heavy and light chains.  As shown in Figure 5.4B, in each case mature IgG 
mAb is seen ~150kDa (labelled by black arrow) while following reduction with 2-
mercaptoethanol, separate heavy and light chains are seen at 49kDa (blue arrow) and 
28kDa (red arrow) respectively.  
Although the Bp-SPN and Bm-SPN-2 show very high sequence similarity 
(99.1%) and identity (96.7%) as discussed in Chapter 4, it would be interesting to 
test that the mAb antibodies reactive against Bm-SPN-2 also react against B. pahangi 
microfilariae extract. B. pahangi microfilariae and adult worms were kindly provided 
by Professor Eileen Devaney’s lab. Surprisingly however, it was found that none of 
the Bm-SPN-2 mAb candidates bound to B. pahangi microfilariae extract (data not 
shown), suggesting that the set of mAbs isolated will not be suitable for experiments 
seeking to interfere with SPN function in B. pahangi.  
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Figure 5.1: Monoclonal antibody production against Bm-SPN-2. 
(A) Schedule of immunizing mice for making monoclonal antibody. BALB/c mice were 
injected with dBm-SPN-2, boosted three times after 6 weeks. Spleen cells were recovered for 
making monoclonal antibody and brachial blood harvested for polyclonal antibody.  
(B) Protocol of making hybridoma cells. SPL stands for the immunized spleen cells; SP2 is 
the mouse myeloma cell line Sp2/0-Ag14 (ATCC® CRL-1581™).  They were fused in 1:1 
ratio by 1 ml polyethylene glycol (PEG). Limiting dilution was followed by the ELISA Screen. 
From Alice Ra’anan and Bill Yates, https://speakingofresearch.com. 
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Figure 5.2: Bm-SPN-2 monoclonal antibody candidate isotype determination and 
specification verification by ELISA   
(A) Isotype determination for monoclonal antibody. The ELISA plate was coated with 
1µg/ml of rBm-SPN-2, ELISA was performed using mAb candidate as primary antibody and 
different secondary antibody aIgG1-HRP, aIgG2a-HRP, aIgM-HRP, aIgA-HRP or aIgE-
HRP, with sera from naïve mice as negative control and polyclonal antibody sera as positive 
control. C1, ..., C9 stand for mAb candidates 1-9. 
(B) Verification that mAb candidates are not against His-tag. Hp1552 and Hp148 are 
proteins including a C-terminal His-tag made in our laboratory. The ELISA plate wells were 
coated with either Hp1552 or Hp148 (1µg/ml). mAb candidates C1-C9 were added as 
primary antibody, naïve mouse serum was included as negative control, polyclonal antibody 
against Hp148 was added as the positive control and aIgG1-HRP was added as the 
secondary antibody. 
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Figure 5.3: Bm-SPN-2 monoclonal and polyclonal antibody candidate verification by 
Western blotting.  
(A) Verification of mAb candidates against Bm-SPN-2 by WB, C1,C2,…C8 stand for 
Candidate 1, 2,…8.  
(B) Verification of polyclonal antibody rat sera against Bm-SPN-2 by WB. 
(C) Verification of mAb candidates against Mf extract by WB. Two of the black arrows are 
likely to be the degraded Bm-SPN-2.  
(D) Specificity of mAb candidates against microfilaria not adult worm extracts. All the 
western blotting were performed by loading 0.25µg Bm-SPN-2 (A and B) or 0.5µg Mf extract 
(C) or adult extract (C and D) and visualized by each mAb candidate 1:2000 dilution as the 
primary antibody, polyclonal antibody as positive control and anti-mouse Immunoglobulins 
(P0260 by Dako) as secondary antibody. The upper arrow is the theoretical size of Bm-SPN-2, 
the two lower bands refer its degradation, as the microfilariae used for extract preparation 
were frozen in -80 ℃ for years. 
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Figure 5.4: Bm-SPN-2 monoclonal antibody candidate purification. 
(A) The UV trace of purified fractions from monoclonal antibody candidate 1. A total of 
250ml supernatant of hybridoma cells was loaded onto the 5ml protein G column. 100% 
Elution buffer 0.1M Glycine-HCl pH2.7 was applied for purification. Fractions are collected 
into 96 well plates, then fractions order are shown as 1F8, 1F9, ..., 1G3, …, 2A1, …, 2C11. 
(B) SDS-PAGE gel of purified mAb candidate visualized by Instant blue. mAb C1-C9 are 
the 9 candidates. The left-hand lane of each mAb candidate was without 2-mercaptoethanol 
whereas on the right hand side was with 2-ME added. The black arrow is the IgG mAb, the 
blue arrow is the heavy chain while the pink arrow is the light chain of the mAb. 
 
                                                                                               Chapter 5. In vivo studies 
	  	   131	  
5.2.2  Alternaria/Bm-­SPN-­2  intranasal  in  vivo  experiment    
In order to test whether Bm-SPN-2 can suppress IL-33 release after intranasal (i.n.) 
Alternaria administration, an in vivo experiment was set up using a model 
established in the laboratory (McSorley et al. 2014). The experimental scheme of 
dBm-SPN-2 administration was shown in Figure 5.5A. Subsequently, IL-33 was 
measured from the bronchoalveolar lavage fluid (BAL) and lung homogenate 
samples (Figure 5.5B and C). Surprisingly, a small increase in IL-33 was seen in the 
group with Bm-SPN-2/PBS administration, for reasons which are as yet not known. 
However, Alternaria elicted very high IL-33 concentrations and although co-
administration in the Bm-SPN-2/ALT group was slightly lower this did not yield a 
significant difference (Figure 5.5B). Also, the IL-33 ELISA of the lung homogenate 
showed no significant difference between the Bm-SPN-2/ALT group and PBS/ALT 
group (Figure 5.5C). In addition, Western blotting was attempted to compare 
responses in the different groups, using anti-IL-33 to probe BAL and lung 
homogenate samples. However, no IL-33 was detected in any group, perhaps 
because there is insufficient IL-33 in a single sample to detect by this method. 
Unfortunately, no IL-33 was detected even pool 5 lung homogenate sample together 
(date not shown). 
Considering that HES (Excretory and secretory products from H. polygyrus) 
and Hp42 (Alarmin release inhibitor form H. polygyrus) are each potently able to 
inhibit IL-33 release upon Alternaria administration (Osbourn et al. 2017), a further 
experiment was performed with HES and Hp42 as positive controls. The results of 
this experiment, shown in Figure 5.5D, were that Bm-SPN-2 could not reduce IL-33 
levels in contrast to HES and Hp42 which both significantly reduced IL-33 release. 
Taken together, these experiments demonstrate that Bm-SPN-2 is not able to inhibit 
IL-33 release in the time-frame of 1.5 hours after Alternaria administration into the 
airways of mice.  
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Figure 5.5: Testing Bm-SPN-2 in vivo by Alternaria intranasal model. 
(A) Workflow of the Alternaria/Bm-SPN-2 intranasal in vivo experiment. Three or five per 
group of eight-week-old female BALB/c mice were administrated with 50µl PBS or 40µg dBm-
SPN-2, or HES or Hp42 (Time 0h) 0.5 hour prior to 50µl PBS or 50 µg Alternaria i.n. (Time 
0.5h), mice were culled at Time 1.5h. The left lung of each mouse was harvested for 
homogenization. Lungs were homogenized in 0.5 ml of cell lysis buffer with PMSF by 
magnetic beads. Bronchoalveolar lavage fluid (BAL) was collected after euthanasia by washing 
the lungs three times with 0.5ml of cold PBS with 0.5% BSA. 
(B) IL-33 measurement of the BAL samples by ELISA. 
(C) IL-33 measurement for the lung homogenate samples by ELISA.  
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(D) IL-33 measurement from the BAL samples from a second experiment. Group size: 5. 
HES: Excretory and Secretory products from H. polygyrus; Hp42: alarmin release inhibitor 
of H. polygyrus. 
5.2.3  Brugia  pahangi  microfilariae  infect  IL-­33R-­/-­  mice    
With the aim of further understanding the function of Bm-SPN-2 in vivo, the approach 
was taken to establish an infection model in the laboratory. It was recently reported that 
in mice infected with L3 stage of the rodent filarial parasite Litomosoides sigmodontis, 
the absence of ST2 (the IL-33-specific subunit of the IL-33 receptor), led to 
significantly increased levels of peripheral blood microfilariae, the filarial progeny, 
whereas adult worm burden was not affected. Based on this finding, an interesting 
question arose as to how wild type (WT) and IL-33R-deficient mice may differ when 
infected with B. malayi. It is important to note that mice do not develop patent 
microfilaraemia following infection with L3 stage, and so it was decided to test the 
outcome of transfer of microfilarial stages alone. In addition, and as discussed above, as 
B. pahangi and B. malayi are closely related in genome (Lau et al. 2015), very similar 
in life cycle (Figure 1.4) (Ash and Riley 1970a, Ash and Riley 1970b) as well as in SPN 
sequence (Figure 4.11), it was decided to use B. pahangi microfilariae (Mff) which 
were available in sufficient quantity through collaboration with the laboratory of Prof 
Eileen Devaney.   
In this section, the aim is to establish a new experimental model to investigate 
the importance of IL-33 during Brugia malayi Mf infection, including the time points, 
dose of infection, method of separating Mf and cells from peritoneal lavage as well as 
choosing the sample for qPCR. Thus, some necessary methodological development is 
included into the results, to obtain a better understanding of this model. 
To assess the effect of lacking IL-33 receptor on Mff infection, B. pahangi 
microfilariae were transferred to wild type BALB/c and ST2-deficient mice. Firstly, a 
pilot experiment was carried out to determine the optimal time point of infected mice 
for microfilaria recovery as well as trialing methods for purifying and enumerating the 
parasites (experimental plan shown in Figure 5.6A). B. pahangi microfilariae were 
kindly provided by Professor Eileen Devaney. The microfilariae were collected from 
the peritoneal lavage of the infected jird and then purified by Histopaque with the 
substantial pellet of B. pahangi microfilariae shown in Figure 5.6B. The Mff were 
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resuspended with HBSS for Mff infection by i.p. injection. The detailed protocol of 
microfilariae purification is described in Section 2.2.1. 
Four mice of each mouse strain were infected with 100,000 B. pahangi 
microfilariae by intraperitoneal injection (i.p.) with one mouse of each strain left 
uninfected. Two infected mice from each mouse strain were culled separately on day 1 
and day 6 post-infection, and 3 successive peritoneal lavages performed on each animal 
(see Figure 5.6C). The great majority of microfilariae were recovered from the 1st 
peritoneal lavage, suggesting that one 5 ml peritoneal lavage will suffice for future 
experiments.  
To both count recovered microfilariae from peritoneal lavage, as well as 
perform RT-PCR for cytokines from peritoneal lavage cells, a separation method is 
necessary. Thus, density gradient centrifugation using Histopaque was applied as 
previously described (Osborne 1997) with separation as shown in Figure 5.6D. 
Unfortunately, it was found that some microfilariae were trapped by peritoneal cells in 
the cell layer, as shown in Figure 5.6E. Thus, the cell layer would be contaminated by 
different numbers of microfilariae, suggesting mesenteric lymph node maybe a more 
stable source for mRNA expression comparison of cytokines between the two different 
mouse strains.   
The microfilariae recovered from the peritoneal lavages were counted on days 1 
and 6 post-infection. Compared to BALB/c mice, the number of microfilariae recovered 
at day 1from infected IL-33R KO was higher as shown in Figure 5.7A, but with only 2 
mice per group did not reach statistical significance. At day 6 post-infection, it was 
shown that Mff cannot be detected from the peritoneal lavage of 3 of 4 mice, suggesting 
a larger initial number of Mff may be needed in this i.p. infection model.  
At the immunological level, the spleens of each mouse were collected and 
weighed immediately after cull. The spleen weights of the infected IL-33R KO and 
BALB/c mice were significantly greater than the uninfected mice. However, there was 
no significant difference between two different mice strain (Figure 5.7 C and D). 
Cytokine ELISAs for IL-4, IL-5, IL-13, IL-33, IFNγ and Relma were then performed 
on peritoneal lavage supernatants from each infected mouse. Interestingly, only IL-5 
was detected in peritoneal lavage of both strains on day 1 post-infection. At this time 
levels appeared lower in the IL-33R-deficient mice, and by day 6 IL-5 was only 
                                                                                               Chapter 5. In vivo studies 
	  	   135	  
detectable in wild-type hosts (Figure 5.7B). However, IL-5 levels did not show a 
statistically significant difference between the two mouse strains, suggesting a larger 
group of mice should be tested to establish if this trend can be robustly replicated. 
Based on the trial, another experiment was set up to repeat and extend the study 
of B. pahangi microfilariae infection in IL-33R deficient mice. As shown in Figure 
5.8A, group sizes were enlarged to 5 each of of BALB/c wild-type and IL-33R KO 
mice. Ten mice of each mouse strain were infected with 150,000 B. pahangi 
microfilariae per mouse, another five mice from each mouse strain were left uninfected. 
B. pahangi microfilariae were again kindly provided by Professor Eileen Devaney’s 
laboratorys. The first 5ml peritoneal lavage was collected for Mff counting and further 
cytokine ELISA. Immediately after cull, spleen was weighed and mesenteric lymph 
node was harvested with RNAlater (Qiagen) for subsequent RT-PCR. At day 1 post-
infection, the peritoneal lavage of the five BALB/c and IL-33R KO mice were 
harvested. Before spinning down the peritoneal lavage, 100µl of peritoneal lavage from 
each mouse was taken for Mff counting (20µl/time). The peritoneal lavage fluid was 
then centrifuged to yield supernatant for ELISA analysis, and the pellet kept as a 
backup for Mff counting.  
The microfilariae recovered from the peritoneal lavage on days 1 and 6 post-
infection showed a broadly similar pattern to the trial experiment, with much higher 
numbers at the earlier time point. Unexpectedly, the number of microfilariae recovered 
from peritoneal lavage in BALB/c and IL-33R KO mice showed no significant 
difference on day 1 post-infection (as shown in Figure 5.8B). By day 6 almost no 
microfilariae were detected in most animals, but surprisingly, one mouse from each 
mouse strain had very high numbers of microfilariae (BALB/c mouse #4: 15,367 mff 
and IL-33R KO mouse #4: 82,387 mff) at that time (Figure 5.8B), Again, the spleen 
weights of the infected IL-33R KO and wild-type Balb/c mice were significantly 
greater than the uninfected mice. However, there was no significant difference between 
two different mouse strains in this respect (Figure 5.8C). As previously, a range of 
cytokine ELISAs (IL-4, IL-5, IL-13, IL-33, IFNγ and Relma) were performed on 
peritoneal lavage supernatants, but unfortunately, none were detected in this experiment 
(data not shown). 
                                                                                               Chapter 5. In vivo studies 
	  	  136	  
As an alternative to ELISA for released proteins, mRNA expression of IL-4, IL-
33, IFNγ, Relma and Arg1 transcripts were measured. RNA extraction was performed 
by conventional methodology (Section 2.9.1) for each mesenteric lymph node (mLN) 
sample from Day 1 and Day 6 infected and uninfected IL-33R KO mice and wild-type 
BALB/c mice. RNA was subjected to DnaseI treatment and purified with an RNeasy® 
Mini Kit (Qiagen) then measured by Nanodrop. cDNA was made with a Quanta qScript 
cDNA kit (Section 2.9.2). Then, the mRNA expression of IL-4, IL-33, IFNγ, Relma 
and Arg1 from mLN was measured by RT-PCR. The details of the protocol for RT-
PCR and the primers is described in Section 2.9.3.  
From the data obtained, it was found that in the absence of IL-33R, IL-4, 
IFNγ, Relma and Arg1 responses to microfilariae were not significantly altered 
compared to wild-type BALB/c mice (Figure 5.9B, C, D and E). There was, 
however, a significant increase in IL-33 expression especially on day 1 post-infection 
(Figure 5.9A). Overall, a high level of intra-group variation was found in the mRNA 
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Figure 5.6:  Trial experiment of Brugia pahangi microfilariae infection to IL-33R 
deficient and BALB/c mice. 
(A) Experimental plan for B. pahangi microfilariae infection. Four mice of infected IL-33R 
KO and BALB/c mice were infected with 100,000 B. pahangi microfilariae (mff) by i.p. and 
one mouse of each strain was left uninfected. Two infected mice from each strain were 
culled on day 1 and day 6 post-infection. Peritoneal lavage was collected for mff counting 
and ELISA. Spleens were harvested and weighed. 
                                                                                               Chapter 5. In vivo studies 
	  	  138	  
(B) Microfilariae purification from infected gerbil peritoneal lavage by density 
centrifugation using Histopaque. The layer indicated by the yellow arrow is HBSS, the pink 
arrow indicates the cell layer, the blue arrow indicates Histopaque and the green arrow 
indicates the Mff pellet. 
(C) Three successive 5 ml peritoneal lavages from the infected mice on day 1 and day 6 
post-infection. The pellets were collected after spinning at RCF 1000, 5min. 
(D) Cells separation from peritoneal lavage on day 1 post–infection using Histopaque 
density centrifugation. Pink arrow indicates the cell layer. 
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Figure 5.7:  Microfilariae recovery count, IL-5 measurement and spleen weight from 
the trial infection experiment. 
(A) B. pahangi microfilariae recovery from peritoneal lavage of the infected IL-33R KO and 
BALB/c mice on Day 1 and Day 6 post infection. 
(B) IL-5 level of peritoneal lavage of the infected IL-33R KO and BALB/c mice on Day 1 
and Day 6 post infection and the uninfected mice. 
(C) The spleen harvested from the infected IL-33R KO and BALB/c mice on Day 6 post 
infection and the uninfected mice. 
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Figure 5.8: B. pahangi microfilariae infect IL-33R deficient and BALB/c mice. 
(A) Experimental plan of the infection experiment to IL-33R deficient and BALB/c mice. 
Ten mice of each mouse strain were infected by 150,000 B. pahangi microfilariae per 
mouse, another five mice from each mouse strain were left uninfected. Five infected mice 
from each mouse strain were culled separately on day 1 and day 6 post-infection. Peritoneal 
lavage was collected for mff counting and ELISA. Spleen was harvested and weighed. 
Mesenteric lymph node was harvested for RT-PCR. 
(B) B. pahangi microfilariae recovery from peritoneal lavage of the infected IL-33R KO and 
BALB/c mice on Day 1 and Day 6 post infection. The number of microfilariae on Day 1 is 
per 20µl, whereas the number for day 6 is total count. The corresponding numbers of mouse 
are also labelled on the microfilariae numbers. 
(C) The spleen weight of the uninfected and infected IL-33R KO and BALB/c mice on day 1 
and day 6 post-infection. As there were extremely large variances, the differences did not 
attain statistical significance. 
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Figure 5.9: The mRNA expression of cytokines of the mesenteric lymph node of 
uninfected and infected IL-33R KO and BALB/c mice.  
(A) IL-33, (B) IFNγ, (C) IL-4, (D) Arg1 and (E) Relma expression from mLN of uninfected 
and infected IL-33R KO and BALB/c mice measured by RT-PCR. As the mRNA expression 
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of IFNγ, IL-4, Arg1 and Relma (B-E) in each mouse group is very variable, makes it 
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5.3  Discussion    
To further investigate the function of Bm-SPN-2 in vivo, three different 
approaches were adopted. First, it was decided to generate monoclonal antibodies 
which could be used to neutralise the parasite inhibitor in vivo. Using a conventional 
method in our laboratory, nine monoclonal antibody candidates against Bm-SPN-2 
were successfully isolated and their isotypes were all determined to be IgG1. It was 
confirmed by ELISA that the monoclonal antibodies selected were specific for Bm-
SPN-2, and they did not react with the C-terminal His-tag encoded by the expression 
vector. In addition, as Bm-SPN-2 is only secreted from Brugia malayi microfilarial 
stage, it was confirmed by western blotting that the mAbs can specifically bind to 
microfilariae extract and not adult worm extract. Finally, it was confirmed that mAb 
candidates specifically bind to rBm-SPN-2 by western blotting. All of these three 
findings establish that the monoclonal antibodies are in fact reactive against Bm-
SPN-2. Unexpectedly, however, the antibodies did not react with Mff of the closely 
related species, Brugia pahangi. As the intention was to administer anti-SPN-2 
mAbs during a B. pahangi infection, this finding suggested that further, cross-
reactive, mAbs need to be generated before in vivo neutralisation experiments can be 
performed. 
In a second approach, it was decided to test whether Bm-SPN-2 could 
suppress IL-33 release induced by Alternaria administration into the airways, as 
release of this cytokine is known to be a rapid and potent response to this allergen. 
This in vivo model was established in our laboratory successfully, by showing that 
HpARI (H. poly alarmin release inhibitor) inhibits the IL-33 release within 1 hour of 
Alternaria administration (Osbourn et al. 2017). In the homeostatic state, IL-33 
localizes in the nucleus of epithelial cells, with no ST2-dependent cytokine activity 
and inflammation (Cayrol and Girard 2014). Cell necrosis alerts the immune system 
to tissue damage or stress, and as an 'alarmin', biologically active full-length IL-33 
(the IL-1-like cytokine domain) is released from the nucleus into the extracellular 
environment followed by the cleavage of IL-33 in the central domain (Miller 2011, 
Molofsky et al. 2015). Thus, released IL-33 should be theoretically equal to the 
cleaved IL-33, as only the cleaved bioactive IL-33 is released into the extracellular 
environment. In this experimental model IL-33 is measured one-hour after Alternaria 
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exposure, and Bm-SPN-2 was co-administered intranasally. Unfortunately, by 
ELISA no reduction in IL-33 was observed. Also, IL-33 was not detected in any 
BAL samples by western blotting, even after concentrating samples from five mice 
into a single sample. Thus, from these experiments, no evidence was found to 
support the primary hypothesis that Bm-SPN-2 can reduce IL-33 release. Some 
caveats may be mentioned; for example, it is possible that the SPN-2 from a human 
parasite is less effective at inhibiting serine proteases from the mouse. 
A second comment relates to the role of neutrophils. As shown in Chapter 4, 
Bm-SPN-2 has the potential to inhibit the enzyme activity of human neutrophil 
elastase and cathepsin. Loebbermann et al. quantified the total numbers of 
macrophages, neutrophils, and eosinophils in the BAL using differential cell 
counting of hematoxylin and eosin-stained cytospin slides (Loebbermann et al. 
2012). It was shown that one hour after Alternaria and Bm-SPN-2 acute 
administration, the percentage of neutrophils is very low in the bronchoalveolar 
lavage fluid, as well as macrophages and eosinophils thus at early time points 
elastase or cathepsin G may not be involved in the response to Alternaria. Instead, 
serine proteases, chymase and tryptase secreted by activated mast cells are known to 
cleave the central domain of IL-33 giving rise to potent activation of group-2 innate 
lymphoid cells (Lefrançais et al. 2014). The fact that neutrophil numbers decreased 
might be because of the short time-frame of the experiment, which suggests that a 
longer time point in vivo experiment or chronic administration with protein and 
Alternaria should be tested. Hence, the mode of action of Bm-SPN-2 may be 
focussed not on the initial release of IL-33 from epithelial cells but later once more 
neutrophils are activated, to prevent the continued release of IL-33 in a more chronic 
setting. 
A third strategy employed here was to establish an infection model for 
analysing whether Bm-SPN-2 inhibition of mature IL-33 production is important to 
expel parasites. As IL-33 is shown to be critically involved in the TH2 response 
initiation against helminth infection, and peak expression was detected at early time 
points upon Trichuris muris infection (Humphreys et al. 2008). In the experiments 
decribed here, timepoints and microfilariae doses were determined in a trial 
experiment (data not shown), from which relatively early time points day 1 and day 6 
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were chosen. B. pahangi microfilariae were utilized for infecting wild type BALB/c 
mice and IL-33 receptor deficient mice. A trial infection experiment established the 
methods, and the limitations, of this system, showing for example that peritoneal 
lavage cells also trap microfilariae so that mesenteric lymph nodes are a preferable 
source for measuring mRNA expression of cytokines by RT-PCR. However, this 
experiment with very small group sizes did indicate a greater susceptibility of the IL-
33R deficient mice. 
Following B. pahangi microfilariae i.p. infection of IL-33R deficient and 
wild-type BALB/c mice, it was surprising to find no significant differences between 
the strains. Indeed, one mouse from each mouse strain had very high microfilariae 
recoveries on day 6 post-infection while the microfilariae of the remaining mice had 
almost vanished, making the data too variable to analyse. The mice with high density 
of microfilairiae also did not correlate with a high or low mRNA expression of IL-4, 
IFNγ, Relma and Arg1 as measured by RT-PCR. Compared to wild-type BALB/c 
mice, it was only found that IL-33 mRNA expression of IL-33 deficient mice is 
significantly increased on day 1 post-infection. This may be because in the absence 
of the IL-33 receptor the immune system compensates by producing more IL-33. 
However, there was also no detectable IL-4, IFNγ, Relma and Arg1 by ELISA, 
suggesting that the murine immune response had still to initiate the TH1 or TH2 
responses very early post-infection.  
Unexpectedly, there was also found to be no difference in microfilariae 
recovery on day 1 post infection between IL-33R/ST2 deficient mice and wild-type 
BALB/c mice, which is not consistent with the previous finding that microfilaria 
numbers were enhanced in ST2 deficient mice (Ajendra et al. 2014). The difference 
between this study and the previous paper is that L. sigmodontis microfilariae were 
inoculated intravenously into the tail vein of the ST2 deficient mice, and peripheral 
blood were collected for microfilariae comparison, whereas the B. pahangi 
microfilariae were i.p. injected directly into the peritoneal cavity. As noted above, 
neutrophils are sparse in the peritoneal cavity but are the most numerous leukocyte in 
the bloodstream. In addition, as the peripheral blood of the host is the physiological 
niche of the microfilariae, their behaviour or susceptibility may be altered by 
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infection in the peritoneal cavity. Thus, future experiments should test the fate of 
microfilariae transferred directly into the peripheral blood by i.v. injection.	  	  
As ST2 (IL-33 receptor) deficient mice develop increased microflilaremia 
following Litomosoides sigmodontis infection (Ajendra et al. 2014), it has been 
demonstrated that the IL-33 receptor plays an important role in the filarial nematode 
infection. Furthermore, reports in recent years demonstrating the action of IL-33 are 
not limited to the activation of immune cells involved in type-2 immune responses 
(Cayrol and Girard 2014). Studies have also uncovered important roles of IL-33 in 
the activation of immune cells involved in type-1 immunity, infection and chronic 
inflammation, such as neutrophils, macrophages, Th1 cells, NK cells, CD8+ T cells, 
B cells and NK T cells (reviewed in (Molofsky et al. 2015, Liew, Girard and 
Turnquist 2016, Cayrol and Girard 2018)). As 1) it was found in this study that Bm-
SPN-2 has the potential to inhibit human neutrophil cathepsin G or elastase; and 2) 
the most abundant product secreted from Brugia malayi microfilariae, Bm-SPN-2 
was found to be able to induce an early and strong Th1 response (Zang et al. 2000), it 
would be meaningful and interesting to investigate how IL-33 or IL-33 receptor 
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Dating back to the 1980s, it has been reported that, by employing a combination of 
sensitive biochemical and immunochemical techniques, the excretory-secretory 
products for Brugia malayi adult worms could be identified and characterized 
(Kaushal et al. 1982). A few years later, Lightowlers and Rickard summarized the 
excretory-secretory (ES) products as a variety of molecules that parasitic helminths 
excrete or secrete into their hosts. It was then proposed that the ES products of 
parasitic helminths potentially contribute to immune evasion strategies of the 
parasites through a suite of mechanisms including shedding of surface-bound ligands 
and cells, alteration of immune cell functions and modulation of complement and 
other host inflammatory responses (Lightowlers and Rickard 1988).  
In 1999, it was discovered, by screening the surface secreted antigens of B. 
malayi, a prominent antigen was Bm-SPN-2, a serpin which is specifically and 
exclusively secreted by microfilariae stage. This serpin has the ability to inhibit 
human neutrophil serine proteinases (Cathepsin G and elastase) (Zang et al. 1999). 
Further experiments were performed to show that Bm-SPN-2, unusually for a 
helminth antigen could induce a Th1-biased immune response in mice and humans 
(Zang et al. 2000).   
More recently, the stage- and gender-specific ES products of B. malayi were 
identified by three groups using proteomic mass spectrometry (Hewitson et al. 2008, 
Moreno and Geary 2008, Bennuru et al. 2009). These authors found again that Bm-
SPN-2 is a major and specific ES product from microfilariae of B. malayi, suggesting 
that Bm-SPN-2 might play an important role in immune evasion specifically by the 
microfilarial stage. 
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In the meantime, new immunological studies had developed our 
understanding of IL-33, a key cytokine of innate immune system. These revealed that 
human and murine full-length IL-33 is processed into mature bioactive IL-33 by 
human neutrophil Cathepsin G and elastase (Lefrançais et al. 2012). As an alarmin 
signal, IL-33 plays an important role developing the initial TH2 response to helminth 
infections. It was shown that mouse infection with the Nippostrongylus brasiliensis 
(Moro and Koyasu 2010), Schistosoma mansoni (Townsend et al. 2000) and 
Trichuris muris (Humphreys et al. 2008) each cause IL-33 release and activation of 
ILC2s and TH2 cytokine production.   
Importantly, microfilariae (Mf) are the long-lived blood-dwelling larval stage 
of B. malayi. The ability of the immune response to reduce or eliminate microfilariae 
in the bloodstream would prevent the spread of parasites to mosquitoes, suggesting 
that stage specific immunity to microfilariae could the best strategy to block 
transmission of B. malayi.  
Putting these findings together, it was then hypothesised that the major 
secreted product Bm-SPN-2 of the microfilarial stage has the potential to block IL-33 
alarmin signals by inhibiting the activity of neutrophil Cathepsin G and elastase. If so, 
Bm-SPN-2 would be a potential drug target or vaccine candidate. 
Based on this, the whole PhD project is focused on the functional analysis of 
Bm-SPN-2, the most abundant protein secreted specifically from microfilarial stage 
of B. malayi. 
6.1  In  vitro  study    
The first set of studies investigated the inhibitory function of Bm-SPN-2 in blocking 
full-length human and murine IL-33 cleavage in vitro.  
 Considering that commercially-available human and murine IL-33 are 
supplied as the cleaved bioactive form of IL-33, it was necessary to make full-length 
human and murine IL-33 in the laboratory. It was verified that the wild type IL-33 is 
not secreted into the supernatant of transfected HEK293T cell cultures, as it is 
retained in the cell nucleus through the chromatin binding motif located in the N-
terminal sequence of the IL-33 full-length protein. However, soluble human and 
mouse full-length IL-33 were successfully purified from the supernatant of 
                                                                                             Chapter 6. Final discussion 
	  	   149	  
transfected HEK293T cells, after mutating residues 47-49 in the chromatin binding 
motif of both human and mouse FL-IL-33. 
Another clear finding of the IL-33 administration was that cleaved human IL-
3395-270 significantly increased IL-6 secretion by mast cells compared to the full-
length protein. Four enzymes including neutrophil elastase, cathepsin G, mast cell 
chymase and tryptase are each known to cleave human full-length IL-331–270 into 
active fragments such as IL-3395-270 (Lefrançais et al. 2012, Lefrançais et al. 2014). It 
was then inferred that the full-length IL-33 is initially cleaved by neutrophil 
cathepsin G and elastase to IL-3395-270 which activates mast cells to release their 
proteases chymase and tryptase, so further amplifying the production of bioactive IL-
33 (Figure 3.13), and ensuring the initiation of the TH2 response. This model is 
consistent with the very recent finding that mast cells play a role as a critical source 
of IL-33, activating ILC2 responsible for parasite expulsion in the early phase, 
following infection with the intestinal helminth, H. polygyrus (Bouchery and Harris 
2017, Shimokawa et al. 2017). 
The second objective was to verify the inhibitory function of Bm-SPN-2 in 
the context of IL-33 cleavage, by western blotting and enzyme activity assay kits 
which were employed in vitro.  
For western blotting, IL-33 cleavage experiments reported in the literature 
assayed with both human and murine full-length IL-33 were each repeated 
successfully. These results of human and murine FL-IL-33 cleavage by neutrophil 
Cathepsin G and Elastase (see Discussion in Chapter 4) are fully consistent with the 
previous report from Lefrançais et al. (Lefrançais et al. 2012). It was further verified 
that via western blotting that Bm-SPN-2 is able to block human IL-33 cleavage by 
inhibiting human neutrophil cathepsin G in a dose-dependent manner, which is 
consistent with the previous finding by Zang et al. (Zang et al. 1999). Notably, 
however, relatively high concentrations of Bm-SPN-2 were required to observe this 
effect. 
However, it was not possible to verify the inhibitory function of Bm-SPN-2 
against human neutrophil cathepsin G by using enzyme activity assay kits with 
small-molecule chromogenic substrates, which were similarly used by another 
laboratory (Stanley and Stein 2003). 
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Hence these results remain controversial because it was shown in our hands 
that Bm-SPN-2 could block IL-33 cleavage in a dose dependent manner by inhibiting 
the activity of human neutrophil cathepsin G. However, it cannot be verified via 
conventional chromogenic enzyme activity assays, suggesting that Bm-SPN-2 may 
have a significantly different mode of inhibition and/or be closely adapted to 
interfering with the cleavage of IL-33. Thus, it will be important to further verify this 
inhibitory function of Bm-SPN-2 through in vivo experimentation. 
6.2  In  vivo  study  
Next, further experiments were performed to use an established animal model 
in vivo for functional analysis of Bm-SPN-2. In particular, an in vivo experiment 
with Brugia pahangi microfilariae infection was set to accomplish two aims: 
1) To test if IL-33 receptor deficient mice show enhanced microfilaria 
survival, which would suggest that IL-33 is important for microfilarial elimination. 
2) Based on the result of Chapter 4 that Bm-SPN-2 could block mature IL-33 
cleavage, as well as the finding that Bm-SPN-2 induces a strong Th1 immune 
response (Zang et al. 2000), the intention would be to use anti-SPN-2 mAb blockade 
in vivo and then measure (a) Th1 and TH2 cytokine responses; and (b) microfilariae 
recovery. 
However, in this study, it was unfortunately found that IL-33R deficient mice 
do not show enhanced microfilariae recovery in the peritoneal cavity, which is not 
consistent with the previous study that ST2 deficiency increased microfilaremia in 
the case of Litomosoides sigmodontis (Ajendra et al. 2014). 
To establish the reason(s) for this discrepancy, two differences between these 
two studies have to be mentioned: (1) The data from B. pahangi are very variable, 
including the Mff number and mRNA expression in the mesenteric lymph node, 
making the comparison difficult to evaluate at this stage. Thus, repeating and 
optimizing this model is necessary. (2) B. pahangi microfilariae were infected by 
intraperitoneal injection, whereas L. sigmodontis microfilariae developed following 
L3 infection and maturation of adult parasites in Ajendra’s study (Ajendra et al. 
2014). These authors allowed a time period of parasite to develop in the mice host, 
which may have developed a more physiological relationship between parasite and 
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host. Similarly, microfilariae were counted in the bloodstream, the natural niche for 
this stage, which may make the data more reliable. Thus B. pahangi microfilariae 
intraperitoneal infection might not be the best way to verify the importance of IL-33 
signalling in microfilariae elimination. Both points suggest that B. malayi 
microfilariae inoculation intravenously would be the best way to develop this model. 
So far, the first hypothesis that IL-33 signalling plays a crucial role in 
expelling microfilariae cannot be verified in our hands, hence it was not possible to 
test the second aim at this stage. 
Similarly, with respect to the allergic airway model in vivo, the short time 
period (one hour) between allergen administration and measurement of IL-33 
release, may not be the appropriate system to test the inhibitory function of Bm-SPN-
2. Notably, at this time macrophages, eosinophils or neutrophils are all in a very low 
percentage in the BAL (Loebbermann et al. 2012). However, the experiments have 
helped define further the setting in which Bm-SPN-2 may be active. 
6.3  Future  work  
The monoclonal antibody strategy to neutralise SPN-2 in vivo remains an 
attractive route for experimentation. However, stronger evidence is required that an 
antibody to be administered in vivo can block SPN-2 function, which remains a 
problem as the inhibitor is not active in chromogenic substrate assays. In addition, it 
appears that surprisingly the mAbs described here do not react with B. pahangi Mff, 
limiting the experimental use of this species.  
After mapping the protein sequence of Bm-SPN-2 against WormBase 
ParaSite website, it was shown to have 99.8 % identity with B. timori serpin and 
96.7% identity with B. pahangi serpin. Furthermore, as reported by Zang et al. 
compared to homologues from other species such as Caenorhabditis elegans, Bm-
SPN-2 has not only acquired a signal peptide but also an extra N-terminal tract (Zang 
et al. 1999), which might be the crucial for interacting with host cells. In order to 
investigate whether the N-terminal extension plays such a role, making Bm-SPN-2-
mCherry fusion proteins with or without this N-terminal sequence is worth trying. As 
Bm-SPN-2-mCherry was successfully constructed with the N-terminal, the first 
ongoing experiment should be tested whether Bm-SPN-2-mCherry bind to any 
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human cells such as neutrophils. Next, it would be interesting to test the ability of 
binding to cells for the truncation of the N-terminal of Bm-SPN2-mCherry. Finally, it 
is worth investigating whether both of them also bind to mouse cells. 
Recombinant Bm-SPN-2 expressed by E. coli was employed throughout this 
study.  As B. malayi is a human parasite, Bm-SPN-2 expressed by human cells such 
as HEK293T might influence their function. It would also be interesting to test this 
especially using a conditional system to induce Bm-SPN-2 expression by HEK293T 
cells in vitro.  
Finally, as the most prominent ES product secreted only by the microfilarial 
stage, establishing the function of Bm-SPN-2 remains an important priority. 
Although a potential function is now suggested, in neutralizing or evading the host 
immune response, this is still at a controversial stage and further validation 
experiments are strongly recommended to further our understanding of this 
fascinating system. 
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Appendices  
1.  Human  and  murine  mutant  IL-­33  gene  synthesis  
1.1  Human  mutant  IL-­33  
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4.2  Gene  synthesis  for  Bm-­SPN-­2-­mCherry  
	  
Fusion  sequence  (BmSPN2  signal  peptide  removed  and  
codon  optimised)  
NdeI  [CATATG]  sequence,  BmSPN2,  NotI  [GCGGCCGC]  sequence,  



























Fusion  protein  (+3  frame  translated)  
NdeI  [CATATG]  sequence,  SPN2,  NotI  sequence,  mCherry  sequence,  














	  	  194	  
	  
 
	  	   195	  
	  
 
	  	  196	  
	  
 
	  	   197	  
	  
 
	  	  198	  
	  
 
	  	   199	  
	  
 
	  	  200	  
4.3  Sequencing  result  of  Mini  prep  product  F  of  Bm-­SPN-­
2-­mCherry  
NdeI  [CATATG]    XhoI  [CTCGAG]  NotI  [GCGGCCGC]  


























H  M  N  S  T  L  N  H  C  S  E  N  N  D  D  S  N  K  L  L  I  T  K  A  Q  M  N  F  A  L  E  L  L  R  Y  S  
S  Q  A  D  E  T  S  L  L  S  P  F  A  I  A  S  V  M  S  L  L  Y  E  G  A  R  G  E  T  E  R  E  M  G  R  V  
L  S  A  D  Q  P  K  N  A  F  G  A  Y  I  E  C  A  I  K  N  I  H  K  Q  S  K  R  N  D  Y  S  L  Y  Y  L  T  K  
F  F  V  Q  Q  N  S  L  K  S  D  F  K  D  I  T  R  R  R  Y  P  Y  E  L  T  Q  I  N  F  A  S  P  L  Q  V  K  S  
I  R  E  I  F  I  K  W  I  K  K  S  M  N  Y  G  A  R  N  I  A  S  I  T  S  T  Q  S  L  N  L  F  N  G  I  H  F  T  
D  D  W  M  Y  E  F  L  P  L  N  H  I  L  P  F  Y  S  P  R  L  R  V  T  D  M  P  M  M  E  R  T  A  K  F  P  
Y  Y  E  N  Q  H  M  Q  A  V  S  L  P  F  K  D  S  E  M  Q  M  L  I  I  L  P  K  K  T  F  D  L  A  K  F  E  
D  K  L  T  G  E  E  L  F  S  Y  I  S  A  L  D  S  S  H  E  I  T  G  T  I  P  K  F  S  T  K  I  R  F  A  C  
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Sequenced  T7  miniprep  F  VS  designed  Bm-­SPN-­2-­mCherry    
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sequenced  T7t  miniprep  F  VS  mCherry  BmSPN2  
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Sequenced  mCherry  and  gene  synthesized  mCherry    
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5.2  Monoclonal  antibody  candidate  purification  trace.  
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